Table Of Contents

List of Included Clinical Trials

1. NCT04668612. Lowering Postprandial Hyperglycemia With Dual-wave Insulin Boluses in Children With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04668612
2. NCT04711382. The Use of Faster Acting Aspart in Type 1 Diabetes Patients: Multi-centre Real-world Experience. https://clinicaltrials.gov/show/NCT04711382
3. NCT04667182. Meal-centric Insulin Dosing for Optimized Post-Prandial Glucose Control in People Using Multiple Daily Injections. https://clinicaltrials.gov/show/NCT04667182
4. NCT04800471. Improving Glycemic Control and Clinical Outcomes in DM2 Patients in the Ambulatory Setting, a Pilot Study. https://clinicaltrials.gov/show/NCT04800471
5. NCT04772729. Does the Use of Faster Insulin Aspart vs. Aspart Lead to the Prolonged Glycemic Time in Range in Children Suffering From Type 1 Diabetes Who Use Continuous Glucose Monitoring?. https://clinicaltrials.gov/show/NCT04772729
6. NCT04145804. Evaluation Of Hybrid Closed Loop (HCL) System On-Boarding Protocol, For Patients With Type 1 Diabetes On Multiple Daily Insulin Injections (MDI) Therapy. https://clinicaltrials.gov/show/NCT04145804
7. CTRI/2020/10/028223. A PROSPECTIVE MULTICENTER OPEN LABEL STUDY TO ASSESS EFFECT OF TENELIGLIPTIN ON GLYCEMIC CONTROL THROUGH TIME-IN-RANGE (TIR) PARAMETERS USING CONTINUOUS GLUCOSE MONITORING. http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=47269
8. NCT04877730. Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation. https://clinicaltrials.gov/show/NCT04877730
9. NCT04558710. The Effect of Frequent Continuous Glucose Monitoring Use on Glucose Variability in Preschoolers With Type 1 Diabetes - The VibRate Study. https://clinicaltrials.gov/show/NCT04558710
10. NCT04160156. Clinical Use of the Long-term Implantable Sensor Improves Glycated Hemoglobin and Time in Range in Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04160156
11. NCT04654676. The Effect of DPP4 Inhibitor on Glycemic Variability in Patients With Type 2 Diabetes Treated With Twice Daily Premixed Human Insulin. https://clinicaltrials.gov/show/NCT04654676
12. NCT04411277. Time in Range (TIR) and Time Below Range (TBR) in Insulin-Treated Elderly Patients With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04411277
13. NCT05218915. Effect of Glucagon-like Peptide 1 Receptor Agonist in Combination With Insulin on Glycaemic Variability and Time-in-range in Diabetic Kidney Disease: a Randomised Controlled Trial. https://clinicaltrials.gov/show/NCT05218915
14. NCT05243628. ABC [Afrezza With Basal Combination]: A Phase 4 Study of Mealtime Control With Afrezza in Adult Subjects With Type 1 Diabetes Mellitus in Combination With an Automated Insulin Pump or Insulin Degludec. https://clinicaltrials.gov/show/NCT05243628
15. NCT04893148. Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes Insufficiently Controlled by Insulin Glargine and Metformin Combination Therapy. https://clinicaltrials.gov/show/NCT04893148
16. NCT04862390. Incidence of Hypoglycemia in Pregnant Women With or Without Diabetes During Fasting in Ramadan. https://clinicaltrials.gov/show/NCT04862390
17. NCT04809311. Virtual Clinical Study Exploring Remote Collection of Glycaemic and Behaviometric Data Among Patients With Type 2 Diabetes Mellitus on Different Treatment Regimens. https://clinicaltrials.gov/show/NCT04809311
18. NCT05200390. Closing the Gap in Health Disparities and Improving Health Outcomes: Evaluation of a Single Center Expansion of Continuous Glucose Monitor Access in Patients With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT05200390
19. NCT04853030. A Double-blind, Multinational, Multicentre, Randomised, 2-period Crossover Study to Assess the Efficacy and Safety of Advanced Closed-loop Insulin Delivery With Minimed 670 4.0 System Comparing Faster Insulin Aspart to Standard Insulin Aspart Therapy Over 4

Weeks in Active Children and Adolescents With Type 1 Diabetes - the FACT Study. https://clinicaltrials.gov/show/NCT04853030
20. NCT04714216. Automated Insulin Delivery for INpatients With DysGlycemia (AIDING) Feasibility Study. https://clinicaltrials.gov/show/NCT04714216
21. NCT04741685. Clinical Efectivity of Two Different Sensor-augmented Pumps With Low Predictive Suspension Function. https://clinicaltrials.gov/show/NCT04741685
22. NCT04430608. Remote Glucose Monitoring of Patients With Diabetes Quarantined During the COVID-19 Pandemic - a Hospital-Based Randomized Controlled Trial of the Effect of Remote Continuous Glucose Monitoring Compared to Usual Glucose Monitoring. https://clinicaltrials.gov/show/NCT04430608
23. CTRI/2021/05/033519. Acceptability and Impact of Basic Carbohydrate Counting on Glycemic Variability in Patients with Type 1 Diabetes. http://ctri.nic.in/Clinicaltrials/pmaindet2.php?trialid=54042
24. NCT04288050. Evaluation of Glycemic Profiles in Diabetic Patients on Dialysis Under Insulin Balsal-bolus Protocol, Using Freestyle Libre. Observational Prospective Study Without Modification of Management.. https://clinicaltrials.gov/show/NCT04288050
25. NCT04623086. A Randomized Comparison of Transitioning From Insulin GLargine to Insulin Degludec usING a Bridging Dose of Glargine Versus Direct Conversion, in Patients With Type 1 Diabetes Mellitus - a Pilot Study. https://clinicaltrials.gov/show/NCT04623086
26. NCT04473001. Continuous Glucose Measurements to Detect Hypoglycemia in Patients Undergoing Major Surgery. https://clinicaltrials.gov/show/NCT04473001
27. NCT04332354. Evaluation by CGMS (Continuous Glucose Monitoring System) of the Evolution of the Glycemic Profile in Diabetic Patients in Immediate Post-operative Bariatric Surgery: An Observational Study in Routine Care. https://clinicaltrials.gov/show/NCT04332354
28. NCT05069727. Evaluation of Two Levels of Health Care Interactions in Adolescents With Type 1 Diabetes on Advanced Hybrid Closed Loop System MiniMed 780G/ Zeus Sensor. https://clinicaltrials.gov/show/NCT05069727
29. NCT04620967. Fast-Acting Insulin Aspart and Insulin Pump Settings: THE FAST PUMP SETTING STUDY. https://clinicaltrials.gov/show/NCT04620967
30. NCT05001815. Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injection in Pregnant Women With Type 2 Diabetes: A Single-center Open Label Randomized Controlled Trial. https://clinicaltrials.gov/show/NCT05001815
31. NCT04871438. Flash CONtinous Glucose Monitoring in TRansition to Outpatient: Libre for Type 2 Diabetes Mellitus (CONTROL-DM). https://clinicaltrials.gov/show/NCT04871438
32. NCT04866823. Meals for Moms: A Postpartum Medically-Tailored Meal Program to Promote Weight Loss and Blood Glucose Control Among Women With Hyperglycemia in Pregnancy. https://clinicaltrials.gov/show/NCT04866823
33. NCT04529824. Glucose Risk Assessment in Employer Populations. https://clinicaltrials.gov/show/NCT04529824
34. NCT04981808. The Diabetes teleMonitoring of Patients in Insulin Therapy (DiaMonT) Trial: Study Protocol for a Randomized Controlled Trial. https://clinicaltrials.gov/show/NCT04981808
35. NCT04790760. Glucose Differences Between the Left Arm and Right Arm in Diabetic Patients Using a Continuous Glucose Monitor. https://clinicaltrials.gov/show/NCT04790760
36. NCT04226378. Canadian Real-World Outcomes of Omnipod Initiation in People With T1D: Evidence From the LMC Diabetes Registry: The COPPER Study. https://clinicaltrials.gov/show/NCT04226378
37. NCT05201846. Effect of Continuous Subcutaneous Insulin Injection in Pediatric Patients With Type 1 Diabetes Using Multiple Daily Insulin Injections. https://clinicaltrials.gov/show/NCT05201846
38. NCT04939766. Impact of the Use of a Closed-loop Insulin Therapy on the Burden of the Diabetes and the Quality of Life in Type 1 Diabetic Patients With Continuous Glucose Monitoring (CGM). https://clinicaltrials.gov/show/NCT04939766

39. NCT04255381. Yale-Harvard Hotel-based Closed-Loop Studies in Children (HY-GRAID). https://clinicaltrials.gov/show/NCT04255381
40. NCT05114590. A 16-week, Multicenter, Prospective, Open-label, Single-arm, Phase 4 Study to Evaluate the Effect of Soliqua™ 100/33 on the Percentage of Time in Range (TIR) From Continuous Glucose Monitoring (CGM) in Insulin-naïve Patients With Very Uncontrolled Type 2 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT05114590
41. NCT04331444. Steno2tech CGM-The Effect of Real-time Continuous Glucose Monitoring vs. Self-monitoring of Blood Glucose on Glycemic Variables and Patient Reported Outcomes in Adults With Type 2 Diabetes Treated With Insulin-A Randomized Controlled Trial. https://clinicaltrials.gov/show/NCT04331444
42. NCT04269655. Scripps Digital Diabetes: Cloud-Based Continuous Glucose Monitoring (CB CGM). https://clinicaltrials.gov/show/NCT04269655
43. NCT04217369. Impacts of Estimated Future Glucose Values on Health. https://clinicaltrials.gov/show/NCT04217369
44. NCT03047486. Smartguard Use in Real Life : a Longitudinal Study in Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT03047486
45. NCT04797208. A Pilot Randomised Study to Assess Use of Real-time Continuous Glucose Monitoring in Comparison to Conventional Capillary Blood Glucose Monitoring During COVID-19 Pandemic in Hospitalised Patients With Diabetes Mellitus.. https://clinicaltrials.gov/show/NCT04797208
46. NCT04847778. Randomized Clinical Trial to Assess the Efficacy of the System Insulclock® 360 for Insulin Treatment Management in Type 1 Diabetes Patients With Insufficient Glycemic Control. https://clinicaltrials.gov/show/NCT04847778
47. NCT04974528. INHALE-1: A 26-week Primary Treatment Phase, With 26-week Extension, Open-label, Randomized Clinical Trial Evaluating the Efficacy and Safety of Afrezza® Versus Rapid-acting Insulin Analog Injections, Both in Combination With a Basal Insulin, in Pediatric Subjects With Type 1 or Type 2 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT04974528
48. NCT04949022. Glycemic Outcomes and Safety With Minimed 780G System in Children With Type 1 Diabetes Aged 2-6 Years. https://clinicaltrials.gov/show/NCT04949022
49. NCT05095610. Clinical Effects of Intermitent Continuous Glucose Monitoring (Flash) in Adult Patients With Type 1 Diabetes in an Spanish Public Health System. https://clinicaltrials.gov/show/NCT05095610
50. NCT04783441. Continuous Glucose Monitoring (CGM) to Improve Glycemic Control in Kidney Transplant Recipients. https://clinicaltrials.gov/show/NCT04783441
51. UMIN000037524. Estimated A1c discordance: Should estimated A1c derive from time in range or mean glucose level ?. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042784
52. NCT04982575. Efficacy and Safety of Co-administration of Cagrilintide s.c. 2.4 mg and Semaglutide s.c. 2.4 mg Once Weekly in Subjects With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04982575
53. NCT04233203. Effectiveness and Safety of Insulin Faster Aspart on Continuous Subcutaneous Insulin Infusion Treated Adult Type 1 Diabetes Mellitus Patients in Routine Clinical Practice. https://clinicaltrials.gov/show/NCT04233203
54. NCT04761094. Clinical Efficacy of Continuous Subcutaneous Insulin Infusion in Type 1 Diabetes Mellitus Patients in Spain. https://clinicaltrials.gov/show/NCT04761094
55. NCT03755479. Evaluation of Minimed 670G Hybrid Closed Loop System On-Boarding Protocol, for Patients With Type 1 Diabetes on Multiple Daily Insulin Injection Therapy. https://clinicaltrials.gov/show/NCT03755479
56. NCT04542148. Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (Close the GAP). https://clinicaltrials.gov/show/NCT04542148

57. UMIN000045896. Assessment of Time in Range by Daily Blood Glucose Monitor and Continuous Glucose Monitoring. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051369
58. UMIN000045290. The distribution of HbA1c corresponding to time in range and the origin of distribution. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051730
59. CHICTR2000037067. Association of time in range, a novel measure of glycemic control, with mortality in type 2 diabetes: a prospective cohort study. http://www.chictr.org.cn/showprojen.aspx?proj=60163
60. ISRCTN63494266. bREaking up prolonged Sitting in People with type 2 diabetes: Optimising the respoNSE (RESPONSE) - a randomized controlled trial. https://www.isrctn.com/ISRCTN63494266
61. NCT04545151. A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of Verapamil SR on Preservation of Beta-cell Function (Ver-A-T1D). https://clinicaltrials.gov/show/NCT04545151
62. NCT04414280. The Impact of Hybrid Closed-loop Insulin Delivery (Medtronic MiniMed 670G and 780G System, and Tandem t:Slim X2 Control-IQ) on Glycemic Control and Patient-reported Outcomes in People Living With Type 1 Diabetes: a Multicenter Real-world Observational Study in Belgium. https://clinicaltrials.gov/show/NCT04414280
63. NCT03143816. Study Comparing Prandial Insulin Aspart vs. Technosphere Insulin in Patients With Type 1 Diabetes on Multiple Daily Injections: Investigator-Initiated A Real-life Pilot Study-STAT Study. https://clinicaltrials.gov/show/NCT03143816
64. NCT05076292. Low-dose Glucagon for Prevention of Exercise-Induced Hypoglycemia in People With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT05076292
65. NCT04765358. Virtual Diabetes Specialty Clinic: A Study Evaluating Remote Initiation of Continuous Glucose Monitoring. https://clinicaltrials.gov/show/NCT04765358
66. NCT05238142. In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2 - Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes. https://clinicaltrials.gov/show/NCT05238142
67. NCT03670017. GIDE - Glucose Time-In-Range Development Evaluation. https://clinicaltrials.gov/show/NCT03670017
68. NCT04816890. A Phase 2 Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in T1DM Subjects. https://clinicaltrials.gov/show/NCT04816890
69. NCT04102657. Blood Glucose Differences Between Left Arm and Right Arm Using a Continuous Glucose. https://clinicaltrials.gov/show/NCT04102657
70. NCT04965051. A Prospective, Randomized, Open-label, Parallel Group Study to Evaluate Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT04965051
71. NCT04948112. Effectiveness of Real-time Continuous Glucose Monitoring (CGMS) to Improve Glycemic Control in Patients With Early Gestational Diabetes Mellitus: A Randomized Controlled Trial Using CGMS vs. Self-monitoring Blood Glucose (SMBG). https://clinicaltrials.gov/show/NCT04948112
72. NCT05224258. Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp® (Insulin Aspart Injection). https://clinicaltrials.gov/show/NCT05224258
73. NCT04864977. Novel Approach for Basal Insulin Titration: A Proof-of-Concept Study. https://clinicaltrials.gov/show/NCT04864977
74. NCT03898076. The Prediction of A1c Based on CGM Data Through Applying Machine Learning Approaches. https://clinicaltrials.gov/show/NCT03898076
75. NCT05109520. Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL: A FUTURE Substudy. https://clinicaltrials.gov/show/NCT05109520

76. UMIN000043500. Achieving Both Target Time-in-Range and Coefficient of Variation. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049674
77. UMIN000042115. Correlation coefficient analysis which determine minimal duration of CGM data needed to estimate time in range. https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048063
78. NCT03785301. Effect of FGM on Glucose Control in Diabetic Patients. https://clinicaltrials.gov/show/NCT03785301
79. NCT04682795. A Prospective, Multi-center, Randomized, Open-label, Parallel Group Study to Evaluate Safety and Efficacy of Needle-free Injector Versus Insulin Pen in Patients With Type 2 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT04682795
80. NCT02516358. Glycaemic Alterations in ICU: an Observational, Prospective Cohort Study. https://clinicaltrials.gov/show/NCT02516358
81. NCT05181917. Carbohydrate Count Aided by a Simulation of Postprandial Glucose Dynamics Generated by a Mathematical Model in People With Type 1 Diabetes Mellitus. A Protocol for a Clinical Trial. https://clinicaltrials.gov/show/NCT05181917
82. NCT04807374. Use of a Hybrid Closed Loop Insulin Delivery System in a High Risk Type 1 Diabetes Population. https://clinicaltrials.gov/show/NCT04807374
83. NCT04164784. Evaluate the Effect of "Therapeutic Monitoring"（Flash Continuous Glucose Monitoring System）on Blood Glucose Control in Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04164784
84. NCT04536480. Time Limited Eating in Adolescents With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04536480
85. NCT04564911. GLucose Monitoring Programme SingaporE, Phase 2(GLiMPSE2). https://clinicaltrials.gov/show/NCT04564911
86. NCT04450563. The Effect of Low-dose Empagliflozin on Glucose Control in Adult Patients With Type 1 Diabetes on a Closed-loop Insulin System: a Randomized Cross-over Controlled Trial. https://clinicaltrials.gov/show/NCT04450563
87. NCT04333823. Adolescent Type 1 Diabetes Treatment With SGLT2i for hyperglycEMia & hyPerfilTration Trial. https://clinicaltrials.gov/show/NCT04333823
88. NCT03987191. Successful Transition From Insulin Pump to Multiple Daily Injections Using Insulin Degludec in Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT03987191
89. NCT03981627. A Randomized, Single-centre, Double-blind, 2-period Cross-over Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT03981627
90. NCT04605497. A Single Center Open-label Randomized Control Pilot Study to Assess the Efficacy of Real-time Continuous Glucose Monitoring in Subjects With Gestational Diabetes to Increase Glucose Time-in-range. https://clinicaltrials.gov/show/NCT04605497
91. NCT04490460. Evaluation of the Safety and Effects on Glycemic Control of Medical Food Formulation WBF-0031 in Subjects With Abnormal Glucose Tolerance. https://clinicaltrials.gov/show/NCT04490460
92. NCT04096794. Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research. https://clinicaltrials.gov/show/NCT04096794
93. NCT05006040. Safety and Feasibility Study of a Hybrid Closed-loop Insulin Delivery System for Children and Young Adults With High Risk Acute Lymphoblastic Leukemia. https://clinicaltrials.gov/show/NCT05006040
94. NCT02434315. Evaluation of the FreeStyle Libre Pro for Individuals With Insulin Managed Type 2 Diabetes in Primary & Secondary Care. https://clinicaltrials.gov/show/NCT02434315
95. NCT04818242. Randomized Controlled Trial To Assess the Benefits of Dexcom Continuous Glucose Monitoring With Glucose Telemetry System for the Management of Diabetes in Long-term Care Setting: The CGM-GTS in Long-term Care. https://clinicaltrials.gov/show/NCT04818242

96. NCT05163054. Cohort Study of Patients With Type 1 Diabetes Registered With Mobile Application in China. https://clinicaltrials.gov/show/NCT05163054
97. NCT05205876. A Safety and Feasibility Study of the Eddii Mobile Application for Glucose Monitoring in Pediatric Patients With Type I Diabetes. https://clinicaltrials.gov/show/NCT05205876
98. NCT04450745. Physical Exercise in Normobaric Hypoxia and Normoxia in Type 1 Diabetic Patients. https://clinicaltrials.gov/show/NCT04450745
99. NCT04308291. The MiniMed™ 780G Glycemic Control and Quality of Life Study for the Treatment of Pediatric and Adult Subjects With Type 1 Diabetes in France (EQOL Study). https://clinicaltrials.gov/show/NCT04308291
100. DRKS00016170. Digital Diabetes Clinic. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00016170
101. NCT04721158. IMPlementation of Continuous Glucose Monitoring in Children With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04721158
102. NCT02821117. An Evaluation of Self-Management of Diabetes Using FreeStyle Libre Flash Glucose Monitoring System in Young People. https://clinicaltrials.gov/show/NCT02821117
103. NCT05229445. Safety of a Real-time Continuous Glucose Monitor-based Insulin Bolus Calculator: The "CGM-IBC" Study. https://clinicaltrials.gov/show/NCT05229445
104. NCT04125082. A Single-Site, Investigator-Initiated Study to Evaluate Time in Range in Subjects With Type 2 Diabetes Mellitus Using Mealtime Inhaled Insulin (Afrezza®) Plus Basal Insulin Compared to Multiple Daily Injections. https://clinicaltrials.gov/show/NCT04125082
105. NCT01713348. Sensor and Software Use for Improved Glucose Control in MDI Managed Diabetes. https://clinicaltrials.gov/show/NCT01713348
106. NCT04161170. Validation of Diabetes Management Effectiveness of Digital Integrated Healthcare Platform Utilizing AI-based Dietary Management Solution and Real-time Continuous Glucose Monitoring System. https://clinicaltrials.gov/show/NCT04161170
107. NCT03983187. Effect of Rotating Magnetic Therapy on Blood Glucose Spectrum of Type 2 Diabetic Patients With Glargine Therapy. https://clinicaltrials.gov/show/NCT03983187
108. NCT04669912. Observational Study of Glycemic Control and Self-management of Young People (Aged 13 to 25 Years) With Type 1 Diabetes During COVID-19 Lockdown.. https://clinicaltrials.gov/show/NCT04669912
109. NCT04141111. ADJUST: Impact of Professional Continuous Glucose Monitoring in People With Insulin-treated Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04141111
110. NCT04016987. Automated Structured Education Intervention Based on an App and Artificial Intelligence in Chinese Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04016987
111. NCT04938557. Automated Insulin Delivery Amongst Pregnant Women With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04938557
112. NCT04562714. IMpact of Flash Glucose Monitoring in pEople With Type 2 Diabetes Inadequately Controlled With Non-insulin Antihyperglycemic ThErapy - IMMEDIATE Study. https://clinicaltrials.gov/show/NCT04562714
113. NCT04721145. IMPaCT: IMPlementing Continuous Glucose Monitoring in High-risk, Poorly Controlled Children With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04721145
114. NCT03427931. Continuous Glucose Monitoring in Islet Transplant Recipients. https://clinicaltrials.gov/show/NCT03427931
115. NCT04161651. Evaluation of Long-Term Implanted Sensor in Patients on Quality of Life. https://clinicaltrials.gov/show/NCT04161651
116. NCT02463682. Early Feasibility Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAS) in the Outpatient Setting. https://clinicaltrials.gov/show/NCT02463682
117. NCT03368807. An Objective Assessment of Mealtime Bolus Insulin Behavior and Associated Factors. https://clinicaltrials.gov/show/NCT03368807

118. NCT03847701. Cardio-metabolic and Inflammatory Impact of Starch Digestibility in Type 2 Diabetic Patients. https://clinicaltrials.gov/show/NCT03847701
119. NCT05107544. Metabolic Effect of High Intensity Interval Training (HIIT) in Adolescents With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT05107544
120. NCT05161793. Telemedicine Continuous Remote Monitoring of Adults With Uncontrolled Diabetes Mellitus. https://clinicaltrials.gov/show/NCT05161793
121. NCT04028960. Intranasal Insulin: A Novel Therapy for Hypoglycemia Unawareness in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04028960
122. NCT04612933. Effectiveness of Video Consultations in Type 1 Diabetes Patients Treated With Insulin Pumps in the Outpatient Clinic. https://clinicaltrials.gov/show/NCT04612933
123. NCT04135248. A Randomized Control Trial in People With Type 1 Diabetes Mellitus Who Will Fast Ramadan: Does Insulin Timing and Dose Matter?. https://clinicaltrials.gov/show/NCT04135248
124. NCT04257344. Association Between Postoperative Glucose Profile, Sleep and Heart Rate Variability and Postoperative Complications in Patients Undergoing Acute, Abdominal Surgery. A Prospective, Explorative Cohort Study. https://clinicaltrials.gov/show/NCT04257344
125. NCT04871958. Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward. https://clinicaltrials.gov/show/NCT04871958
126. NCT04817215. A Double-Blinded, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Uncontrolled Type 2 DM Subjects on Diet Control Alone, Metformin Monotherapy, or Two or Three Oral Glucose-lowering Agents. https://clinicaltrials.gov/show/NCT04817215
127. DRKS00015439. Assessment of safety and glycaemia during application of the hybrid closed-loop system on the basis of the AndroidAPS application.. https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00015439
128. NCT04810026. Transform Type 2: Examining How Meal-Delivery and Education Resources Affect Prediabetes and Type 2 Diabetes Symptoms and Self-Care. https://clinicaltrials.gov/show/NCT04810026
129. CHICTR2000039222. Study on the relationship between TIR and obstetrical outcome in patients with gestational diabetes mellitus and type 2 diabetes mellitus complicated with pregnancy in Northeast China. http://www.chictr.org.cn/showprojen.aspx?proj=55790
130. NCT04726657. Comparison of Two Biphasic Insulin Regimens in Well-controlled Patients With the Use of Continuous Glucose Monitoring and New Glycemic Control Indices. https://clinicaltrials.gov/show/NCT04726657
131. NCT04051632. Analysis of Glycemic Control in Type 1 Diabetes Patients Using Hybrid Closed Loop Insulin Pump Therapy (Medtronic 670G). https://clinicaltrials.gov/show/NCT04051632
132. NCT04438018. Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control Leading to Personalised Interventions for People With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04438018
133. NCT03811132. Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control Leading to Personalised Interventions for People With Diabetes (DIA-LINK Study). https://clinicaltrials.gov/show/NCT03811132
134. NCT04901143. Meal Handling of Advanced Closed Loop Insulin Delivery.. https://clinicaltrials.gov/show/NCT04901143
135. NCT04479826. Unannounced Meal Handling of Advanced Closed Loop Insulin Delivery in Monitored Condition. https://clinicaltrials.gov/show/NCT04479826
136. NCT03554486. Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy: To Assess How the 670G System Adapts to the Introduction of Fiasp® Insulin. https://clinicaltrials.gov/show/NCT03554486
137. NCT04176731. Prepivotal Evaluation of the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04176731

138. NCT04520971. Closed-loop Insulin Delivery in Pregnant Women With Type 1 Diabetes: a Randomized Controlled Trial: the CRISTAL Study. https://clinicaltrials.gov/show/NCT04520971
139. NCT04545567. Fully Automated Closed Loop Control in Adolescents With Type 1 Diabetes (Rocket AP). https://clinicaltrials.gov/show/NCT04545567
140. NCT03970772. Mini-Dose Glucagon to Treat Fasting-induced Hypoglycemia During Ramadan. https://clinicaltrials.gov/show/NCT03970772
141. NCT04899271. A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of 400 mg Twice a Day Oral Ladarixin in Patients With New-onset Type 1 Diabetes and Preserved Beta-cell Function at Baseline.. https://clinicaltrials.gov/show/NCT04899271
142. NCT03940300. Farming for Life - a Program to Prescribe Fresh Organic Vegetables for Adults Living With or at Risk of Type 2 Diabetes.. https://clinicaltrials.gov/show/NCT03940300
143. NCT04443153. Adapting Diabetes Treatment Expert Systems to Patient's Expectations and Psychobehavioral Characteristics in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04443153
144. NCT05014789. A Control-IQ Technology 2.0 Feasibility Study in Adult and Adolescent Subjects. https://clinicaltrials.gov/show/NCT05014789
145. NCT04964128. Evaluation of Meal Gesture Dosing in Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04964128
146. NCT04847219. Efficacy and Safety of Premixed Insulin Treatment in Patients With Type 2 Diabetes Mellitus Observed by Different Type of Flash Glucose Mornitoring. https://clinicaltrials.gov/show/NCT04847219
147. NCT04793165. Is the Artificial Pancreas, Without Carbohydrate Counting, Efficient and Safe for Ambulatory Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04793165
148. NCT04233229. Evaluation of a Closed-loop Insulin Delivery System at Home With Tailored Home Care Services in Poorly Controlled Type 2 Diabetes: a Randomized Controlled Trial vs Usual Care. https://clinicaltrials.gov/show/NCT04233229
149. NCT03955107. The Effect of Continuous Glucose Monitoring on Glycemic Control and Pregnancy Outcomes in Gestational Diabetes Mellitus：A Randomized Controlled Trial.. https://clinicaltrials.gov/show/NCT03955107
150. NCT03474393. A Randomised Trial of Evaluating a Systematic Intensive Therapy Using Continuous Glucose Monitoring (CGM) and Flash Glucose Monitoring (FGM) in Clinical Diabetes Care. https://clinicaltrials.gov/show/NCT03474393
151. ACTRN12621000648820. A Randomised Cross Over Trial Investigating the Impact of Smart Watch Integrated Do-it-yourself (DIY) Continuous Glucose Monitoring on Glycaemic Control in Adults with Type 1 Diabetes. http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12621000648820&isBasic=True
152. ACTRN12620000200987. Effect of a novel values-guided intervention on glucose management adherence among adolescents and young adults with Type 1 diabetes: Pilot study. http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000200987&isBasic=True
153. NCT03809858. Pilot Study to Test Efficacy of Real-time Reminders on Apple Watch To Decrease Late or Missed Meal Boluses. https://clinicaltrials.gov/show/NCT03809858
154. NCT03668808. Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Travelling Across Multiple Time Zones. A Pilot Study.. https://clinicaltrials.gov/show/NCT03668808
155. NCT04249102. Prospective Randomized Clinical Study Assessing the Clinical Impact of Continuous vs Flash Glucose Monitoring During a 8 Weeks Period in Children, Adolescents and Young Adults 4 to 20 Years Old With Type 1 Diabetes Previously Using Flash Glucose Monitoring. https://clinicaltrials.gov/show/NCT04249102
156. NCT04149262. An Open Label, Single-center, Randomized, Cross-over Trial Comparing the Efficacy and Safety of Faster-acting Insulin Aspart (Fiasp®) Compared to Insulin Aspart

(NovoRapid)® Used in the Medtronic MiniMed 640G Insulin Pump Equipped With Sensor. https://clinicaltrials.gov/show/NCT04149262
157. NCT02651181. Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes -Single-arm, Single-center, in Clinic Study-The DREAMED Trail. https://clinicaltrials.gov/show/NCT02651181
158. NCT04421001. RCT for Evaluation of Insulin Administration, Time in Range of Glucose, Adverse Events and Quality of Life, While Using the iPORT System in Pediatric Population With Recent-onset Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04421001
159. NCT04628481. Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy - Safety of 400 mg Twice a Day Oral Ladarixin in Pts With New-onset Type 1 Diabetes and Low Residual β-cell Function at Baseline (GLADIATOR STUDY). https://clinicaltrials.gov/show/NCT04628481
160. NCT04617795. Evaluating the Safety and Effectiveness of the Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04617795
161. NCT04320069. Evaluating the Safety and Effectiveness of the Omnipod Horizon™ CGM-informed Bolus Calculator in Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04320069
162. NCT03175315. Evaluation of a Newly Developed Psychoeducational Treatment and Education Program for People With Type 1 and Type 2 Diabetes on an Intensified Insulin Therapy Who Use Flash Glucose Monitoring. https://clinicaltrials.gov/show/NCT03175315
163. NCT02232698. Randomised Controlled Study to Evaluate the Impact of Novel Glucose Sensing Technology on Hypoglycaemia in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT02232698
164. NCT02082184. Randomised Controlled Study to Evaluate the Impact of Novel Glucose Sensing Technology on HbA1c in Type 2 Diabetes. https://clinicaltrials.gov/show/NCT02082184
165. NCT04841837. Effect of Time-restricted Eating on Blood Glucose and Behavior in Patients With Type 2 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT04841837
166. NCT04784975. Bone Health and Gut Microbiome in Persons With Preclinical and Clinical Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04784975
167. NCT04454827. Fear of Hypoglycemia in Children and Adolecents With Type 1 Diabetes and Their Parents. https://clinicaltrials.gov/show/NCT04454827
168. NCT04182867. Measuring the Cardio-metabolic Response to Diet Quality Modification During Night Work: Shift-eat (Night) Pilot Study. https://clinicaltrials.gov/show/NCT04182867
169. NCT04074317. A Phase 2, Single-Dose, Randomized, Open-Label, Active-Controlled, Crossover, Pharmacodynamic, and Pharmacokinetic Comparative Study of a Novel Pramlintide-Insulin Co-Formulation in Adults With Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT04074317
170. NCT03944616. Effect of Artificially Sweetened Beverages on Diabetes Control in Adults With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT03944616
171. NCT03799796. Combining Flash Glucose Monitoring and Online Peer Support to Improve Outcomes in Hispanic Spanish-Speaking People With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT03799796
172. NCT05150041. A Pilot Study for the Efficacy of Guardian Connect to Modify Lifestyle in Patients With Type 2 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT05150041
173. NCT04975230. Sleep, Glycemia, and Self-Management in Young Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04975230
174. NCT04738799. The Impact of Food Order/Nutrient Sequence on Glycemic Excursions in Type 2 Diabetes Assessed by Continuous Glucose Monitoring. https://clinicaltrials.gov/show/NCT04738799
175. NCT04729985. Daibetes Discharge Transitional CGM Study. https://clinicaltrials.gov/show/NCT04729985
176. NCT04650945. In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part A. https://clinicaltrials.gov/show/NCT04650945

177. NCT04630925. In-hospital Diabetes Management With Flash Glucose Monitoring (isCGM) - the INDIGO Study, Part B. https://clinicaltrials.gov/show/NCT04630925
178. NCT04398030. Randomized Crossover Euglycemic Clamp Study in Adult Patients With Type 1 Diabetes to Assess Pharmacokinetics and Pharmacodynamics of Subcutaneously Infused Insulin Using an Investigational Extended Wear Continuous Subcutaneous Insulin Infusion Cannula Compared to a Commercial Infusion Set. https://clinicaltrials.gov/show/NCT04398030
179. NCT04223973. Demonstration Study of the Interest of the MEDTRUM A7+ TouchCare Insulin Patch Pump Versus INSULET Omnipod® Patch Pump. https://clinicaltrials.gov/show/NCT04223973
180. NCT04211220. Clinical Evaluation of Insulin Real-Time Advisor (IRTA©): a Decision Support Software for Insulin Therapy Combined With Freestyle Libre®, a Continuous Glucose Monitoring System: Glycemic Impact and Satisfaction in Type 1 Diabetic Patients. https://clinicaltrials.gov/show/NCT04211220
181. NCT04172441. A Randomized Trial in 2 Parts: Double-Blind, Placebo-Controlled, Crossover Part 1 and Open-label Part 2, Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism. https://clinicaltrials.gov/show/NCT04172441
182. NCT03830216. Connected Pens for Diabetes Study. https://clinicaltrials.gov/show/NCT03830216
183. NCT03777176. A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children With Congenital Hyperinsulinism. https://clinicaltrials.gov/show/NCT03777176
184. NCT03096392. A Randomized Controlled Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro Alone to Further Improve Glycemic Control in Type 1 Diabetes Mellitus Subjects With Good Glycemic Control. https://clinicaltrials.gov/show/NCT03096392
185. NCT02773875. A Randomized Crossover Study to Evaluate the Efficacy of Fault Detection Algorithms Using the ZoneMPC Algorithm and DiAs System in Adult Subjects With Type 1 Diabetes in the Outpatient Setting. https://clinicaltrials.gov/show/NCT02773875
186. NCT02608177. Continuous Glucose Monitoring to Assess Glycemia in Chronic Kidney Disease - Changing Glucose Management. https://clinicaltrials.gov/show/NCT02608177
187. NCT01939834. Early Feasibility Study of Adaptive Advisory/Automated (AAA) Control of Type 1 Diabetes. https://clinicaltrials.gov/show/NCT01939834
188. ACTRN12620000687998. Evaluation of PostPrandial Glucose Control with the Medtronic Advanced Hybrid Closed Loop System (A-HCL): 12-month free living study in adults with type 1 diabetes. http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620000687998&isBasic=True
189. ACTRN12619001340123. Systems performance and glucose control with the Medtronic advanced hybrid closed loop system (A-HCL) using insulin aspart vs faster acting insulin aspart (FiASP): Extension study evaluating meal-time glucose control. http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619001340123&isBasic=True
190. ACTRN12619000469112. Systems performance and glucose control using an advanced hybrid closed-loop system in type 1 diabetes: Insulin aspart vs. faster acting insulin aspart (FiASP). http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12619000469112&isBasic=True
191. NCT04090242. An Assessment of the Impact of an App Based Diabetes Training Program in Conjunction With the Use of BD Nano 2nd Gen 4mm Pen Needle on Diabetes Self-efficacy in People With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04090242
192. NCT04510506. Artificial Pancreas - Adolescent Physiology & Psychology Longitudinal Evaluation. https://clinicaltrials.gov/show/NCT04510506
193. NCT04878419. Acceptability of a Virtual Educational Intervention Targeted Towards Improving Diabetes Self- Efficacy and Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes Mellitus (T1DM): a Pilot Study. https://clinicaltrials.gov/show/NCT04878419
194. NCT05234944. A Brief Telehealth Intervention to Address Diabetes Health-related Quality of Life (HRQOL) in Families of Youth and Adults With Type 1 Diabetes Across Clinical Settings: A Pilot and Feasibility Study. https://clinicaltrials.gov/show/NCT05234944

195. NCT04837989. Diabetes Body Project: Effectiveness of a Virtually Delivered Eating Disorder Prevention Program Among Young Females With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04837989
196. NCT04663061. Data-Assisted Approach for High Intensity Medical Weight Loss for Diabetes Remission. https://clinicaltrials.gov/show/NCT04663061
197. NCT04612257. A Pilot Study to Assess Closed-loop Insulin Delivery to Regulate Glucose Levels in Children With Type 1 Diabetes in Outpatient Free-living Settings.. https://clinicaltrials.gov/show/NCT04612257
198. NCT04476472. Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Children With Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort. https://clinicaltrials.gov/show/NCT04476472
199. NCT03522870. Effects of Novel Flash Glucose Monitoring System on Glycemic Control in Adult Patients With Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT03522870
200. NCT02411578. Mini-Dose Glucagon for Adults With Type 1 Diabetes: A Study to Assess the Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT02411578
201. NCT05163002. Effectiveness of Nutrition Education in Carbohydrate Counting, in a Group Context, on Glycemic Control in People With Type 1 Diabetic. https://clinicaltrials.gov/show/NCT05163002
202. NCT04436796. The International Diabetes Closed Loop (iDCL) Trial: A Randomized Crossover Comparison of Adaptive Model Predictive Control (MPC) Artificial Pancreas Versus Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) in the Outpatient Setting in Type 1 Diabetes (DCLP4). https://clinicaltrials.gov/show/NCT04436796
203. NCT04431947. Sleep and Psychosocial Outcomes After Initiation of Advanced Hybrid Closed-Loop Insulin Delivery Systems in Youth With Type 1 Diabetes and Their Parents. https://clinicaltrials.gov/show/NCT04431947
204. NCT04209348. Project Wellness: A Pilot Feasibility Randomized Controlled Trial. https://clinicaltrials.gov/show/NCT04209348
205. NCT04196140. Evaluating the Safety and Effectiveness of the Omnipod Horizon™ Automated Glucose Control System in Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04196140
206. NCT03970044. Effectiveness of Once-weekly Exenatide (BCise) Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.. https://clinicaltrials.gov/show/NCT03970044
207. NCT03838783. Flexible Insulin Therapy Untethered Insulin Regimen Using Insulin Degludec and Continuous Subcutaneous Insulin Infusion in Avidly Exercising Patients With Type 1 Diabetes: FIT Untethered. https://clinicaltrials.gov/show/NCT03838783
208. NCT03643692. Adaptive, Real-time, Intelligent System to Enhance Self-care of Chronic Disease. https://clinicaltrials.gov/show/NCT03643692
209. NCT02604524. Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp. https://clinicaltrials.gov/show/NCT02604524
210. ISRCTN10603608. Pilot study to determine Time in HYpoglycaemia when using pre-MixEd (biphasic) insulin. https://www.isrctn.com/ISRCTN10603608
211. CHICTR2000039424. Using continuous glucose monitoring to compare the effects of metformin combined with acarbose or sitagliptin treatment on glycemic fluctuation in patients with type 2 diabetes mellitus: a randomized control parallel clinical trial. http://www.chictr.org.cn/showprojen.aspx?proj=44067
212. NCT05111301. Control-IQ Technology in Individuals With Type 2 Diabetes (2IQ). https://clinicaltrials.gov/show/NCT05111301
213. NCT05061030. A Double-blinded, Randomized, Parallel, Placebo-controlled Trial of Wharton's Jelly-derived Allogeneic Mesenchymal Stromal Cells to Treat Type 1 Diabetes in Children and Adolescents. https://clinicaltrials.gov/show/NCT05061030

214. NCT04835350. Feasibility Study of the Pancreas4ALL Closed-loop Automated Glycemic Control System in Patients With Type 1 Diabetes Mellitus: Pancreas4ALL Project - Good News Study - Phase I. https://clinicaltrials.gov/show/NCT04835350
215. NCT04809285. Use of the Guardian™ Connect System With Smart Connected Devices. https://clinicaltrials.gov/show/NCT04809285
216. NCT04632849. The Use of Libre to Educate, Motivate and Activate Adults With Newly Diagnosed Type 2 Diabetes to Improve Metabolic Control and Reduce Their Reliance on Medication: A Pilot Study. https://clinicaltrials.gov/show/NCT04632849
217. NCT03908125. A Post- Approval Study to Evaluate the Long-term Safety and Effectiveness of the Eversense® Continuous Glucose Monitoring (CGM) System. https://clinicaltrials.gov/show/NCT03908125
218. NCT03877068. Management of Inpatient Hyperglycemia by Continuous Glucose Monitoring in Insulin-treated Patients With Diabetes: Dexcom G6 Intervention Study. https://clinicaltrials.gov/show/NCT03877068
219. NCT03320993. Evaluación Del Impacto de la composición Nutricional de la Ingesta y Del Consumo de Alcohol en el Control glucémico Postprandial en Pacientes Con Diabetes Tipo 1. https://clinicaltrials.gov/show/NCT03320993
220. NCT03017482. Clinical Startup of the 670G Closed Loop Insulin Delivery System. https://clinicaltrials.gov/show/NCT03017482
221. "ACTRN12620001017910. Developing a multicomponent intervention targeting short-term glycaemic control in youth with type 1 diabetes: An optimisation trial of glucose monitoring, sleep hygiene, snacking education and values-guided self-management interventions . http://www.anzctr.org.au/TrialSearch.aspx?searchTxt=ACTRN12620001017910&isBasic=True"
222. NCT04200313. The Insulin-Only Bionic Pancreas Pivotal Trial: Testing the iLet in Adults and Children With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04200313
223. NCT02282397. Multiple Daily Injections and Continuous Glucose Monitoring in Diabetes. https://clinicaltrials.gov/show/NCT02282397
224. NCT03844789. The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas in Pediatrics: A Study of t:Slim X2 With Control-IQ Technology. https://clinicaltrials.gov/show/NCT03844789
225. NCT04381429. Effect of Postprandial Insulin Administration of Faster-acting Insulin Analogue Versus Pre-prandial Administration of Acting-insulin Analogue in Cystic Fibrosis Related Diabetes : MIRE Trial. https://clinicaltrials.gov/show/NCT04381429
226. NCT03981328. The Effectiveness of Real Time Continuous Glucose Monitoring to Improve Glycemic Control and Pregnancy Outcome in Patients With Gestational Diabetes Mellitus. https://clinicaltrials.gov/show/NCT03981328
227. NCT03772600. Comparing Continuous With Flash Glucose Monitoring in Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT03772600
228. NCT03761615. Observational Study of Patient Important Outcomes in Pregnant Patients With Type 1 Diabetes Mellitus on Insulin Pump. https://clinicaltrials.gov/show/NCT03761615
229. NCT03682640. Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT03682640
230. NCT03662217. Personalized Nutrition for Diabetes Type 2. https://clinicaltrials.gov/show/NCT03662217
231. CHICTR2100049215. Application value of scanning glucose monitoring in ICU patients with intravenous insulin infusion. http://www.chictr.org.cn/showprojen.aspx?proj=130567
232. CHICTR2100048107. Effect of short-term acute moderate-intensity resistance training on blood glucose in elderly patients with type 2 diabetes mellitus combined with sarcopenia. http://www.chictr.org.cn/showprojen.aspx?proj=128238
233. CHICTR1900026285. A Randomized Controlled Trial for Comparing the Effects of Dapagliflozin and Sitagliptin on Glucose Fluctuation and Control Measured by CGM in Chinese Type 2 Diabetes Mellitus. http://www.chictr.org.cn/showprojen.aspx?proj=22676

234. NCT05233592. Glycemic Effects of the COVID-19 Booster Vaccine in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT05233592
235. NCT05197829. Glycemic Optimization On Discharge From the Emergency Room. https://clinicaltrials.gov/show/NCT05197829
236. NCT05188014. Effects of the Menstrual Cycle on Blood Glucose Changes During Exercise in Women With Type 1 Diabetes Using Oral Contraceptives. https://clinicaltrials.gov/show/NCT05188014
237. NCT05168488. Repeatability of Blood Glucose Responses to Fasted and Fed Resistance Exercise in Individuals With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT05168488
238. NCT05159453. A Randomised, Multiple-Dose, Single Period, Phase II/III Dose Response Study to Examine Transdermal Human Insulin in Adult Diabetic Patients. https://clinicaltrials.gov/show/NCT05159453
239. NCT05074667. Use of Continuous Glucose Monitors in Publicly-Insured Youth With Type 2 Diabetes - A Pilot and Feasibility Study. https://clinicaltrials.gov/show/NCT05074667
240. NCT05069545. A Multi-centre Prospective Non-interventional Clinical Investigation Studying the Glycaemic Control in Patients With Type 1 Diabetes When Introducing a NovoPen® 6 for Treatment With Tresiba® (Insulin Degludec) & Fiasp® (Fast-acting Insulin Aspart) in a Real-world Setting. https://clinicaltrials.gov/show/NCT05069545
241. NCT05036343. Smart Insulin Pens: A Randomized, Crossover Prospective Interventional Pilot Study Assessing the Effect on Glycemic Control and Diabetes Related Burdens. https://clinicaltrials.gov/show/NCT05036343
242. NCT04784637. Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery: A Randomized, Controlled Pilot Study. https://clinicaltrials.gov/show/NCT04784637
243. NCT04767880. Acute Metabolic Effects of Pre-meal Consumption of Whey in Women at Risk of Gestational Diabetes Mellitus. https://clinicaltrials.gov/show/NCT04767880
244. NCT04764968. Pen-Administered Low-Dose Dasiglucagon for Prevention and Treatment of Hypoglycemia in People With Type 1 Diabetes: A Randomized, Open-Label, Two-Period Crossover Outpatient Study. https://clinicaltrials.gov/show/NCT04764968
245. NCT04642534. Molecular and Functional Interplay Between the Circadian Clocks and Eating Patterns in Patients With Cardio-metabolic Diseases (Cohort). https://clinicaltrials.gov/show/NCT04642534
246. NCT04605991. A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring. https://clinicaltrials.gov/show/NCT04605991
247. NCT04589689. Insul-In This Together Program: Optimizing Family-based Interventions for Adolescents With Type 1 Diabetes and Their Parents. https://clinicaltrials.gov/show/NCT04589689
248. NCT04524949. A Phase IIa, Randomized, Double-blind Placebo-controlled, Dose Comparison, Multi-centre Adaptive Design Clinical Trial to Evaluate the Immune Signature of the Treatment With the Imotope IMCY-0098 and Its Effect on the Preservation of Beta-cell Function in Adult Patients With a Recent Onset Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04524949
249. NCT04439903. Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT04439903
250. NCT04404556. Diabetes Journey: An Intervention to Improve Adherence Barriers for Adolescents With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04404556
251. NCT04047537. A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Metabolic Effects of Two Formulations of a Food Product (WBF-0011) When Administered to Subjects With Type 2 Diabetes Treated With Diet and Exercise Alone or in Combination With Metformin. https://clinicaltrials.gov/show/NCT04047537
252. NCT04016155. Randomised Controlled Trial of Flash Glucose Monitoring in Reduction of Hypoglycaemia in Diabetes Patients With Chronic Kidney Disease. https://clinicaltrials.gov/show/NCT04016155

253. NCT03970889. Pilot Study to Test Efficacy of Real-time Reminders on Apple Watch To Decrease Late or Missed Meal Boluses. https://clinicaltrials.gov/show/NCT03970889
254. NCT03819790. Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial). https://clinicaltrials.gov/show/NCT03819790
255. NCT03815487. Comparison of the Efficacy of Sensor-augmented Pump Therapy Versus Hybrid Closed-loop Glucose Management (MiniMed670G™) in Patients With Type 1 Diabetes at Home in a Randomized Controlled Trial. https://clinicaltrials.gov/show/NCT03815487
256. NCT03794973. A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT03794973
257. NCT03794960. A Phase 2b Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With Established Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT03794960
258. NCT03389490. A Pilot Study to Describe the Glycaemic Variability of Insulin Glargine 300U/ml Versus NPH (Neutral Protamine Hagedorn) in the Insulin-naïve Type 2 Diabetes Patients Following a Patient-adjusted Insulin Algorithm in Hong Kong. https://clinicaltrials.gov/show/NCT03389490
259. NCT03263494. CGM Intervention in Teens and Young Adults With T1D (CITY): A Randomized Clinical Trial to Assess the Efficacy and Safety of Continuous Glucose Monitoring in Young Adults 14-<25 With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT03263494
260. NCT03258853. Feasibility of Outpatient Automated Blood Glucose Control With the iLet Bionic Pancreas for Treatment of Cystic Fibrosis Related Diabetes. https://clinicaltrials.gov/show/NCT03258853
261. NCT02733588. A Phase 2 Proof-of-Concept Study of Sensor-Guided, Clinician-Administered Delivery of G-Pump™ (Glucagon Infusion) From an OmniPod® to Prevent Post-Prandial Hypoglycemia in Post-Bariatric Surgery Patients. https://clinicaltrials.gov/show/NCT02733588
262. NCT02366767. Assessment of an Automatic Closed-loop Insulin Delivery System. https://clinicaltrials.gov/show/NCT02366767
263. NCT02137512. Pilot Study 3 of Outpatient Control-to-Range: Safety and Efficacy With Day-and-Night In-Home Use. https://clinicaltrials.gov/show/NCT02137512
264. NCT01582139. Feasibility Study of Closed Loop Control in Type 1 Diabetes Using Heart Rate Monitoring as an Exercise Marker. https://clinicaltrials.gov/show/NCT01582139
265. NCT01512654. Assessment of an Enhanced Version of a Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor-2) for Diabetic Patients Treated by Basal-Bolus Insulin Regimens. https://clinicaltrials.gov/show/NCT01512654
266. NCT01120444. A Single Center, Open-label, Randomized Study Examining the Glycemic Effects of ID vs SC Bolus Dosing of Insulin Lispro in Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT01120444
267. ISRCTN63739203. Endothelial progenitor cell (EPCs) response to exercise in individuals with and without type 1 diabetes. https://www.isrctn.com/ISRCTN63739203
268. ISRCTN36033130. Pilot Study to Assess use of FreeStyle Libre Pro with HbA1c in Determining Diabetes Management. https://www.isrctn.com/ISRCTN36033130
269. ISRCTN15304729. A pilot study to determine glycaemic variability in people with impaired glucose tolerance (prediabetes). https://www.isrctn.com/ISRCTN15304729
270. DRKS00022384. Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control Leading to Personalised Interventions for People With Diabetes (DIA-LINK2 Study). https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00022384
271. DRKS00016593. Towards a Better Understanding of Diabetes Distress, Depression and Poor Glycaemic Control Leading to Personalised Interventions for People With Diabetes (DIA-LINK

Study). https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00016593
272. NCT04089462. Effects of Frequency and Duration of Exercise in People With Type 1 Diabetes - A Randomized Crossover Study. https://clinicaltrials.gov/show/NCT04089462
273. NCT05078658. Low-carbohydrate Diet in Paediatric Type 1 Diabetes: Effects on Glycaemic Control and Islet Autoimmunity. https://clinicaltrials.gov/show/NCT05078658
274. NCT04938388. Comparison of Oral Semaglutide With Matched Oral Semaglutide Placebo as an Early Treatment for Latino Adults With Type 2 Diabetes Receiving Enhanced Lifestyle Care. https://clinicaltrials.gov/show/NCT04938388
275. NCT04753099. A Randomized Control Pilot Study to Examine the Effectiveness of Telehealth Occupation-Based Coaching for Families With a Child With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04753099
276. NCT03240432. Wireless Innovation for Seniors With Diabetes Mellitus (WISDM). https://clinicaltrials.gov/show/NCT03240432
277. NCT02714972. Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing in Children and Young Adolescents (PHM3). https://clinicaltrials.gov/show/NCT02714972
278. NCT02660242. The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT02660242
279. NCT02438189. Reduction of Nocturnal Hypoglycemia and Hyperglycemia in the Home Using Predictive Algorithms, Pump Suspension, and Insulin Dosing. https://clinicaltrials.gov/show/NCT02438189
280. NCT05135676. Time in Glucose Hospital Target (TIGHT) - A Randomized Clinical Trial to Evaluate the Use of CGM to Achieve a Mean Glucose Target of 90 to 130 mg/dL Without Hypoglycemia in Hospitalized Adults With Type 2 Diabetes. https://clinicaltrials.gov/show/NCT05135676
281. NCT05013229. A 52 Week Study Comparing the Efficacy and Safety of Once Weekly IcoSema and Daily Insulin Glargine 100 Units/mL Combined With Insulin Aspart, Both Treatment Arms With or Without Oral Anti Diabetic Drugs, in Participants With Type 2 Diabetes Inadequately Controlled With Daily Basal Insulin. COMBINE 3. https://clinicaltrials.gov/show/NCT05013229
282. NCT04936633. Efficacy of Remote Intervention by Medical Staff Based on a Cloud System of Continuous Glucose Monitoring Data in Patients With Insulin-dependent Diabetes Using a Flash Sensor-based Glucose Monitoring (FSGM). https://clinicaltrials.gov/show/NCT04936633
283. NCT04854135. Continuous Glucose Monitoring Initiation at Hospital Discharge: A Feasibility Pilot Study. https://clinicaltrials.gov/show/NCT04854135
284. NCT04545411. Effect of Glucagon Receptor Antagonism on Ketogenesis in SGLT-2i Treated Subjects With T1D. https://clinicaltrials.gov/show/NCT04545411
285. NCT04427189. Better Control in Pediatric and Adolescent diabeteS: Working to crEate CEnTers of Reference. https://clinicaltrials.gov/show/NCT04427189
286. NCT04233034. Hybrid Closed Loop Therapy and Verapamil for Beta Cell Preservation in New Onset Type 1 Diabetes (CLVer). https://clinicaltrials.gov/show/NCT04233034
287. NCT04192292. Study of Sulphonylurea Synergy With DPP4 Inhibitors. https://clinicaltrials.gov/show/NCT04192292
288. NCT04161131. A Pilot of ONBOARD: OvercomiNg Barriers & Obstacles to Adopting Diabetes Devices for Adults With T1D. https://clinicaltrials.gov/show/NCT04161131
289. NCT04147637. Crossover Randomized Controlled Trial of FreeStyle Libre Plus Bluetooth Transmitter Compared to FreeStyle Libre Alone in People With Type 1 Diabetes Mellitus. Can This Improve Accuracy and Reduce Burden of Hypoglycaemia. https://clinicaltrials.gov/show/NCT04147637
290. NCT04129424. Preliminary Exploration on the Operational Standards of Insulin Pump Installation in Diabetes Clinic in China. https://clinicaltrials.gov/show/NCT04129424

291. NCT04128995. Surgical or Medical Treatment for Pediatric Type 2 Diabetes. https://clinicaltrials.gov/show/NCT04128995
292. NCT03977727. An Exploratory, Single-center, Randomized, Open Label, Active-control, Cross-over Trial Comparing the Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart (Fiasp®) Compared to NovoLog® Used in the Medtronic 670G Closed Loop System in Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT03977727
293. NCT03899402. Triple Therapy for Type 1 Diabetes With Insulin, Semaglutide, and Dapagliflozin. https://clinicaltrials.gov/show/NCT03899402
294. NCT03746769. Improving Islet Transplantation Outcomes With Gastrin. https://clinicaltrials.gov/show/NCT03746769
295. NCT03623139. Effects of Basic Carbohydrate Counting Versus Standard Outpatient Nutritional Education: A Randomized Controlled Trial Focusing on HbA1c and Glucose Variability in Patients With Type 2 Diabetes (The BCC Study). https://clinicaltrials.gov/show/NCT03623139
296. NCT03623113. The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study): A Randomized, Parallel, Open-label, Intervention Study Comparing Different Approaches to Dietary Self-management in Patients With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT03623113
297. NCT02987738. A Randomized, Double-Blind, Placebo-controlled, Single-center, Phase 1 Inpatient Pilot Study to Explore the Safety and Efficacy of DAPAglifozin as Add-on to Day and Night Closed-loop Control in Patients Type 1 Diabetes (T1D). https://clinicaltrials.gov/show/NCT02987738
298. ISRCTN25071503. Pregnant women with type 1 diabetes - does wearable technology improve outcomes?. https://www.isrctn.com/ISRCTN25071503
299. ISRCTN17386990. A randomised, controlled crossover study of short-term use of continuous glucose monitoring (CGM) to support self-management behaviour in complex type 2 diabetes mellitus: the DISCO GM study. https://www.isrctn.com/ISRCTN17386990
300. NCT04796779. The Pediatric Artificial Pancreas (PEDAP) Trial: A Randomized Controlled Comparison of the Control-IQ Technology Versus Standard of Care in Young Children in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04796779
301. NCT04914910. Advanced Hybrid Closed-Loop Treatment in Adults With Type 1 Diabetes Not Meeting Glycaemic Targets: A Randomised Controlled Trial - The Steno 780G Study. https://clinicaltrials.gov/show/NCT04914910
302. NCT05035849. Comparison of the FGM Profiles in Patients of Type 2 Diabetes Treated With Sitagliptin and Acarbose. https://clinicaltrials.gov/show/NCT05035849
303. NCT04343131. The Effect of Three Different Types of Diet on Glycemia Assessed by Continuous Glucose Monitoring in Patients With Type 1 Diabetes on Multiple Daily Insulin Treatment. https://clinicaltrials.gov/show/NCT04343131
304. CHICTR2000034884. Analysis of blood glucose control in patients with type 2 diabetes based on continuous glucose monitoring: a single-center, retrospective study. http://www.chictr.org.cn/showprojen.aspx?proj=51264
305. NCT05203653. Effectiveness of Aerobic Exercise to Mitigate Hyperglycemia After Fasted Resistance Exercise. https://clinicaltrials.gov/show/NCT05203653
306. NCT05203640. Acute Glycemic Effects of Resistance Exercise in Post-menopausal Women With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT05203640
307. NCT05159856. Early Detection of Long-term Diabetic Complications in Children and Adolescents With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT05159856
308. NCT05059860. An Evaluation of the Tandem IQ Insulin Pump and DEXCOM G6 Continuous Blood Glucose Monitoring Hybrid Closed Loop Insulin Delivery System (Control-IQ) on Patient Wellbeing and Diabetes Control in Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT05059860
309. NCT04949867. Dual-Hormone Closed-Loop Glucose Control in Adolescents With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04949867

310. NCT04848480. Efficacy and Safety of Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec 100 Units/mL, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes. A 26-week, Randomised, Multicentre, Open-label, Active-controlled, Parallel Group, Two Armed, Treat-to-target Trial Investigating the Effect on Glycaemic Control and Safety of Treatment With Once Weekly Insulin Icodec Compared to Once Daily Insulin Degludec, Both in Combination With Insulin Aspart in Adults With Type 1 Diabetes, With a 26-week Extension Investigating Long Term Safety. https://clinicaltrials.gov/show/NCT04848480
311. NCT04836273. Ready-to-use Dasiglucagon for the Treatment of Postprandial Hypoglycaemia in Roux-en-Y Gastric Bypass Operated Patients. https://clinicaltrials.gov/show/NCT04836273
312. NCT04758884. Telemedicine in Patients With Type 1 Diabetes Mellitus. Efficacy Study of a Specific Virtual Consultation.. https://clinicaltrials.gov/show/NCT04758884
313. NCT04731142. Type 2 Diabetes Exemplar (T2DEx): A Remote Care Service for North West London. https://clinicaltrials.gov/show/NCT04731142
314. NCT04667728. The Effects of Professional Continuous Glucose Monitoring as an Adjuvant Educational Tool in Patients With Type 2 Diabetes and Poor Glycemic Control. https://clinicaltrials.gov/show/NCT04667728
315. NCT04540536. Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents With Poorly Controlled Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04540536
316. NCT04428723. Mechanisms of Hypoglycemia in Patients Without Diabetes. https://clinicaltrials.gov/show/NCT04428723
317. NCT04125160. Markers for Glycaemic Control and Continuous Glucose Monitoring in Persons With Type 2 Diabetes on Peritoneal Dialysis. https://clinicaltrials.gov/show/NCT04125160
318. NCT03953963. Evaluation of the Removal of Excess Intra-Abdominal Fat in Subjects With Type 2 Diabetes and Obesity, Using the HydraSolve T2D™ System, on Glucose Control, Insulin Resistance and Body Weight. https://clinicaltrials.gov/show/NCT03953963
319. NCT03895437. A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of TOL-3021 in Patients With New Onset or Established Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT03895437
320. NCT03804983. Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin. https://clinicaltrials.gov/show/NCT03804983
321. NCT03736083. Introducing Continuous Glucose Monitoring Technology at Diagnosis in Pediatric Type 1 Diabetes: A Proof of Concept Study. https://clinicaltrials.gov/show/NCT03736083
322. NCT03687827. A Randomised, Cross-over, Open-label, Multi-centre Trial Comparing the Effect of Insulin Degludec and Insulin Glargine 100U/mL, With or Without OADs in Subjects With Type 2 Diabetes Using Flash Glucose Monitoring. https://clinicaltrials.gov/show/NCT03687827
323. NCT03670641. Remission Through Early Monitored Insulin Therapy - Duration Month. https://clinicaltrials.gov/show/NCT03670641
324. NCT03544892. The Effects of a Low Carbohydrate, Non-Ketogenic Diet Versus Standard Diabetes Diet on Glycemic Control in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT03544892
325. NCT03289494. A Pilot Randomized Controlled Trial Evaluating the Effect of Two Diets With Different Starch Digestibility Profiles on Daily Glycemic Profile Measured by Continuous Glucose Monitoring System (CGMS), in Type 2 Diabetic Patients. https://clinicaltrials.gov/show/NCT03289494
326. NCT02258373. A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT02258373
327. NCT04963777. Effect of Prebiotic Fibre on Glycemic Control, Gut Microbiota, and Intestinal Permeability in Newly Diagnosed (<12 Months) Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04963777

328. NCT04235504. ADvanced Hybrid Closed Loop Study in Adult Population With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04235504
329. NCT05031429. Time Limited Eating in New-Onset Type 1 Diabetes: Feasibility, Acceptability, and Effect on Beta-cell Function. https://clinicaltrials.gov/show/NCT05031429
330. NCT04902378. Closed-loop Insulin Delivery by Glucose Responsive CompUter Algorithms In Type 1 Diabetes Pregnancies (CIRCUIT) - Internal Pilot. https://clinicaltrials.gov/show/NCT04902378
331. NCT04162067. Type 1 Diabetes in Canada: The Demographic, Care Profiles and Glycemic Control of Patients Living With Type 1 Diabetes From the LMC Diabetes Patient Registry. https://clinicaltrials.gov/show/NCT04162067
332. NCT01484457. Controlled Insulin Delivery: Combining Technology With Treatment. https://clinicaltrials.gov/show/NCT01484457
333. ISRCTN17674908. The effect of acute aerobic exercise on the time spent in hypoglycaemia after Roux-en-Y gastric bypass. https://www.isrctn.com/ISRCTN17674908
334. NCT04616391. Transition of Patients With T1D From Multiple Daily Injection (MDI) and Self-Monitoring of Blood Glucose (SMBG) Directly to MiniMed™ 780G Advanced Hybrid Closed Loop (AHCL) System :Impact on Glucose Control and Quality of Life Measures. https://clinicaltrials.gov/show/NCT04616391
335. NCT04509362. An 8-Day Initiation Protocol of Advanced Hybrid Closed Loop System In Children and Adolescents With Diabetes Type 1 On Multiple Daily Insulin Injection. https://clinicaltrials.gov/show/NCT04509362
336. NCT04726163. Tele-expertise for Glycemic Control Monitoring in Patients With Diabetes Hospitalized for Covid-19 Infection. https://clinicaltrials.gov/show/NCT04726163
337. NCT04201496. SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT04201496
338. NCT03895515. The Effect of Fiasp® (Fast-acting Insulin Aspart) in Type 1 Diabetes Patients Using Continuous Glucose Monitoring / Flash Glucose Monitoring in Real-world Clinical Practice in Sweden. A Non-interventional, Retrospective Chart and Database Review Study. https://clinicaltrials.gov/show/NCT03895515
339. NCT05037526. Diabetes in Pregnancy Project Und Mobile Health in Gestational Diabetes: An Open Label Randomized Controlled Monocentric Trial on the Utility of Real Time Continuous Glucose Monitoring in the Care of Gestational Diabetes Versus Standard Care. https://clinicaltrials.gov/show/NCT05037526
340. NCT04621890. Behavioral Incentive Meal Dose Engagement in Adolescents With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04621890
341. NCT04614168. Can Maximising Time in Range Using Automated Insulin Delivery and a Low Carbohydrate Diet Restore the Glucagon Response to Hypoglycaemic in Type 1 Diabetes?. https://clinicaltrials.gov/show/NCT04614168
342. NCT04509791. MELD-ATG: Phase II, Dose Ranging, Efficacy Study of Anti-thymocyte Globulin (ATG) Within 6 Weeks of Diagnosis of Type 1 Diabetes (T1D). https://clinicaltrials.gov/show/NCT04509791
343. NCT04335513. Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D. https://clinicaltrials.gov/show/NCT04335513
344. NCT04053712. Dual-hormone Closed-loop Glucose Control in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT04053712
345. NCT04023487. Evaluation of a Complex Intervention for Young Adults With Diabetes: The Resilient, Empowered, Active Living-Telehealth (REAL-T) Study. https://clinicaltrials.gov/show/NCT04023487
346. NCT03774186. Pregnancy Intervention With a Closed-Loop System (PICLS) Study. https://clinicaltrials.gov/show/NCT03774186
347. NCT03591354. An Extension Study of t:Slim X2 With Control-IQ Technology. https://clinicaltrials.gov/show/NCT03591354

348. NCT02881060. The Late Effects of Ethanol Intake on the Glucose Response to Subcutaneous Glucagon in Type 1 Diabetes. https://clinicaltrials.gov/show/NCT02881060
349. NCT01788527. Continuous Glucose Monitoring in Women With Type 1 Diabetes in Pregnancy Trial. https://clinicaltrials.gov/show/NCT01788527
350. ISRCTN15487120. Remission of diabetes and improved diastolic function by combining structured exercise with meal replacement and food reintroduction: the RESET for Remission trial. https://www.isrctn.com/ISRCTN15487120
351. NCT05134025. Optimising Glycaemia Around Dynamic Physical Exercise With Advanced Hybrid-closed-loop Therapy Use in Type 1 Diabetes: "The SMART Study". https://clinicaltrials.gov/show/NCT05134025
352. NCT05133765. Optimising Glycaemia Around Dynamic Physical Exercise With Advanced Hybrid-closed-loop Therapy Use in Type 1 Diabetes: "The SMART Study". https://clinicaltrials.gov/show/NCT05133765
353. NCT05000021. Telemedicine-Delivered Cognitive Behavioral Therapy to Reduce Diabetes Distress in Young Adults With Type 1 Diabetes. https://clinicaltrials.gov/show/NCT05000021
354. NCT05205928. Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care: a Double-blind, Cross-over, Randomized Controlled Trial. https://clinicaltrials.gov/show/NCT05205928
355. ISRCTN11362144. Comparison between two types of novel insulin delivery systems among adults living with type 1 diabetes. https://www.isrctn.com/ISRCTN11362144
356. NCT05207774. Pre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes remissionPre-operative Intranasal Oxytocin for Enhancing Bariatric-induced Diabetes Remission. https://clinicaltrials.gov/show/NCT05207774
357. NCT05147324. Individualized Eating Patterns to Improve Glycemic Control in Adolescents With Type 1 Diabetes: A Pilot Clinical Trial. https://clinicaltrials.gov/show/NCT05147324
358. NCT05121844. Use of Continuous Glucose Monitoring in Non-Diabetic Population to Compliment Signos Mobile Health Platform: Comprehensive Weight Optimization Program and Customized Lifestyle Modifications. https://clinicaltrials.gov/show/NCT05121844
359. NCT04979377. Prevalence of Hyperandrogenism in Young Women With Type 1 Diabetes and Study of the Underlying Pathophysiological Mechanisms. https://clinicaltrials.gov/show/NCT04979377
360. NCT04749693. Observational Study of the Use of DBLG1 System in Real Life. https://clinicaltrials.gov/show/NCT04749693
361. NCT03784027. An Open-label, Multi-centre, Multi-national, Randomised, 2-period Crossover Study to Assess the Efficacy, Safety and Utility of Closed Loop Insulin Delivery in Comparison With Sensor Augmented Pump Therapy Over 4 Months in Children With Type 1 Diabetes Aged 1 to 7 Years in the Home Setting With Extension to Evaluate the Efficacy of Home Use of Closed Loop Insulin Delivery.. https://clinicaltrials.gov/show/NCT03784027
362. NCT03734367. Intervention in Emotional Intelligence in Adolescents With Type 1 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT03734367
363. NCT03563313. A Pivotal Study of t:Slim X2 With Control-IQ Technology. https://clinicaltrials.gov/show/NCT03563313
364. NCT02583776. NEONATAL HYPOGLYCEMIA and CONTINUOUS GLUCOSE MONITORING: A RANDOMIZED CONTROLLED TRIAL IN PRETERM INFANTS. https://clinicaltrials.gov/show/NCT02583776
365. NCT05071950. The Effect of D-allulose on the Glycemic Changes in Patients With Type 2 Diabetes Mellitus During Ramadan Fasting. https://clinicaltrials.gov/show/NCT05071950
366. ISRCTN14889127. Comparison of ambulatory glucose profile prior to and during pancreatic enzyme replacement therapy in patients with diabetes and pancreatic exocrine insufficiency: a single-arm phase IV trial. https://www.isrctn.com/ISRCTN14889127
367. NCT04614623. Defining the Role of Management Factors in Outcome Disparity in Pediatric T1D. https://clinicaltrials.gov/show/NCT04614623

368. NCT03951805. A Trial Comparing NNC0148-0287 C (Insulin 287) Versus Insulin Glargine U100, Both in Combination With Metformin, With or Without DPP4 Inhibitors and With or Without SGLT2 Inhibitors, in Insulin-naïve Subjects With Type 2 Diabetes Mellitus. https://clinicaltrials.gov/show/NCT03951805
369. ISRCTN11342830. The effect of canagliflozin 300 mg, in subjects without diabetes after bariatric surgery, on glucose homeostasis (the CONTROL study): a proof-of-concept, randomised, open-label, two-period crossover study. https://www.isrctn.com/ISRCTN11342830
370. ISRCTN56898625. Evaluation of the biomedical and psychosocial impact of closed-loop (artificial pancreas) insulin delivery in women with type 1 diabetes during pregnancy. https://www.isrctn.com/ISRCTN56898625
371. NCT03761186. DANCE (Diabetes ANd CarbohydratEs). Does the Amount of Dietary Carbohydrates Affect Insulin Requirements and Metabolic Control in Type 1 Diabetes? Comparative Study of Traditional Diabetes, Moderately Low and Strictly Low Carbohydrate Diet. https://clinicaltrials.gov/show/NCT03761186
372. ISRCTN92877235. Randomised controlled trial to compare interstitial glucose monitoring with self-monitoring of blood glucose in gestational diabetes. https://www.isrctn.com/ISRCTN92877235
373. NCT04758858. Carbohydrates Under Target for Type 1 Diabetes Management. https://clinicaltrials.gov/show/NCT04758858

List of Included Publications

1. Abdoli S, Miller-Bains K, Fanti P, Silveira M, Hessler D. Development and validation of a scale to measure diabetes burnout. *J Clin Transl Endocrinol.* 2021;23:100251.
2. Abdoli S, Silveira M, Doosti-Irani M, et al. Cross-national comparison of psychosocial well-being and diabetes outcomes in adults with type 1 diabetes during the COVID-19 pandemic in US, Brazil, and Iran. *Diabetol Metab Syndr.* 2021;13(1):63.
3. Abdulhussein FS, Chesser H, Boscardin WJ, Gitelman SE, Wong JC. Youth with Type 1 Diabetes Had Improvement in Continuous Glucose Monitoring Metrics During the COVID-19 Pandemic. *Diabetes Technol Ther.* 2021;23(10):684-691.
4. Abdulrahman A, Manhas J, Linane H, Gurney M, Fitzgerald C, O'Sullivan E. Use of continuous glucose monitoring for sport in type 1 diabetes. *BMJ Open Sport Exerc Med.* 2018;4(1):e000432.
5. Abolbaghaei A, Langlois MA, Murphy HR, Feig DS, Burger D, Group CC. Circulating extracellular vesicles during pregnancy in women with type 1 diabetes: a secondary analysis of the CONCEPTT trial. *Biomark Res.* 2021;9(1):67.
6. Abraham MB, de Bock M, Smith GJ, et al. Effect of a Hybrid Closed-Loop System on Glycemic and Psychosocial Outcomes in Children and Adolescents With Type 1 Diabetes: A Randomized Clinical Trial. *JAMA Pediatr.* 2021;175(12):1227-1235.
7. Abraham MB, Smith GJ, Nicholas JA, et al. Effect of frequency of sensor use on glycaemic control in individuals on sensor-augmented pump therapy with and without Predictive Low Glucose Management System. *Diabetes Res Clin Pract.* 2020;159:107989.
8. Adams JA, Banderas V, Lopez JR, Sackner MA. Portable Gentle Jogger Improves Glycemic Indices in Type 2 Diabetic and Healthy Subjects Living at Home: A Pilot Study. *J Diabetes Res.* 2020;2020:8317973.
9. Adams RN, Tanenbaum ML, Hanes SJ, et al. Psychosocial and Human Factors During a Trial of a Hybrid Closed Loop System for Type 1 Diabetes Management. *Diabetes Technol Ther.* 2018;20(10):648-653.
10. Addala A, Zaharieva DP, Gu AJ, et al. Clinically Serious Hypoglycemia Is Rare and Not Associated With Time-in-range in Youth With New-onset Type 1 Diabetes. *J Clin Endocrinol Metab.* 2021;106(11):3239-3247.
11. Adolfsson P, Hartvig NV, Kaas A, Moller JB, Hellman J. Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen. *Diabetes Technol Ther.* 2020;22(10):709-718.
12. Advani A. Positioning time in range in diabetes management. *Diabetologia.* 2020;63(2):242-252.
13. Ajcevic M, Candido R, Assaloni R, Accardo A, Francescato MP. Personalized Approach for the Management of Exercise-Related Glycemic Imbalances in Type 1 Diabetes: Comparison with Reference Method. *J Diabetes Sci Technol.* 2021;15(5):1153-1160.
14. Ajjan RA, Jackson N, Thomson SA. Reduction in HbA1c using professional flash glucose monitoring in insulin-treated type 2 diabetes patients managed in primary and secondary care settings: A pilot, multicentre, randomised controlled trial. *Diab Vasc Dis Res.* 2019;16(4):385-395.
15. Akturk HK, Dowd R, Shankar K, Derdzinski M. Real-World Evidence and Glycemic Improvement Using Dexcom G6 Features. *Diabetes Technol Ther.* 2021;23(S1):S21-S26.
16. Akturk HK, Giordano D, Champakanath A, Brackett S, Garg S, Snell-Bergeon J. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. *Diabetes Obes Metab.* 2020;22(4):583-589.
17. Akturk HK, Snell-Bergeon JK, Rewers A, et al. Improved Postprandial Glucose with Inhaled Technosphere Insulin Compared with Insulin Aspart in Patients with Type 1 Diabetes on Multiple Daily Injections: The STAT Study. *Diabetes Technol Ther.* 2018;20(10):639-647.
18. Akturk HK, Snell-Bergeon JK, Shah VN. Continuous Glucose Monitor with Siri Integration Improves Glycemic Control in Legally Blind Patients with Diabetes. *Diabetes Technol Ther.* 2021;23(1):81-83.
19. Al Hayek AA, Robert AA, Al Dawish MA. Effectiveness of the freestyle libre 2 flash glucose monitoring system on diabetes-self-management practices and glycemic parameters among patients with type 1 diabetes using insulin pump. *Diabetes Metab Syndr.* 2021;15(5):102265.

20. Aldawi N, Darwiche G, Abusnana S, Elbagir M, Elgzyri T. Initial increase in glucose variability during Ramadan fasting in non-insulin-treated patients with diabetes type 2 using continuous glucose monitoring. *Libyan J Med.* 2019;14(1):1535747.
21. Aleppo G, Beck RW, Bailey R, et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin. *Diabetes Care.* 2021;44(12):2729-2737.
22. Aleppo G, Ruedy KJ, Riddlesworth TD, et al. REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes. *Diabetes Care.* 2017;40(4):538-545.
23. AlGhatam G, O'Keeffe D, Taha H. Effects of Alternate Insulin Pump Settings in Patients With Type 1 Diabetes During Ramadan: A Randomized Pilot Study. *J Diabetes Sci Technol.* 2021:19322968211059217.
24. Alharthi SK, Alyusuf EY, Alguwaihes AM, Alfadda A, Al-Sofiani ME. The impact of a prolonged lockdown and use of telemedicine on glycemic control in people with type 1 diabetes during the COVID-19 outbreak in Saudi Arabia. *Diabetes Res Clin Pract.* 2021;173:108682.
25. Amadou C, Franc S, Benhamou PY, et al. Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up. *Diabetes Care.* 2021;44(3):844-846.
26. Anderson SM, Dassau E, Raghinaru D, et al. The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability. *Diabetes Technol Ther.* 2019;21(2):73-80.
27. Anderson SM, Raghinaru D, Pinsker JE, et al. Multinational Home Use of Closed-Loop Control Is Safe and Effective. *Diabetes Care.* 2016;39(7):1143-1150.
28. Aragona M, Rodia C, Bertolotto A, et al. Type 1 diabetes and COVID-19: The "lockdown effect". *Diabetes Res Clin Pract.* 2020;170:108468.
29. Araujo DB, Dantas JR, Silva KR, et al. Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study. *Front Immunol.* 2020;11:993.
30. Aronson R, Mahoney E, Saliu D, et al. Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes. *Diabetes Technol Ther.* 2020;22(5):352-359.
31. Asarani NAM, Reynolds AN, Elbalshy M, et al. Efficacy, safety, and user experience of DIY or open-source artificial pancreas systems: a systematic review. *Acta Diabetol.* 2021;58(5):539-547.
32. Augstein P, Heinke P, Vogt L, Kohnert KD, Salzsieder E. Patient-Tailored Decision Support System Improves Short- and Long-Term Glycemic Control in Type 2 Diabetes. *J Diabetes Sci Technol.* 2021:19322968211008871.
33. Avari P, Leal Y, Herrero P, et al. Safety and Feasibility of the PEPPER Adaptive Bolus Advisor and Safety System: A Randomized Control Study. *Diabetes Technol Ther.* 2021;23(3):175-186.
34. Avari P, Uduku C, George D, Herrero P, Reddy M, Oliver N. Differences for Percentage Times in Glycemic Range Between Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG Dataset. *Diabetes Technol Ther.* 2020;22(3):222-227.
35. Avari P, Unsworth R, Rilstone S, et al. Improved glycaemia during the Covid-19 pandemic lockdown is sustained post-lockdown and during the "Eat Out to Help Out" Government Scheme, in adults with Type 1 diabetes in the United Kingdom. *PLoS One.* 2021;16(7):e0254951.
36. Babaya N, Noso S, Hiromine Y, et al. Relationship of continuous glucose monitoring-related metrics with HbA1c and residual beta-cell function in Japanese patients with type 1 diabetes. *Sci Rep.* 2021;11(1):4006.
37. Bacon S, Burger D, Tailor M, et al. Can placental growth factors explain birthweight variation in offspring of women with type 1 diabetes? *Diabetologia.* 2021;64(7):1527-1537.
38. Bahillo-Curieses MP, Diaz-Soto G, Vidueira-Martinez AM, Torres-Ballester I, Gomez-Hoyos E, de Luis-Roman D. Assessment of metabolic control and use of flash glucose monitoring systems in a cohort of pediatric, adolescents, and adults patients with Type 1 diabetes. *Endocrine.* 2021;73(1):47-51.

39. Bajaj HS, Bergenstal RM, Christoffersen A, et al. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. *Diabetes Care.* 2021;44(7):1586-1594.
40. Barchetta I, Cimini FA, Bertoccini L, et al. Effects of work status changes and perceived stress onglycaemiccontrol in individuals with type 1 diabetes during COVID-19 lockdown in Italy. *Diabetes Res Clin Pract.* 2020;170:108513.
41. Barnard KD, Pinsker JE, Oliver N, Astle A, Dassau E, Kerr D. Future artificial pancreas technology for type 1 diabetes: what do users want? *Diabetes Technol Ther.* 2015;17(5):311-315.
42. Barua S, Sabharwal A, Glantz N, et al. Dysglycemia in adults at risk for or living with non-insulin treated type 2 diabetes: Insights from continuous glucose monitoring. *EClinicalMedicine.* 2021;35:100853.
43. Bassi M, Minuto N, Fichera G, et al. Practical Approach to Using Trend Arrows on Real-Time Continuous Glucose Monitoring System in Type 1 Diabetes Adolescents Living Camp Setting Treated With Multiple Daily Injection or Continuous Subcutaneous Insulin Infusion Insulin Therapy. *J Diabetes Sci Technol.* 2021;15(5):1098-1103.
44. Bassi M, Minuto N, Fichera G, et al. Practical Approach to Using Trend Arrows on Real-Time Continuous Glucose Monitoring System in Type 1 Diabetes Adolescents Living Camp Setting Treated With Multiple Daily Injection or Continuous Subcutaneous Insulin Infusion Insulin Therapy. *J Diabetes Sci Technol.* 2021;15(5):1098-1103.
45. Battelino T, Bosnyak Z, Danne T, et al. InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design. *Diabetes Ther.* 2020;11(4):1017-1027.
46. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. *Diabetes Care.* 2019;42(8):1593-1603.
47. Battelino T, Edelman SV, Nishimura R, Bergenstal RM. Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring. *Diabetes Technol Ther.* 2021;23(1):20-30.
48. Beato-Vibora PI, Gallego-Gamero F, Ambrojo-Lopez A. Real-world outcomes with different technology modalities in type 1 diabetes. *Nutr Metab Cardiovasc Dis.* 2021;31(6):1845-1850.
49. Beato-Vibora PI, Gallego-Gamero F, Ambrojo-Lopez A, Gil-Poch E, Martin-Romo I, Arroyo-Diez FJ. Rapid Improvement in Time in Range After the Implementation of an Advanced Hybrid Closed-Loop System in Adolescents and Adults with Type 1 Diabetes. *Diabetes Technol Ther.* 2021;23(9):609-615.
50. Beato-Vibora PI, Gallego-Gamero F, Ambrojo-Lopez A, Gil-Poch E, Martin-Romo I, Arroyo-Diez FJ. Amelioration of user experiences and glycaemic outcomes with an Advanced Hybrid Closed Loop System in a real-world clinical setting. *Diabetes Res Clin Pract.* 2021;178:108986.
51. Beato-Vibora PI, Gallego-Gamero F, Lazaro-Martin L, Romero-Perez MDM, Arroyo-Diez FJ. Prospective Analysis of the Impact of Commercialized Hybrid Closed-Loop System on Glycemic Control, Glycemic Variability, and Patient-Related Outcomes in Children and Adults: A Focus on Superiority Over Predictive Low-Glucose Suspend Technology. *Diabetes Technol Ther.* 2020;22(12):912-919.
52. Beato-Vibora PI, Quiros-Lopez C, Lazaro-Martin L, et al. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes. *Diabetes Technol Ther.* 2018;20(11):738-743.
53. Beck RW, Bergenstal RM, Cheng P, et al. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c. *J Diabetes Sci Technol.* 2019;13(4):614-626.
54. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. *Diabetes Care.* 2019;42(3):400-405.
55. Bellido V, Pines-Corrales PJ, Villar-Taibo R, Ampudia-Blasco FJ. Time-in-range for monitoring glucose control: Is it time for a change? *Diabetes Res Clin Pract.* 2021;177:108917.
56. Benhalima K, van Nes F, Laenen A, Gillard P, Mathieu C. Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT. *Diabetologia.* 2021;64(12):2725-2730.

57. Benhamou PY, Lablanche S, Vambergue A, Doron M, Franc S, Charpentier G. Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed-loop insulin delivery system: A series of N-of-1 randomized controlled trials. *Diabetes Obes Metab.* 2021;23(1):186-194.
58. Bergenstal RM, Johnson ML, Aroda VR, et al. Comparing Patch vs Pen Bolus Insulin Delivery in Type 2 Diabetes Using Continuous Glucose Monitoring Metrics and Profiles. *J Diabetes Sci Technol.* 2021:19322968211016513.
59. Berget C, Akturk HK, Messer LH, et al. Real-world performance of hybrid closed loop in youth, young adults, adults and older adults with type 1 diabetes: Identifying a clinical target for hybrid closed-loop use. *Diabetes Obes Metab.* 2021;23(9):2048-2057.
60. Berget C, Messer LH, Vigers T, et al. Six months of hybrid closed loop in the real-world: An evaluation of children and young adults using the 670G system. *Pediatr Diabetes.* 2020;21(2):310-318.
61. Berian J, Bravo I, Gardel-Vicente A, Lazaro-Galilea JL, Rigla M. Dynamic Insulin Basal Needs Estimation and Parameters Adjustment in Type 1 Diabetes. *Sensors (Basel).* 2021;21(15).
62. Biester T, Grimsmann JM, Heidtmann B, et al. Intermittently Scanned Glucose Values for Continuous Monitoring: Cross-Sectional Analysis of Glycemic Control and Hypoglycemia in 1809 Children and Adolescents with Type 1 Diabetes. *Diabetes Technol Ther.* 2021;23(3):160-167.
63. Biester T, Muller I, von dem Berge T, et al. Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study. *Diabetes Obes Metab.* 2021;23(2):599-608.
64. Billion L, Charleer S, Verbraeken LJR, et al. Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. *Diabetes Obes Metab.* 2021;23(12):2716-2727.
65. Bisio A, Brown SA, McFadden R, et al. Sleep and diabetes-specific psycho-behavioral outcomes of a new automated insulin delivery system in young children with type 1 diabetes and their parents. *Pediatr Diabetes.* 2021;22(3):495-502.
66. Bisio A, Gonder-Frederick L, McFadden R, et al. The Impact of a Recently Approved Automated Insulin Delivery System on Glycemic, Sleep, and Psychosocial Outcomes in Older Adults With Type 1 Diabetes: A Pilot Study. *J Diabetes Sci Technol.* 2021;16(3):663-669.
67. Blauw H, Onvlee AJ, Klaassen M, van Bon AC, DeVries JH. Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial. *Diabetes Care.* 2021;44(3):836-838.
68. Blevins T, Lane W, Rodbard D, et al. Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM Findings from the VIVID Study. *Diabetes Technol Ther.* 2021;23(1):51-58.
69. Bode B, Carlson A, Liu R, et al. Ultrarapid Lispro Demonstrates Similar Time in Target Range to Lispro with a Hybrid Closed-Loop System. *Diabetes Technol Ther.* 2021;23(12):828-836.
70. Bode B, King A, Russell-Jones D, Billings LK. Leveraging advances in diabetes technologies in primary care: a narrative review. *Ann Med.* 2021;53(1):805-816.
71. Bode BW, Garg SK, Norwood P, et al. Compatibility and Safety of Ultra Rapid Lispro with Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: PRONTO-Pump Study. *Diabetes Technol Ther.* 2021;23(1):41-50.
72. Bonora BM, Boscari F, Avogaro A, Bruttomesso D, Fadini GP. Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy. *Diabetes Ther.* 2020;11(6):1369-1379.
73. Boonin A, Balinski B, Sauter J, Martinez J, Abbott S. A Retrospective Chart Review of Two Different Insulin Administration Systems on Glycemic Control in Older Adults in Long-Term Care. *J Gerontol Nurs.* 2017;43(1):10-16.
74. Boscari F, Vettoretti M, Cavallin F, et al. Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance. *J Endocrinol Invest.* 2021;45(1):115-124.
75. Bosoni P, Calcaterra V, Tibollo V, et al. Exploring the inter-subject variability in the relationship between glucose monitoring metrics and glycated hemoglobin for pediatric patients with type 1 diabetes. *J Pediatr Endocrinol Metab.* 2021;34(5):619-625.

76. Boughton CK, Tripyla A, Hartnell S, et al. Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. *Nat Med.* 2021;27(8):1471-1476.
77. Braune K, Boss K, Schmidt-Herzel J, et al. Shaping Workflows in Digital and Remote Diabetes Care During the COVID-19 Pandemic via Service Design: Prospective, Longitudinal, Open-label Feasibility Trial. *JMIR Mhealth Uhealth.* 2021;9(4):e24374.
78. Braune K, O'Donnell S, Cleal B, et al. Real-World Use of Do-It-Yourself Artificial Pancreas Systems in Children and Adolescents With Type 1 Diabetes: Online Survey and Analysis of Self-Reported Clinical Outcomes. *JMIR Mhealth Uhealth.* 2019;7(7):e14087.
79. Braune K, Waldchen M, Raile K, et al. Open-Source Technology for Real-Time Continuous Glucose Monitoring in the Neonatal Intensive Care Unit: Case Study in a Neonate With Transient Congenital Hyperinsulinism. *J Med Internet Res.* 2020;22(12):e21770.
80. Braune K, Wäldchen M, Raile K, et al. ePoster Sessions. *Pediatric Diabetes.* 2021;22(S29):25-105.
81. Brener A, Mazor-Aronovitch K, Rachmiel M, et al. Lessons learned from the continuous glucose monitoring metrics in pediatric patients with type 1 diabetes under COVID-19 lockdown. *Acta Diabetol.* 2020;57(12):1511-1517.
82. Breton MD, Chernavvsky DR, Forlenza GP, et al. Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type 1 Diabetes: The Artificial Pancreas Ski Study. *Diabetes Care.* 2017;40(12):1644-1650.
83. Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. *Diabetes Technol Ther.* 2021;23(9):601-608.
84. Breyton AE, Goux A, Lambert-Porcheron S, et al. Starch digestibility modulation significantly improves glycemic variability in type 2 diabetic subjects: A pilot study. *Nutr Metab Cardiovasc Dis.* 2021;31(1):237-246.
85. Breyton AE, Lambert-Porcheron S, Laville M, Vinoy S, Nazare JA. CGMS and Glycemic Variability, Relevance in Clinical Research to Evaluate Interventions in T2D, a Literature Review. *Front Endocrinol (Lausanne).* 2021;12:666008.
86. Brockman NK, Sigal RJ, Kenny GP, Riddell MC, Perkins BA, Yardley JE. Afternoon aerobic and resistance exercise have limited impact on 24-h CGM outcomes in adults with type 1 diabetes: A secondary analysis. *Diabetes Res Clin Pract.* 2021;177:108874.
87. Broos B, Charleer S, Bolsens N, et al. Diabetes Knowledge and Metabolic Control in Type 1 Diabetes Starting With Continuous Glucose Monitoring: FUTURE-PEAK. *J Clin Endocrinol Metab.* 2021;106(8):e3037-e3048.
88. Brown SA, Basu A, Kovatchev BP. Beyond HbA1c : using continuous glucose monitoring metrics to enhance interpretation of treatment effect and improve clinical decision-making. *Diabet Med.* 2019;36(6):679-687.
89. Brown SA, Beck RW, Raghinaru D, et al. Glycemic Outcomes of Use of CLC Versus PLGS in Type 1 Diabetes: A Randomized Controlled Trial. *Diabetes Care.* 2020;43(8):1822-1828.
90. Brown SA, Forlenza GP, Bode BW, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. *Diabetes Care.* 2021;44(7):1630-1640.
91. Bui A, Kim J. Continuous Glucose Monitoring for Underserved and Minority Patients with Type 2 Diabetes in an Interprofessional Internal Medicine Clinic. *Innov Pharm.* 2020;11(4).
92. Bukhari K, Malek R. Open-source automated insulin delivery systems for the management of type 1 diabetes during pregnancy. *BMJ Case Rep.* 2021;14(9).
93. Burckhardt MA, Chetty T, Smith GJ, et al. Use of Continuous Glucose Monitoring Trends to Facilitate Exercise in Children with Type 1 Diabetes. *Diabetes Technol Ther.* 2019;21(1):51-55.
94. Buschur EO, Campbell K, Pyle L, et al. Exploratory Analysis of Glycemic Control and Variability Over Gestation Among Pregnant Women with Type 1 Diabetes. *Diabetes Technol Ther.* 2021;23(11):768-772.
95. Calhoun P, Price D, Beck RW. Glycemic Improvement Using Continuous Glucose Monitoring by Baseline Time in Range: Subgroup Analyses from the DIAMOND Type 1 Diabetes Study. *Diabetes Technol Ther.* 2021;23(3):230-233.

96. Calliari LEP, Krakauer M, Vianna AGD, et al. Real-world flash glucose monitoring in Brazil: can sensors make a difference in diabetes management in developing countries? *Diabetol Metab Syndr.* 2020;12:3.
97. Camerlingo N, Vettoretti M, Sparacino G, et al. Design of clinical trials to assess diabetes treatment: Minimum duration of continuous glucose monitoring data to estimate time-in-ranges with the desired precision. *Diabetes Obes Metab.* 2021;23(11):2446-2454.
98. Campbell FM, Murphy NP, Stewart C, Biester T, Kordonouri O. Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study. *Pediatr Diabetes.* 2018;19(7):1294-1301.
99. Camps SG, Kaur B, Lim J, et al. Improved Glycemic Control and Variability: Application of Healthy Ingredients in Asian Staples. *Nutrients.* 2021;13(9).
100. Carlson AL, Criego AB, Martens TW, Bergenstal RM. HbA1c: The Glucose Management Indicator, Time in Range, and Standardization of Continuous Glucose Monitoring Reports in Clinical Practice. *Endocrinol Metab Clin North Am.* 2020;49(1):95-107.
101. Carlson AL, Kanapka LG, Miller KM, et al. Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study. *J Diabetes Sci Technol.* 2021;15(3):582-592.
102. Carlson AL, Kanapka LG, Miller KM, et al. Hypoglycemia and Glycemic Control in Older Adults With Type 1 Diabetes: Baseline Results From the WISDM Study. *J Diabetes Sci Technol.* 2021;15(3):582-592.
103. Caruso I, Di Molfetta S, Guarini F, et al. Reduction of hypoglycaemia, lifestyle modifications and psychological distress during lockdown following SARS-CoV-2 outbreak in type 1 diabetes. *Diabetes Metab Res Rev.* 2021;37(6):e3404.
104. Castellana M, Parisi C, Di Molfetta S, et al. Efficacy and safety of flash glucose monitoring in patients with type 1 and type 2 diabetes: a systematic review and meta-analysis. *BMJ Open Diabetes Res Care.* 2020;8(1).
105. Castle JR, El Youssef J, Wilson LM, et al. Randomized Outpatient Trial of Single- and Dual-Hormone Closed-Loop Systems That Adapt to Exercise Using Wearable Sensors. *Diabetes Care.* 2018;41(7):1471-1477.
106. Cescon M, Deshpande S, Nimri R, Doyle Iii FJ, Dassau E. Using Iterative Learning for Insulin Dosage Optimization in Multiple-Daily-Injections Therapy for People With Type 1 Diabetes. *IEEE Trans Biomed Eng.* 2021;68(2):482-491.
107. Chakarova N, Dimova R, Grozeva G, Tankova T. Assessment of glucose variability in subjects with prediabetes. *Diabetes Res Clin Pract.* 2019;151:56-64.
108. Chan AJ, Halperin IJ. Beyond Glycated Hemoglobin: Harnessing Data From Sensor-Based Technology to Improve Glucose Variability, Time in Range and Hypoglycemia in Adult Patients With Type 1 Diabetes. *Can J Diabetes.* 2021;45(3):269-272 e263.
109. Chan CL. Continuous Glucose Monitoring in cystic fibrosis – a practical approach to the evaluation and management of cystic fibrosis-related diabetes. *Pediatr Pulmonol.* 2019;54 (2):S38-S154.
110. Chantrel F, Munch M, Alenabi F, et al. SaO007EFFECT OF ADDING VILDAGLIPTIN TO INSULIN THERAPY IN TYPE 2 DIABETIC DIALYSIS PATIENTS : THE VILDDIAL STUDY A RANDOMIZED MULTICENTRIC PROSPECTIVE STUDY. *Nephrology Dialysis Transplantation.* 2018;33(1):i317-i317.
111. Charleer S, De Block C, Van Huffel L, et al. Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study. *Diabetes Care.* 2020;43(2):389-397.
112. Chehregosha H, Khamseh ME, Malek M, Hosseinpanah F, Ismail-Beigi F. A View Beyond HbA1c: Role of Continuous Glucose Monitoring. *Diabetes Ther.* 2019;10(3):853-863.
113. Chernavvsky DR, DeBoer MD, Keith-Hynes P, et al. Use of an artificial pancreas among adolescents for a missed snack bolus and an underestimated meal bolus. *Pediatr Diabetes.* 2016;17(1):28-35.
114. Cherubini V, Bonfanti R, Casertano A, et al. Time In Range in Children with Type 1 Diabetes Using Treatment Strategies Based on Nonautomated Insulin Delivery Systems in the Real World. *Diabetes Technol Ther.* 2020;22(7):509-515.

115. Cherubini V, Gesuita R, Skrami E, et al. Optimal predictive low glucose management settings during physical exercise in adolescents with type 1 diabetes. *Pediatr Diabetes.* 2019;20(1):107-112.
116. Cherubini V, Marino M, Marigliano M, et al. Rethinking Carbohydrate Intake and Time in Range in Children and Adolescents with Type 1 Diabetes. *Nutrients.* 2021;13(11).
117. Chetboun M, Jannin A, Kerr-Conte J, Pattou F, Vantyghem MC. 1921-2021: From insulin discovery to islet transplantation in type 1 diabetes. *Ann Endocrinol (Paris).* 2021;82(2):74-77.
118. Chiang JI, Manski-Nankervis JA, Thuraisingam S, et al. Multimorbidity, glycaemic variability and time in target range in people with type 2 diabetes: A baseline analysis of the GP-OSMOTIC trial. *Diabetes Res Clin Pract.* 2020;169:108451.
119. Cho KY, Nomoto H, Nakamura A, et al. Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study. *J Diabetes Investig.* 2021;12(8):1417-1424.
120. Choudhary P, De Portu S, Lyon J, Arrieta A, Castaneda J, Campbell F. Basic and clinical science posters: Adipocyte function. *Diabetic Medicine.* 2019;36(S1):34-35.
121. Christiansen M, Bartee A, Lalonde A, et al. Performance of an Automated Insulin Delivery System: Results of Early Phase Feasibility Studies. *Diabetes Technol Ther.* 2021;23(3):187-194.
122. Christiansen SC, Fougner AL, Stavdahl O, Kolle K, Ellingsen R, Carlsen SM. A Review of the Current Challenges Associated with the Development of an Artificial Pancreas by a Double Subcutaneous Approach. *Diabetes Ther.* 2017;8(3):489-506.
123. Christoforidis A, Kavoura E, Nemtsa A, Pappa K, Dimitriadou M. Coronavirus lockdown effect on type 1 diabetes management omicronn children wearing insulin pump equipped with continuous glucose monitoring system. *Diabetes Res Clin Pract.* 2020;166:108307.
124. Chung SM, Lee YH, Kim CO, et al. Daytime Glycemic Variability and Frailty in Older Patients with Diabetes: a Pilot Study Using Continuous Glucose Monitoring. *J Korean Med Sci.* 2021;36(27):e190.
125. Cobry EC, Kanapka LG, Cengiz E, et al. Health-Related Quality of Life and Treatment Satisfaction in Parents and Children with Type 1 Diabetes Using Closed-Loop Control. *Diabetes Technol Ther.* 2021;23(6):401-409.
126. Colas A, Varela M, Mraz M, et al. Influence of glucometric 'dynamical' variables on duodenal-jejunal bypass liner (DJBL) anthropometric and metabolic outcomes. *Diabetes Metab Res Rev.* 2020;36(4):e3287.
127. Conget I, Mangas MA, Morales C, et al. Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study. *Diabetes Ther.* 2021;12(11):2993-3009.
128. Cordon NM, Smart CEM, Smith GJ, et al. The relationship between meal carbohydrate quantity and the insulin to carbohydrate ratio required to maintain glycaemia is non-linear in young people with type 1 diabetes: A randomized crossover trial. *Diabet Med.* 2021;39(2):e14675.
129. Cowart K, Updike WH, Franks R. Continuous glucose monitoring in persons with type 2 diabetes not using insulin. *Expert Rev Med Devices.* 2021;18(11):1049-1055.
130. Cusinato M, Martino M, Sartori A, et al. Anxiety, depression, and glycemic control during Covid-19 pandemic in youths with type 1 diabetes. *J Pediatr Endocrinol Metab.* 2021;34(9):1089-1093.
131. Cutruzzola A, Parise M, Scavelli FB, Barone M, Gnasso A, Irace C. Time in Range Does Not Associate With Carotid Artery Wall Thickness and Endothelial Function in Type 1 Diabetes. *J Diabetes Sci Technol.* 2021;16(4):904-911.
132. D'Onofrio L, Coraggio L, Zurru A, et al. Short-term safety profile of Sars-Cov2 vaccination on glucose control: Continuous glucose monitoring data in people with autoimmune diabetes. *Diabetes Res Clin Pract.* 2021;179:109022.
133. Da Silva J, Bosi E, Jendle J, et al. Real-world performance of the MiniMed 670G system in Europe. *Diabetes Obes Metab.* 2021;23(8):1942-1949.
134. Dadlani V, Kaur RJ, Stegall M, et al. Continuous glucose monitoring to assess glycemic control in the first 6 weeks after pancreas transplantation. *Clin Transplant.* 2019;33(10):e13719.
135. Daly A, Hartnell S, Boughton CK, Evans M. Hybrid Closed-loop to Manage Gastroparesis in People With Type 1 Diabetes: a Case Series. *J Diabetes Sci Technol.* 2021;15(6):1216-1223.

136. Danne T, Axel Schweitzer M, Keuthage W, et al. Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study. *Diabetes Technol Ther.* 2021;23(3):203-212.
137. Danne T, Cariou B, Buse JB, et al. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program. *Diabetes Care.* 2019;42(5):919-930.
138. Danne T, Edelman S, Frias JP, et al. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index >/= 27 kg/m(2). *Diabetes Obes Metab.* 2021;23(3):854-860.
139. Danne T, Limbert C, Puig Domingo M, et al. Telemonitoring, Telemedicine and Time in Range During the Pandemic: Paradigm Change for Diabetes Risk Management in the Post-COVID Future. *Diabetes Ther.* 2021;12(9):2289-2310.
140. Dauber A, Corcia L, Safer J, Agus MS, Einis S, Steil GM. Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial. *Diabetes Care.* 2013;36(2):222-227.
141. Davidson MB, Davidson SJ. Effective use of computerized insulin dose adjustment algorithms on continuous glucose monitoring results by a clinical pharmacist - Proof-of-concept. *J Diabetes.* 2021.
142. Davis G, Bailey R, Calhoun P, Price D, Beck RW. Magnitude of Glycemic Improvement in Patients with Type 2 Diabetes Treated with Basal Insulin: Subgroup Analyses from the MOBILE Study. *Diabetes Technol Ther.* 2021;24(5):324-331.
143. Davis GM, Faulds E, Walker T, et al. Remote Continuous Glucose Monitoring With a Computerized Insulin Infusion Protocol for Critically Ill Patients in a COVID-19 Medical ICU: Proof of Concept. *Diabetes Care.* 2021;44(4):1055-1058.
144. De Ridder F, den Brinker M, De Block C. The road from intermittently scanned continuous glucose monitoring to hybrid closed-loop systems. Part B: results from randomized controlled trials. *Ther Adv Endocrinol Metab.* 2019;10:2042018819871903.
145. Deeb A, Muammar T, Alsaffar H, et al. Use of ambulatory glucose monitoring and analysis of ambulatory glucose profile in clinical practice for diabetes management; a position statement of the Arab Society of Paediatric Endocrinology and diabetes. *Diabetes Res Clin Pract.* 2021;173:108671.
146. Dehghani Zahedani A, Shariat Torbaghan S, Rahili S, et al. Improvement in Glucose Regulation Using a Digital Tracker and Continuous Glucose Monitoring in Healthy Adults and Those with Type 2 Diabetes. *Diabetes Ther.* 2021;12(7):1871-1886.
147. Deichmann J, Bachmann S, Burckhardt MA, Szinnai G, Kaltenbach HM. Simulation-Based Evaluation of Treatment Adjustment to Exercise in Type 1 Diabetes. *Front Endocrinol (Lausanne).* 2021;12:723812.
148. Demir G, Ozen S, Cetin H, Darcan S, Goksen D. Effect of Education on Impaired Hypoglycemia Awareness and Glycemic Variability in Children and Adolescents with Type 1 Diabetes Mellitus. *J Clin Res Pediatr Endocrinol.* 2019;11(2):189-195.
149. den Braber N, Vollenbroek-Hutten MMR, Westerik KM, et al. Glucose Regulation Beyond HbA1c in Type 2 Diabetes Treated With Insulin: Real-World Evidence From the DIALECT-2 Cohort. *Diabetes Care.* 2021;44.
150. Di Dalmazi G, Maltoni G, Bongiorno C, et al. Comparison of the effects of lockdown due to COVID-19 on glucose patterns among children, adolescents, and adults with type 1 diabetes: CGM study. *BMJ Open Diabetes Res Care.* 2020;8(2).
151. Díaz-Soto G, Bahíllo-Curieses MP, Jimenez R, et al. Relación entre hemoglobina glucosilada, tiempo en rango y variabilidad glucémica en una cohorte de pacientes pediátricos y adultos con diabetes tipo 1 con monitorización flash de glucosa. *Endocrinología, Diabetes y Nutrición.* 2021;68(7):465-471.
152. Dicembrini I, Cosentino C, Monami M, Mannucci E, Pala L. Effects of real-time continuous glucose monitoring in type 1 diabetes: a meta-analysis of randomized controlled trials. *Acta Diabetol.* 2021;58(4):401-410.

153. Dillmann C, Amoura L, Fall Mostaine F, Coste A, Bounyar L, Kessler L. Feasibility of Real-Time Continuous Glucose Monitoring Telemetry System in an Inpatient Diabetes Unit: A Pilot Study. *J Diabetes Sci Technol.* 2021;16(4):955-961.
154. Dovc K, Battelino T. Evolution of Diabetes Technology. *Endocrinol Metab Clin North Am.* 2020;49(1):1-18.
155. Dovc K, Battelino T. Time in range centered diabetes care. *Clin Pediatr Endocrinol.* 2021;30(1):1-10.
156. Dovc K, Piona C, Mutlu GY, Bratina N, Battelino T. Faster Compared With Standard Insulin Aspart During Day-and-Night Fully Closed-Loop Insulin Therapy in Type 1 Diabetes: A Double-Blind Randomized Crossover Trial. 2020;43.
157. Dover AR, Ritchie SA, McKnight JA, et al. Assessment of the effect of the COVID-19 lockdown on glycaemic control in people with type 1 diabetes using flash glucose monitoring. *Diabet Med.* 2021;38(1):e14374.
158. Dowling L, Wilmot EG, Choudhary P. Do-it-yourself closed-loop systems for people living with type 1 diabetes. *Diabet Med.* 2020;37(12):1977-1980.
159. Duffus SH, Ta'ani ZA, Slaughter JC, Niswender KD, Gregory JM. Increased proportion of time in hybrid closed-loop "Auto Mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump. *Diabetes Obes Metab.* 2020;22(4):688-693.
160. Dunn TC, Xu Y, Hayter G, Ajjan RA. Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests. *Diabetes Res Clin Pract.* 2018;137:37-46.
161. Eberle C, Stichling S. Impact of COVID-19 lockdown on glycemic control in patients with type 1 and type 2 diabetes mellitus: a systematic review. *Diabetol Metab Syndr.* 2021;13(1):95.
162. Eckstein ML, Knoll L, Pottler T, et al. Interpreting the recent consensus on time in range for interstitial glucose right - Or wrong? *Diabetes Res Clin Pract.* 2020;162:108106.
163. Eckstein ML, Weilguni B, Tauschmann M, et al. Time in Range for Closed-Loop Systems versus Standard of Care during Physical Exercise in People with Type 1 Diabetes: A Systematic Review and Meta-Analysis. *J Clin Med.* 2021;10(11).
164. Ehrmann D, Priesterroth L, Schmitt A, Kulzer B, Hermanns N. Associations of Time in Range and Other Continuous Glucose Monitoring-Derived Metrics With Well-Being and Patient-Reported Outcomes: Overview and Trends. *Diabetes Spectr.* 2021;34(2):149-155.
165. Ekhlaspour L, Schoelwer MJ, Forlenza GP, et al. Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and Preschoolers. *Diabetes Technol Ther.* 2021;23(5):384-391.
166. Elkon-Tamir E, Lebenthal Y, Laurian I, et al. Type 1 diabetes outcomes of children born in Israel of Eritrean asylum seekers. *Acta Diabetol.* 2021;58(2):145-152.
167. Evin F, Er E, Ata A, et al. The Value of Telemedicine for the Follow-up of Patients with New Onset Type 1 Diabetes Mellitus During COVID-19 Pandemic in Turkey: A Report of Eight Cases. *J Clin Res Pediatr Endocrinol.* 2021;13(4):468-472.
168. Ewers B, Vilsboll T, Andersen HU, Bruun JM. The dietary education trial in carbohydrate counting (DIET-CARB Study): study protocol for a randomised, parallel, open-label, intervention study comparing different approaches to dietary self-management in patients with type 1 diabetes. *BMJ Open.* 2019;9(9):e029859.
169. Fabris C, Heinemann L, Beck R, Cobelli C, Kovatchev B. Estimation of Hemoglobin A1c from Continuous Glucose Monitoring Data in Individuals with Type 1 Diabetes: Is Time In Range All We Need? *Diabetes Technol Ther.* 2020;22(7):501-508.
170. Fang Z, Liu M, Tao J, Li C, Zou F, Zhang W. Efficacy and safety of closed-loop insulin delivery versus sensor-augmented pump in the treatment of adults with type 1 diabetes: a systematic review and meta-analysis of randomized-controlled trials. *J Endocrinol Invest.* 2021;45(3):471-481.
171. Faulds ER, Boutsicaris A, Sumner L, et al. Use of Continuous Glucose Monitor in Critically Ill COVID-19 Patients Requiring Insulin Infusion: An Observational Study. *J Clin Endocrinol Metab.* 2021;106(10):e4007-e4016.
172. Faulds ER, Hoffman RP, Grey M, et al. Self-management among pre-teen and adolescent diabetes device users. *Pediatr Diabetes.* 2020;21(8):1525-1536.

173. Feng ZQ, Guo QY, Wang W, et al. Time in range, especially overnight time in range, is associated with sudomotor dysfunction in patients with type 1 diabetes. *Diabetol Metab Syndr.* 2021;13(1):119.
174. Ferm ML, DeSalvo DJ, Prichett LM, Sickler JK, Wolf RM, Channa R. Clinical and Demographic Factors Associated With Diabetic Retinopathy Among Young Patients With Diabetes. *JAMA Netw Open.* 2021;4(9):e2126126.
175. Fernandez E, Cortazar A, Bellido V. Impact of COVID-19 lockdown on glycemic control in patients with type 1 diabetes. *Diabetes Res Clin Pract.* 2020;166:108348.
176. Ferstad JO, Vallon JJ, Jun D, et al. Population-level management of type 1 diabetes via continuous glucose monitoring and algorithm-enabled patient prioritization: Precision health meets population health. *Pediatr Diabetes.* 2021;22(7):982-991.
177. Forlenza GP, Buckingham BA, Brown SA, et al. First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes. *Diabetes Technol Ther.* 2021;23(6):410-424.
178. Forlenza GP, Ekhlaspour L, Breton M, et al. Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled Trial. *Diabetes Technol Ther.* 2019;21(4):159-169.
179. Forlenza GP, Raghinaru D, Cameron F, et al. Predictive hyperglycemia and hypoglycemia minimization: In-home double-blind randomized controlled evaluation in children and young adolescents. *Pediatr Diabetes.* 2018;19(3):420-428.
180. Fortmann AL, Spierling Bagsic SR, Talavera L, et al. Glucose as the Fifth Vital Sign: A Randomized Controlled Trial of Continuous Glucose Monitoring in a Non-ICU Hospital Setting. *Diabetes Care.* 2020;43(11):2873-2877.
181. Freckmann G, Pleus S, Schauer S, et al. Choice of Continuous Glucose Monitoring Systems May Affect Metrics: Clinically Relevant Differences in Times in Ranges. *Exp Clin Endocrinol Diabetes.* 2021;130(5):343-350.
182. Freckmann G, Pleus S, Schauer S, et al. Choice of Continuous Glucose Monitoring Systems May Affect Metrics: Clinically Relevant Differences in Times in Ranges. *Exp Clin Endocrinol Diabetes.* 2021;130(5):343-350.
183. Frontino G, Raouf T, Canarutto D, et al. Case Report: Off-Label Liraglutide Use in Children With Wolfram Syndrome Type 1: Extensive Characterization of Four Patients. *Front Pediatr.* 2021;9:755365.
184. Gabbay MAL, Rodacki M, Calliari LE, et al. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes. *Diabetol Metab Syndr.* 2020;12:22.
185. Gaborova M, Donicova V, Bacova I, et al. Glycaemic Variability and Risk Factors of Pregnant Women with and without Gestational Diabetes Mellitus Measured by Continuous Glucose Monitoring. *Int J Environ Res Public Health.* 2021;18(7).
186. Gal RL, Cohen NJ, Kruger D, et al. Diabetes Telehealth Solutions: Improving Self-Management Through Remote Initiation of Continuous Glucose Monitoring. *J Endocr Soc.* 2020;4(9):bvaa076.
187. Gao F, Ma X, Peng J, et al. The Effect of Acarbose on Glycemic Variability in Patients with Type 2 Diabetes Mellitus Using Premixed Insulin Compared to Metformin (AIM): An Open-Label Randomized Trial. *Diabetes Technol Ther.* 2020;22(4):256-264.
188. Garcia-Tirado J, Diaz JL, Esquivel-Zuniga R, et al. Advanced Closed-Loop Control System Improves Postprandial Glycemic Control Compared With a Hybrid Closed-Loop System Following Unannounced Meal. *Diabetes Care.* 2021.
189. Garofolo M, Aragona M, Rodia C, et al. Glycaemic control during the lockdown for COVID-19 in adults with type 1 diabetes: A meta-analysis of observational studies. *Diabetes Res Clin Pract.* 2021;180:109066.
190. Gaudillere M, Pollin-Javon C, Brunot S, Villar Fimbel S, Thivolet C. Effects of remote care of patients with poorly controlled type 1 diabetes included in an experimental telemonitoring programme. *Diabetes Metab.* 2021;47(6):101251.
191. Gawel WB, Deja G, Kaminska H, Tabor A, Skala-Zamorowska E, Jarosz-Chobot P. How does a predictive low glucose suspend (PLGS) system tackle pediatric lifespan challenges in diabetes treatment? Real world data analysis. *Pediatr Diabetes.* 2020;21(2):280-287.

192. Gawrecki A, Zozulinska-Ziolkiewicz D, Michalak MA, et al. Safety and glycemic outcomes of do-it-yourself AndroidAPS hybrid closed-loop system in adults with type 1 diabetes. *PLoS One.* 2021;16(4):e0248965.
193. Gimenez M, Conget I, Oliver N. Automated Insulin Delivery Systems: Today, Tomorrow and User Requirements. *J Diabetes Sci Technol.* 2021;15(6):1252-1257.
194. Goldenberg RM, Aroda VR, Billings LK, et al. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia. *Diabetes Obes Metab.* 2021;23(11):2572-2581.
195. Gomez AM, Henao D, Parra D, et al. Virtual training on the hybrid close loop system in people with type 1 diabetes (T1D) during the COVID-19 pandemic. *Diabetes Metab Syndr.* 2021;15(1):243-247.
196. Gomez AM, Henao DC, Munoz OM, et al. Glycemic control metrics using flash glucose monitoring and hospital complications in patients with COVID-19. *Diabetes Metab Syndr.* 2021;15(2):499-503.
197. Gomez AM, Imitola Madero A, Henao Carrillo DC, et al. Hypoglycemia Incidence and Factors Associated in a Cohort of Patients With Type 2 Diabetes Hospitalized in General Ward Treated With Basal Bolus Insulin Regimen Assessed by Continuous Glucose Monitoring. *J Diabetes Sci Technol.* 2020;14(2):233-239.
198. Gomez AM, Imitola Madero A, Henao Carrillo DC, et al. Hypoglycemia Incidence and Factors Associated in a Cohort of Patients With Type 2 Diabetes Hospitalized in General Ward Treated With Basal Bolus Insulin Regimen Assessed by Continuous Glucose Monitoring. *J Diabetes Sci Technol.* 2020;14(2):233-239.
199. Gomez-Peralta F, Abreu C, Gomez-Rodriguez S, et al. Efficacy of Insulclock in Patients with Poorly Controlled Type 1 Diabetes Mellitus: A Pilot, Randomized Clinical Trial. *Diabetes Technol Ther.* 2020;22(9):686-690.
200. Gomez-Peralta F, Dunn T, Landuyt K, Xu Y, Merino-Torres JF. Flash glucose monitoring reduces glycemic variability and hypoglycemia: real-world data from Spain. *BMJ Open Diabetes Res Care.* 2020;8(1).
201. Griggs S, Grey M, Toly VB, Hickman RL, Jr. Exploring Sleep Health in Young Adults with Type 1 Diabetes. *West J Nurs Res.* 2021;43(12):1169-1176.
202. Griggs S, Redeker NS, Jeon S, Grey M. Daily variations in sleep and glucose in adolescents with type 1 diabetes. *Pediatr Diabetes.* 2020;21(8):1493-1501.
203. Grosman B, Ilany J, Roy A, et al. Hybrid Closed-Loop Insulin Delivery in Type 1 Diabetes During Supervised Outpatient Conditions. *J Diabetes Sci Technol.* 2016;10(3):708-713.
204. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus. *Endocr Pract.* 2021;27(6):505-537.
205. Guo J, Wang J, Zhao Z, Yu L. Association between glycemic control assessed by continuous glucose monitoring and stroke in patients with atrial fibrillation and diabetes mellitus. *Ann Palliat Med.* 2021;10(8):9157-9164.
206. Guo Q, Zang P, Xu S, et al. Time in Range, as a Novel Metric of Glycemic Control, Is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes. *J Diabetes Res.* 2020;2020:5817074.
207. Guo QY, Lu B, Guo ZH, et al. Continuous glucose monitoring defined time-in-range is associated with sudomotor dysfunction in type 2 diabetes. *World J Diabetes.* 2020;11(11):489-500.
208. Haak T, Hanaire H, Ajjan R, Hermanns N, Riveline JP, Rayman G. Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes. *Diabetes Ther.* 2017;8(3):573-586.
209. Haidar A, Legault L, Raffray M, et al. Comparison Between Closed-Loop Insulin Delivery System (the Artificial Pancreas) and Sensor-Augmented Pump Therapy: A Randomized-Controlled Crossover Trial. *Diabetes Technol Ther.* 2021;23(3):168-174.
210. Haidar A, Tsoukas MA, Bernier-Twardy S, et al. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial. *Diabetes Care.* 2020;43(3):597-606.

211. Hallstrom S, Hirsch IB, Ekelund M, et al. Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections. *Diabetes Technol Ther.* 2021;23(6):425-433.
212. Hansen KW, Bibby BM. The Frequency of Intermittently Scanned Glucose and Diurnal Variation of Glycemic Metrics. *J Diabetes Sci Technol.* 2021:19322968211019382.
213. Haskova A, Radovnicka L, Petruzelkova L, et al. Real-time CGM Is Superior to Flash Glucose Monitoring for Glucose Control in Type 1 Diabetes: The CORRIDA Randomized Controlled Trial. *Diabetes Care.* 2020;43(11):2744-2750.
214. Hayashi A, Shimizu N, Suzuki A, et al. Hemodialysis-Related Glycemic Disarray Proven by Continuous Glucose Monitoring; Glycemic Markers and Hypoglycemia. *Diabetes Care.* 2021;44(7):1647-1656.
215. Heimburger SMN, Hoe B, Nielsen CN, et al. The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. *Diabetologia.* 2021;64(11):2425-2431.
216. Heinemann L, Freckmann G, Muller-Wieland D, Kellerer M. Critical Reappraisal of the Time-in-Range: Alternative or Useful Addition to Glycated Hemoglobin? *J Diabetes Sci Technol.* 2020;14(5):922-927.
217. Heinemann L, Freckmann G, Muller-Wieland D, Kellerer M. Critical Reappraisal of the Time-in-Range: Alternative or Useful Addition to Glycated Hemoglobin? *J Diabetes Sci Technol.* 2020;14(5):922-927.
218. Helleputte S, De Backer T, Calders P, Pauwels B, Shadid S, Lapauw B. The Added and Interpretative Value of Cgm-Derived Parameters in Type 1 Diabetes Depends on the Level of Glycemic Control. *Endocr Pract.* 2021;27(1):44-50.
219. Hernando ME, Garcia-Saez G, Gomez EJ, Perez-Gandia C, Rodriguez-Herrero A. Automated Insulin Delivery: The Artificial Pancreas Technical Challenges. *Am J Ther.* 2020;27(1):e62-e70.
220. Herzog AL, Busch J, Wanner C, von Jouanne-Diedrich HK. Survey about do-it-yourself closed loop systems in the treatment of diabetes in Germany. *PLoS One.* 2020;15(12):e0243465.
221. Hirsch IB. Professional flash continuous glucose monitoring as a supplement to A1C in primary care. *Postgrad Med.* 2017;129(8):781-790.
222. Hirsch IB, Balo AK, Sayer K, Garcia A, Buckingham BA, Peyser TA. A Simple Composite Metric for the Assessment of Glycemic Status from Continuous Glucose Monitoring Data: Implications for Clinical Practice and the Artificial Pancreas. *Diabetes Technol Ther.* 2017;19(S3):S38-S48.
223. Hirsch IB, Sherr JL, Hood KK. Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes. *Diabetes Care.* 2019;42(3):345-348.
224. Hirsch IB, Welsh JB, Calhoun P, Puhr S, Walker TC, Price DA. Associations between HbA1c and continuous glucose monitoring-derived glycaemic variables. *Diabet Med.* 2019;36(12):1637-1642.
225. Hohendorff J, Gumprecht J, Mysliwiec M, Zozulinska-Ziolkiewicz D, Malecki MT. Intermittently Scanned Continuous Glucose Monitoring Data of Polish Patients from Real-Life Conditions: More Scanning and Better Glycemic Control Compared to Worldwide Data. *Diabetes Technol Ther.* 2021;23(8):577-585.
226. Holzer R, Schulte-Korne B, Seidler J, Predel HG, Brinkmann C. Effects of Acute Resistance Exercise with and without Whole-Body Electromyostimulation and Endurance Exercise on the Postprandial Glucose Regulation in Patients with Type 2 Diabetes Mellitus: A Randomized Crossover Study. *Nutrients.* 2021;13(12).
227. Horowitz ME, Kaye WA, Pepper GM, et al. An analysis of Medtronic MiniMed 670G insulin pump use in clinical practice and the impact on glycemic control, quality of life, and compliance. *Diabetes Res Clin Pract.* 2021;177:108876.
228. Hsu L, Buckingham B, Basina M, et al. Fast-Acting Insulin Aspart Use with the MiniMed(TM) 670G System. *Diabetes Technol Ther.* 2021;23(1):1-7.
229. Hu K, Peng H, Ma Y, et al. Analysis of Glycemic Improvement in Hemodialysis Patients Based on Time in Range, Assessed by Flash Glucose Monitoring. *Blood Purif.* 2021;50(6):883-890.
230. Huang F, Wu X, Xie Y, et al. An automated structured education intervention based on a smartphone app in Chinese patients with type 1 diabetes: a protocol for a single-blinded randomized controlled trial. *Trials.* 2020;21(1):944.

231. Huang ZX, Zhang HH, Huang Y, et al. Association of time in range with postoperative wound healing in patients with diabetic foot ulcers. *Int Wound J.* 2021.
232. Igata M, Yagi Y, Hanatani S, et al. Rapid and dramatic glucose-lowering effect of bromocriptine in an inadequately controlled type 2 diabetes patient with prolactinoma. *J Diabetes Investig.* 2021;12(4):668-671.
233. Ilesanmi I, Tharakan G, Alexiadou K, et al. Roux-en-Y Gastric Bypass Increases Glycemic Variability and Time in Hypoglycemia in Patients With Obesity and Prediabetes or Type 2 Diabetes: A Prospective Cohort Study. *Diabetes Care.* 2021;44(2):614-617.
234. Irace C, Cutruzzola A, Nuzzi A, et al. Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes. *Diabetes Obes Metab.* 2020;22(7):1056-1061.
235. Irace C, Cutruzzola A, Tweden K, Kaufman FR. Device profile of the eversense continuous glucose monitoring system for glycemic control in type-1 diabetes: overview of its safety and efficacy. *Expert Rev Med Devices.* 2021;18(10):909-914.
236. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al. Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop Trial. *Diabetes Technol Ther.* 2021;23(5):342-349.
237. Jaffar F, Laycock K, Huda MSB. Type 1 Diabetes in Pregnancy: A Review of Complications and Management. *Curr Diabetes Rev.* 2021;18(7):e051121197761.
238. Jain AB. Glycemic improvement with a novel interim intervention technique using retrospective professional continuous glucose monitoring (GLITTER study): A study from Mumbai, India. *Diabetes Metab Syndr.* 2021;15(3):703-709.
239. Janapala RN, Jayaraj JS, Fathima N, et al. Continuous Glucose Monitoring Versus Self-monitoring of Blood Glucose in Type 2 Diabetes Mellitus: A Systematic Review with Meta-analysis. *Cureus.* 2019;11(9):e5634.
240. Janez A, Battelino T, Klupa T, et al. Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. *Diabetes Ther.* 2021;12(12):3107-3135.
241. Janssens B, Caerels S, Mathieu C. SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects. *Ther Adv Endocrinol Metab.* 2020;11:2042018820938545.
242. Jarosinski MA, Chen YS, Varas N, Dhayalan B, Chatterjee D, Weiss MA. New Horizons: Next-Generation Insulin Analogues: Structural Principles and Clinical Goals. *J Clin Endocrinol Metab.* 2021;107(4):909-928.
243. Jaser SS, Jordan LC. Brain Health in Children with Type 1 Diabetes: Risk and Protective Factors. *Curr Diab Rep.* 2021;21(4):12.
244. Jensen MH, Cichosz SL, Hirsch IB, Vestergaard P, Hejlesen O, Seto E. Smoking is Associated With Increased Risk of Not Achieving Glycemic Target, Increased Glycemic Variability, and Increased Risk of Hypoglycemia for People With Type 1 Diabetes. *J Diabetes Sci Technol.* 2021;15(4):827-832.
245. Jensen MH, Cichosz SL, Hirsch IB, Vestergaard P, Hejlesen O, Seto E. Smoking is Associated With Increased Risk of Not Achieving Glycemic Target, Increased Glycemic Variability, and Increased Risk of Hypoglycemia for People With Type 1 Diabetes. *J Diabetes Sci Technol.* 2021;15(4):827-832.
246. Jeyaventhan R, Gallen G, Choudhary P, Hussain S. A real-world study of user characteristics, safety and efficacy of open-source closed-loop systems and Medtronic 670G. *Diabetes Obes Metab.* 2021;23(8):1989-1994.
247. Kalra S, Shaikh S, Priya G, et al. Individualizing Time-in-Range Goals in Management of Diabetes Mellitus and Role of Insulin: Clinical Insights From a Multinational Panel. *Diabetes Ther.* 2021;12(2):465-485.
248. Kanapka LG, Wadwa RP, Breton MD, et al. Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 Diabetes. *Diabetes Care.* 2021;44(2):473-478.
249. Kang J, Chen Y, Zhao Y, Zhang C. Effect of remote management on comprehensive management of diabetes mellitus during the COVID-19 epidemic. *Prim Care Diabetes.* 2021;15(3):417-423.

250. Kapoor R, Timsina LR, Gupta N, et al. Maintaining Blood Glucose Levels in Range (70-150 mg/dL) is Difficult in COVID-19 Compared to Non-COVID-19 ICU Patients-A Retrospective Analysis. *J Clin Med.* 2020;9(11).
251. Karastogiannidou C, Giannoulaki P, Samaras I, et al. The Diabetes Eating Problem Survey-Revised (DEPS-R) in a Greek Adult Population with Type 1 Diabetes Mellitus: Model Comparison Supporting a Single Factor Structure. *Nutrients.* 2021;13(7).
252. Kawakatsu S, Liu X, Tran B, et al. Differences in Glucose Readings Between Right Arm and Left Arm Using a Continuous Glucose Monitor. *J Diabetes Sci Technol.* 2021:19322968211008838.
253. Kerr D, Barua S, Glantz N, et al. Farming for life: impact of medical prescriptions for fresh vegetables on cardiometabolic health for adults with or at risk of type 2 diabetes in a predominantly Mexican-American population. *BMJ Nutr Prev Health.* 2020;3(2):239-246.
254. Kesavadev J, Saboo B, Kar P, Sethi J. DIY artificial pancreas: A narrative of the first patient and the physicians' experiences from India. *Diabetes Metab Syndr.* 2021;15(2):615-620.
255. Kieu A, Govender RD, Ostlundh L, King J. Benefits of the addition of continuous or flash glucose monitoring versus standard practice using self-monitored blood glucose and haemoglobin A1c in the primary care of diabetes mellitus: a systematic review protocol. *BMJ Open.* 2021;11(8):e050027.
256. Kim MY, Kim G, Park JY, et al. The Association Between Continuous Glucose Monitoring-Derived Metrics and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes. *Diabetes Technol Ther.* 2021;23(6):434-442.
257. Kim N, Pham K, Shek A, Lim J, Liu X, Shah SA. Differences in glucose level between right arm and left arm using continuous glucose monitors. *Digit Health.* 2020;6:2055207620970342.
258. Klarskov CK, Hamid YH, Tjalk-Boggild R, Tarnow L, Kristensen PL. A New Medical Device for Improved Rotation of Insulin Injections in Type 1 Diabetes Mellitus: A Proof-of-Concept Study. *J Diabetes Sci Technol.* 2021;15(5):1111-1120.
259. Klarskov CK, Lindegaard B, Pedersen-Bjergaard U, Kristensen PL. Remote continuous glucose monitoring during the COVID-19 pandemic in quarantined hospitalized patients in Denmark: A structured summary of a study protocol for a randomized controlled trial. *Trials.* 2020;21(1):968.
260. Kong X, Luo M, Cai L, et al. Needle-free jet injection of insulin glargine improves glycemic control in patients with type 2 diabetes mellitus: a study based on the flash glucose monitoring system. *Expert Opin Drug Deliv.* 2021;18(5):635-641.
261. Krakauer M, Botero JF, Lavalle-Gonzalez FJ, Proietti A, Barbieri DE. A review of flash glucose monitoring in type 2 diabetes. *Diabetol Metab Syndr.* 2021;13(1):42.
262. Kudva YC, Laffel LM, Brown SA, et al. Patient-Reported Outcomes in a Randomized Trial of Closed-Loop Control: The Pivotal International Diabetes Closed-Loop Trial. *Diabetes Technol Ther.* 2021;23(10):673-683.
263. Kuroda N, Kusunoki Y, Osugi K, et al. Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study. *J Diabetes Investig.* 2021;12(2):244-253.
264. Kuroda N, Kusunoki Y, Osugi K, et al. Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study. *J Diabetes Investig.* 2021;12(2):244-253.
265. Kurozumi A, Okada Y, Tanaka Y. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study. *Endocr J.* 2021;68(3):361-369.
266. Kushner PR, Kruger DF. The Changing Landscape of Glycemic Targets: Focus on Continuous Glucose Monitoring. *Clin Diabetes.* 2020;38(4):348-356.
267. Lachal S, Tourki Y, Franc S, Huneker E, Charpentier G, Benhamou PY. Hybrid Closed-Loop Control with Ultrarapid Lispro Compared with Standard Insulin Aspart and Faster Insulin Aspart: An In silico Study. *J Diabetes Sci Technol.* 2021:19322968211046021.
268. Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System. *Diabetes Care.* 2019;42(12):2190-2196.

269. Landstra CP, Andres A, Chetboun M, et al. Examination of the Igls Criteria for Defining Functional Outcomes of beta-cell Replacement Therapy: IPITA Symposium Report. *J Clin Endocrinol Metab.* 2021;106(10):3049-3059.
270. Lanspa MJ, Krinsley JS, Hersh AM, et al. Percentage of Time in Range 70 to 139 mg/dL Is Associated With Reduced Mortality Among Critically Ill Patients Receiving IV Insulin Infusion. *Chest.* 2019;156(5):878-886.
271. Laurenzi A, Caretto A, Barrasso M, et al. Frequency of flash glucose monitoring readings, hemoglobin A1c and time in range: a real life study in adults with type 1 diabetes. *Acta Diabetol.* 2020;57(11):1395-1397.
272. Lee AS, Way KL, Johnson NA, Twigg SM. High-intensity interval exercise and hypoglycaemia minimisation in adults with type 1 diabetes: A randomised cross-over trial. *J Diabetes Complications.* 2020;34(3):107514.
273. Lee JM, Rusnak A, Garrity A, et al. Feasibility of Electronic Health Record Assessment of 6 Pediatric Type 1 Diabetes Self-management Habits and Their Association With Glycemic Outcomes. *JAMA Netw Open.* 2021;4(10):e2131278.
274. Lee K, Gunasinghe S, Chapman A, et al. Real-World Outcomes of Glucose Sensor Use in Type 1 Diabetes-Findings from a Large UK Centre. *Biosensors (Basel).* 2021;11(11).
275. Lee MA, Holmes-Walker DJ, Farrell K, Clark-Luccitti A. Impact of continuous glucose monitoring in youth with type 1 diabetes aged 15-21 years. *Intern Med J.* 2021.
276. Lee MH, Paldus B, Vogrin S, et al. Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. *Diabetes Care.* 2021.
277. Lee MH, Vogrin S, Paldus B, et al. Glucose and Counterregulatory Responses to Exercise in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia Using Closed-Loop Insulin Delivery: A Randomized Crossover Study. *Diabetes Care.* 2020;43(2):480-483.
278. Lee MH, Vogrin S, Paldus B, et al. Glucose Control in Adults with Type 1 Diabetes Using a Medtronic Prototype Enhanced-Hybrid Closed-Loop System: A Feasibility Study. *Diabetes Technol Ther.* 2019;21(9):499-506.
279. Leelarathna L, Thabit H, Wilinska ME, et al. Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index. *J Diabetes Sci Technol.* 2020;14(2):277-283.
280. Leelarathna L, Thabit H, Wilinska ME, et al. Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index. *J Diabetes Sci Technol.* 2020;14(2):277-283.
281. Lehmann V, Zueger T, Zeder A, et al. Lower Daily Carbohydrate Intake Is Associated With Improved Glycemic Control in Adults With Type 1 Diabetes Using a Hybrid Closed-Loop System. *Diabetes Care.* 2020;43(12):3102-3105.
282. Leng Y, Zhou X, Xie Z, et al. Efficacy and safety of Chinese herbal medicine on blood glucose fluctuations in patients with type 2 diabetes mellitus: A protocol of systematic review and meta-analysis. *Medicine (Baltimore).* 2020;99(34):e21904.
283. Levin P, Hoogwerf BJ, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Ultra Rapid-Acting Inhaled Insulin Improves Glucose Control in Patients With Type 2 Diabetes Mellitus. *Endocr Pract.* 2021;27(5):449-454.
284. Lewis D. History and Perspective on DIY Closed Looping. *J Diabetes Sci Technol.* 2019;13(4):790-793.
285. Lewis D. How It Started, How It Is Going: The Future of Artificial Pancreas Systems (Automated Insulin Delivery Systems). *J Diabetes Sci Technol.* 2021;15(6):1258-1261.
286. Li C, Ma X, Yin J, et al. The dawn phenomenon across the glycemic continuum: Implications for defining dysglycemia. *Diabetes Res Clin Pract.* 2020;166:108308.
287. Li F, Zhang Y, Li H, et al. TIR generated by continuous glucose monitoring is associated with peripheral nerve function in type 2 diabetes. *Diabetes Res Clin Pract.* 2020;166:108289.
288. Li J, Li Y, Ma W, et al. Association of Time in Range levels with Lower Extremity Arterial Disease in patients with type 2 diabetes. *Diabetes Metab Syndr.* 2020;14(6):2081-2085.
289. Liao B, Chen Y, Chigutsa F, Piras de Oliveira C. Fasting and postprandial plasma glucose contribution to glycated haemoglobin and time in range in people with type 2 diabetes on basal and bolus insulin therapy: Results from a pooled analysis of insulin lispro clinical trials. *Diabetes Obes Metab.* 2021;23(7):1571-1579.

290. Lim STJ, Huang F, Lek N, Pereira K. Flash Continuous Home Glucose Monitoring to Improve Adherence to Self-Monitoring of Blood Glucose and Self-Efficacy in Adolescents With Type 1 Diabetes. *Clin Diabetes.* 2020;38(2):152-158.
291. Lin R, Brown F, James S, Jones J, Ekinci E. Continuous glucose monitoring: A review of the evidence in type 1 and 2 diabetes mellitus. *Diabet Med.* 2021;38(5):e14528.
292. Lin YK, Groat D, Chan O, et al. Alarm Settings of Continuous Glucose Monitoring Systems and Associations to Glucose Outcomes in Type 1 Diabetes. *J Endocr Soc.* 2020;4(1):bvz005.
293. Lind N, Lindqvist Hansen D, Saetre Rasmussen S, Norgaard K. Real-time continuous glucose monitoring versus self-monitoring of blood glucose in adults with insulin-treated type 2 diabetes: a protocol for a randomised controlled single-centre trial. *BMJ Open.* 2021;11(1):e040648.
294. Ling J, Poon EWM, Yang A, et al. Glycemic Variability and Time in Range During Self-titration of Once Daily Insulin Glargine 300 U/ml Versus Neutral Protamine Hagedorn Insulin in Insulin-naive Chinese Type 2 Diabetes Patients. *Diabetes Ther.* 2021;12(5):1399-1413.
295. Ling P, Yang D, Gu N, et al. Achieving the HbA1c Target Requires Longer Time in Range in Pregnant Women With Type 1 Diabetes. *J Clin Endocrinol Metab.* 2021;106(11):e4309-e4317.
296. Lingvay I, Buse JB, Franek E, et al. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. *Diabetes Care.* 2021;44(7):1595-1603.
297. Liu W, Chen J, He L, et al. Flash glucose monitoring data analysed by detrended fluctuation function on beta-cell function and diabetes classification. *Diabetes Obes Metab.* 2021;23(3):774-781.
298. Liu Y, Yu J, Ma C, et al. Hemoglobin A1c modifies the association between triglyceride and time in hypoglycemia determined by flash glucose monitoring in adults with type 1 diabetes: implications for individualized therapy and decision-making. *Ann Transl Med.* 2021;9(7):537.
299. Lombardo F, Salzano G, Bombaci B, et al. Has COVID-19 lockdown improved glycaemic control in pediatric patients with type 1 diabetes? An analysis of continuous glucose monitoring metrics. *Diabetes Res Clin Pract.* 2021;178:108988.
300. Longo M, Caruso P, Petrizzo M, et al. Glycemic control in people with type 1 diabetes using a hybrid closed loop system and followed by telemedicine during the COVID-19 pandemic in Italy. *Diabetes Res Clin Pract.* 2020;169:108440.
301. Lu J, Home PD, Zhou J. Comparison of Multiple Cut Points for Time in Range in Relation to Risk of Abnormal Carotid Intima-Media Thickness and Diabetic Retinopathy. *Diabetes Care.* 2020;43(8):e99-e101.
302. Lu J, Ma X, Shen Y, et al. Time in Range Is Associated with Carotid Intima-Media Thickness in Type 2 Diabetes. *Diabetes Technol Ther.* 2020;22(2):72-78.
303. Lu J, Ma X, Zhang L, et al. Glycemic variability modifies the relationship between time in range and hemoglobin A1c estimated from continuous glucose monitoring: A preliminary study. *Diabetes Res Clin Pract.* 2020;161:108032.
304. Lu J, Ma X, Zhou J, et al. Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes. *Diabetes Care.* 2018;41(11):2370-2376.
305. Lu J, Wang C, Shen Y, et al. Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study. *Diabetes Care.* 2021;44(2):549-555.
306. Lu JC, Vogrin S, McAuley SA, et al. Meal-time glycaemia in adults with type 1 diabetes using multiple daily injections vs insulin pump therapy following carbohydrate-counting education and bolus calculator provision. *Diabetes Res Clin Pract.* 2021;179:109000.
307. Lu M, Zuo Y, Guo J, Wen X, Kang Y. Continuous glucose monitoring system can improve the quality of glucose control and glucose variability compared with point-of-care measurement in critically ill patients: A randomized controlled trial. *Medicine (Baltimore).* 2018;97(36):e12138.
308. Lum JW, Bailey RJ, Barnes-Lomen V, et al. A Real-World Prospective Study of the Safety and Effectiveness of the Loop Open Source Automated Insulin Delivery System. *Diabetes Technol Ther.* 2021;23(5):367-375.
309. Luo M, Kong X, Wang H, et al. Effect of Dapagliflozin on Glycemic Variability in Patients with Type 2 Diabetes under Insulin Glargine Combined with Other Oral Hypoglycemic Drugs. *J Diabetes Res.* 2020;2020:6666403.

310. Ly TT, Breton MD, Keith-Hynes P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. *Diabetes Care.* 2014;37(8):2310-2316.
311. Ly TT, Keenan DB, Roy A, et al. Automated Overnight Closed-Loop Control Using a Proportional-Integral-Derivative Algorithm with Insulin Feedback in Children and Adolescents with Type 1 Diabetes at Diabetes Camp. *Diabetes Technol Ther.* 2016;18(6):377-384.
312. Ly TT, Roy A, Grosman B, et al. Day and Night Closed-Loop Control Using the Integrated Medtronic Hybrid Closed-Loop System in Type 1 Diabetes at Diabetes Camp. *Diabetes Care.* 2015;38(7):1205-1211.
313. Ly TT, Weinzimer SA, Maahs DM, et al. Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance. *Pediatr Diabetes.* 2017;18(5):348-355.
314. Maiorino MI, Signoriello S, Maio A, et al. Effects of Continuous Glucose Monitoring on Metrics of Glycemic Control in Diabetes: A Systematic Review With Meta-analysis of Randomized Controlled Trials. *Diabetes Care.* 2020;43(5):1146-1156.
315. Majdpour D, Tsoukas MA, Yale JF, et al. Fully Automated Artificial Pancreas for Adults With Type 1 Diabetes Using Multiple Hormones: Exploratory Experiments. *Can J Diabetes.* 2021;45(8):734-742.
316. Majithia AR, Kusiak CM, Armento Lee A, et al. Glycemic Outcomes in Adults With Type 2 Diabetes Participating in a Continuous Glucose Monitor-Driven Virtual Diabetes Clinic: Prospective Trial. *J Med Internet Res.* 2020;22(8):e21778.
317. Malecki MT, Cao D, Liu R, et al. Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy. *Diabetes Technol Ther.* 2020;22(11):853-860.
318. Mao Y, Zhao X, Zhou L, et al. Evaluating perioperative glycemic status after different types of pancreatic surgeries via continuous glucose monitoring system: a pilot study. *Gland Surg.* 2021;10(10):2945-2955.
319. Marcalo J, Oliveira A, Nunes PA, do Vale S. Type la glycogen storage disease complicated with diabetes mellitus: the role of flash continuous glucose monitoring. *BMJ Case Rep.* 2021;14(3).
320. Marquez-Pardo R, Torres-Barea I, Cordoba-Dona JA, et al. Continuous Glucose Monitoring and Glycemic Patterns in Pregnant Women with Gestational Diabetes Mellitus. *Diabetes Technol Ther.* 2020;22(4):271-277.
321. Martens TW, Bergenstal RM, Pearson T, et al. Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C). *Postgrad Med.* 2021;133(3):253-264.
322. Matei FC, onei NA, Simion AM, Popa SG. Pitfalls in establishing type of diabetes and optimal therapy: Clinical cases series. 2021;28.
323. Mathieu C, Dandona P, Phillip M, et al. Glucose Variables in Type 1 Diabetes Studies With Dapagliflozin: Pooled Analysis of Continuous Glucose Monitoring Data From DEPICT-1 and -2. *Diabetes Care.* 2019;42(6):1081-1087.
324. Mattsson S, Jendle J, Adolfsson P. Carbohydrate Loading Followed by High Carbohydrate Intake During Prolonged Physical Exercise and Its Impact on Glucose Control in Individuals With Diabetes Type 1-An Exploratory Study. *Front Endocrinol (Lausanne).* 2019;10:571.
325. Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. *BMJ Open Diabetes Res Care.* 2020;8(1).
326. McAuley SA, Lee MH, Paldus B, et al. Six Months of Hybrid Closed-Loop Versus Manual Insulin Delivery With Fingerprick Blood Glucose Monitoring in Adults With Type 1 Diabetes: A Randomized, Controlled Trial. *Diabetes Care.* 2020;43(12):3024-3033.
327. McAuley SA, Trawley S, Vogrin S, et al. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL): A Randomized, Crossover Trial. *Diabetes Care.* 2021;45(2):381-390.
328. McAuley SA, Vogrin S, Lee MH, et al. Less Nocturnal Hypoglycemia but Equivalent Time in Range Among Adults with Type 1 Diabetes Using Insulin Pumps Versus Multiple Daily Injections. *Diabetes Technol Ther.* 2021;23(6):460-466.

329. McEachron KR, Yang Y, Hodges JS, et al. Performance of modified Igls criteria to evaluate islet autograft function after total pancreatectomy with islet autotransplantation - a retrospective study. *Transpl Int.* 2021;34(1):87-96.
330. McVean J, Miller J. MiniMed(TM)780G Insulin pump system with smartphone connectivity for the treatment of type 1 diabetes: overview of its safety and efficacy. *Expert Rev Med Devices.* 2021;18(6):499-504.
331. McVey E, Hirsch L, Sutter DE, et al. Pharmacokinetics and postprandial glycemic excursions following insulin lispro delivered by intradermal microneedle or subcutaneous infusion. *J Diabetes Sci Technol.* 2012;6(4):743-754.
332. Meek CL, Oram RA, McDonald TJ, et al. Reappearance of C-Peptide During the Third Trimester of Pregnancy in Type 1 Diabetes: Pancreatic Regeneration or Fetal Hyperinsulinism? *Diabetes Care.* 2021;44(8):1826-1834.
333. Meek CL, Tundidor D, Feig DS, et al. Novel Biochemical Markers of Glycemia to Predict Pregnancy Outcomes in Women With Type 1 Diabetes. *Diabetes Care.* 2021;44(3):681-689.
334. Melmer A, Zuger T, Lewis DM, Leibrand S, Stettler C, Laimer M. Glycaemic control in individuals with type 1 diabetes using an open source artificial pancreas system (OpenAPS). *Diabetes Obes Metab.* 2019;21(10):2333-2337.
335. Messer LH, Berget C, Ernst A, Towers L, Slover RH, Forlenza GP. Initiating hybrid closed loop: A program evaluation of an educator-led Control-IQ follow-up at a large pediatric clinic. *Pediatr Diabetes.* 2021;22(4):586-593.
336. Messer LH, Berget C, Pyle L, et al. Real-World Use of a New Hybrid Closed Loop Improves Glycemic Control in Youth with Type 1 Diabetes. *Diabetes Technol Ther.* 2021;23(12):837-843.
337. Messer LH, Berget C, Vigers T, et al. Real world hybrid closed-loop discontinuation: Predictors and perceptions of youth discontinuing the 670G system in the first 6 months. *Pediatr Diabetes.* 2020;21(2):319-327.
338. Messer LH, Forlenza GP, Sherr JL, et al. Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System. *Diabetes Care.* 2018;41(4):789-796.
339. Mialon F, Catargi B, Rami L, et al. [Biomarkers in diabetes mellitus: contributions and discrepancies of new technologies. A case report]. *Ann Biol Clin (Paris).* 2021;79(5):445-451.
340. Michalak A, Pagacz K, Mlynarski W, Szadkowska A, Fendler W. Discrepancies between methods of continuous glucose monitoring in key metrics of glucose control in children with type 1 diabetes. *Pediatr Diabetes.* 2019;20(5):604-612.
341. Millson V, Hammond P. How to analyse CGM data: A structured and practical approach. 2020;24.
342. Monnier L, Colette C, Owens D. Application of medium-term metrics for assessing glucose homoeostasis: Usefulness, strengths and weaknesses. *Diabetes Metab.* 2021;47(2):101173.
343. Morandi A, Corradi M, Orsi S, et al. Oxidative stress in youth with type 1 diabetes: Not only a matter of gender, age, and glycemic control. *Diabetes Res Clin Pract.* 2021;179:109007.
344. Moreno-Fernandez J, Garcia-Seco JA. Commercialized Hybrid Closed-Loop System (Minimed Medtronic 670G) Results During Pregnancy. *AACE Clin Case Rep.* 2021;7(3):177-179.
345. Moscardo V, Diez JL, Bondia J. Parallel Control of an Artificial Pancreas with Coordinated Insulin, Glucagon, and Rescue Carbohydrate Control Actions. *J Diabetes Sci Technol.* 2019;13(6):1026-1034.
346. Moscardo V, Herrero P, Reddy M, Hill NR, Georgiou P, Oliver N. Assessment of Glucose Control Metrics by Discriminant Ratio. *Diabetes Technol Ther.* 2020;22(10):719-726.
347. Moser O, Dietrich M, McCarthy O, Bracken RM, Eckstein ML. Bolus insulin dose depends on previous-day race intensity during 5 days of professional road-cycle racing in athletes with type 1 diabetes: A prospective observational study. *Diabetes Obes Metab.* 2020;22(10):1714-1721.
348. Moser O, Mueller A, Eckstein ML, et al. Improved glycaemic variability and basal insulin dose reduction during a running competition in recreationally active adults with type 1 diabetes-A single-centre, prospective, controlled observational study. *PLoS One.* 2020;15(9):e0239091.
349. Murphy HR. Continuous glucose monitoring targets in type 1 diabetes pregnancy: every 5% time in range matters. *Diabetologia.* 2019;62(7):1123-1128.
350. Musso G, Gambino R, Cassader M, Paschetta E. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials. *BMJ.* 2019;365:l1328.
351. Napoli A. Insulin Therapy and Diabetic Pregnancy. *Am J Ther.* 2020;27(1):e91-e105.

352. Neuman V, Plachy L, Pruhova S, et al. Low-Carbohydrate Diet among Children with Type 1 Diabetes: A Multi-Center Study. *Nutrients.* 2021;13(11).
353. Nimri R, Grosman B, Roy A, et al. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses. *Diabetes Technol Ther.* 2021;23(4):268-276.
354. Nusca A, Bernardini F, Mangiacapra F, et al. Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study. *J Diabetes Res.* 2021;2021:4952447.
355. Nwosu BU, Yeasmin S, Ayyoub S, et al. Continuous glucose monitoring reduces pubertal hyperglycemia of type 1 diabetes. *J Pediatr Endocrinol Metab.* 2020;33(7):865-872.
356. O'Malley G, Messer LH, Levy CJ, et al. Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical Trial. *Diabetes Technol Ther.* 2021;23(4):245-252.
357. O'Malley G, Ozaslan B, Levy CJ, et al. Longitudinal Observation of Insulin Use and Glucose Sensor Metrics in Pregnant Women with Type 1 Diabetes Using Continuous Glucose Monitors and Insulin Pumps: The LOIS-P Study. *Diabetes Technol Ther.* 2021;23(12):807-817.
358. Ogawa W, Hirota Y, Osonoi T, et al. Effect of the FreeStyle Libre flash glucose monitoring system on glycemic control in individuals with type 2 diabetes treated with basal-bolus insulin therapy: An open label, prospective, multicenter trial in Japan. *J Diabetes Investig.* 2021;12(1):82-90.
359. Ohara M, Nagaike H, Fujikawa T, et al. Effects of omarigliptin on glucose variability and oxidative stress in type 2 diabetes patients: A prospective study. *Diabetes Res Clin Pract.* 2021;179:108999.
360. Omar AS, Salama A, Allam M, et al. Association of time in blood glucose range with outcomes following cardiac surgery. *BMC Anesthesiol.* 2015;15:14.
361. Pan J, Xu Y, Chen S, et al. The Effectiveness of Traditional Chinese Medicine Jinlida Granules on Glycemic Variability in Newly Diagnosed Type 2 Diabetes: A Double-Blinded, Randomized Trial. *J Diabetes Res.* 2021;2021:6303063.
362. Pankowska E, Ladyzynski P, Foltynski P, Mazurczak K. A Randomized Controlled Study of an Insulin Dosing Application That Uses Recognition and Meal Bolus Estimations. *J Diabetes Sci Technol.* 2017;11(1):43-49.
363. Parise M, Tartaglione L, Cutruzzola A, et al. Teleassistance for Patients With Type 1 Diabetes During the COVID-19 Pandemic: Results of a Pilot Study. *J Med Internet Res.* 2021;23(4):e24552.
364. Pease A, Lo C, Earnest A, Kiriakova V, Liew D, Zoungas S. Time in Range for Multiple Technologies in Type 1 Diabetes: A Systematic Review and Network Meta-analysis. *Diabetes Care.* 2020;43(8):1967-1975.
365. Peng J, Lu J, Ma X, et al. Breakfast replacement with a liquid formula improves glycaemic variability in patients with type 2 diabetes: a randomised clinical trial. *Br J Nutr.* 2019;121(5):560-566.
366. Petersson J, Akesson K, Sundberg F, Sarnblad S. Translating glycated hemoglobin A1c into time spent in glucose target range: A multicenter study. *Pediatr Diabetes.* 2019;20(3):339-344.
367. Petrie JR, Peters AL, Bergenstal RM, Holl RW, Fleming GA, Heinemann L. Improving the clinical value and utility of CGM systems: issues and recommendations : A joint statement of the European Association for the Study of Diabetes and the American Diabetes Association Diabetes Technology Working Group. *Diabetologia.* 2017;60(12):2319-2328.
368. Petrovski G, Al Khalaf F, Campbell J, Fisher H, Umer F, Hussain K. 10-Day structured initiation protocol from multiple daily injection to hybrid closed-loop system in children and adolescents with type 1 diabetes. *Acta Diabetol.* 2020;57(6):681-687.
369. Petrovski G, Al Khalaf F, Hussain K, Campbell J. Optimizing a Hybrid Closed Loop System in Type 1 Diabetes: A Case Report. *Diabetes Ther.* 2018;9(5):2173-2177.
370. Petrovski G, Campbell J, Almajali D, Al Khalaf F, Hussain K. Successful Initiation of Hybrid Closed-Loop System Using Virtual Pump Training Program in a Teenager With Type 1 Diabetes Previously Treated with Multiple Daily Injections. *J Diabetes Sci Technol.* 2021;15(6):1394-1398.
371. Petrovski G, Campbell J, Almajali D, Al Khalaf F, Hussain K. Successful Initiation of Hybrid Closed-Loop System Using Virtual Pump Training Program in a Teenager With Type 1 Diabetes Previously Treated with Multiple Daily Injections. *J Diabetes Sci Technol.* 2021;15(6):1394-1398.

372. Petruzelkova L, Jiranova P, Soupal J, et al. Pre-school and school-aged children benefit from the switch from a sensor-augmented pump to an AndroidAPS hybrid closed loop: A retrospective analysis. *Pediatr Diabetes.* 2021;22(4):594-604.
373. Pettus J, Gill J, Paranjape S, et al. Efficacy and safety of a morning injection of insulin glargine 300 units/mL versus insulin glargine 100 units/mL in adult patients with type 1 diabetes: A multicentre, randomized controlled trial using continuous glucose monitoring. *Diabetes Obes Metab.* 2019;21(8):1906-1913.
374. Pettus JH, Kushner JA, Valentine V, et al. Adjunct Therapy in Type 1 Diabetes: A Survey to Uncover Unmet Needs and Patient Preferences Beyond HbA1c Measures. *Diabetes Technol Ther.* 2019;21(6):336-343.
375. Piccini B, Pessina B, Pezzoli F, Casalini E, Toni S. COVID-19 vaccination in adolescents and young adults with type 1 diabetes: Glycemic control and side effects. *Pediatr Diabetes.* 2021;23(4):469-472.
376. Pietrzak I, Szadkowska A. Ultrafast acting insulin analog - a new way to prevent postprandial hyperglycemia and improve quality of life in type 1 diabetes patients - case reports. *Pediatr Endocrinol Diabetes Metab.* 2021;27(4):305-310.
377. Pinheiro SL, Bastos M, Barros L, Melo M, Paiva I. Flash glucose monitoring and glycemic control in type 1 diabetes with subcutaneous insulin infusion. *Acta Diabetol.* 2021;59(4):509-515.
378. Pinsker JE, Leas S, Muller L, Habif S. Real-World Improvements in Hypoglycemia in an Insulin-Dependent Cohort With Diabetes Mellitus Pre/Post Tandem Basal-Iq Technology Remote Software Update. *Endocr Pract.* 2020;26(7):714-721.
379. Pinsker JE, Lee JB, Dassau E, et al. Randomized Crossover Comparison of Personalized MPC and PID Control Algorithms for the Artificial Pancreas. *Diabetes Care.* 2016;39(7):1135-1142.
380. Pinsker JE, Muller L, Constantin A, et al. Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology. *Diabetes Technol Ther.* 2021;23(2):120-127.
381. Pinsker JE, Singh H, McElwee Malloy M, et al. A Virtual Training Program for the Tandem t:slim X2 Insulin Pump: Implementation and Outcomes. *Diabetes Technol Ther.* 2021;23(6):467-470.
382. Pla B, Arranz A, Knott C, et al. Impact of COVID-19 Lockdown on Glycemic Control in Adults with Type 1 Diabetes Mellitus. *J Endocr Soc.* 2020;4(12):bvaa149.
383. Pleus S, Kamecke U, Waldenmaier D, et al. Time in Specific Glucose Ranges, Glucose Management Indicator, and Glycemic Variability: Impact of Continuous Glucose Monitoring (CGM) System Model and Sensor on CGM Metrics. *J Diabetes Sci Technol.* 2021;15(5):1104-1110.
384. Pleus S, Kamecke U, Waldenmaier D, et al. Time in Specific Glucose Ranges, Glucose Management Indicator, and Glycemic Variability: Impact of Continuous Glucose Monitoring (CGM) System Model and Sensor on CGM Metrics. *J Diabetes Sci Technol.* 2021;15(5):1104-1110.
385. Polonsky WH, Fortmann AL. The influence of time in range on daily mood in adults with type 1 diabetes. *J Diabetes Complications.* 2020;34(12):107746.
386. Polsky S, Akturk HK. Case series of a hybrid closed-loop system used in pregnancies in clinical practice. *Diabetes Metab Res Rev.* 2020;36(3):e3248.
387. Porcel-Chacon R, Antunez-Fernandez C, Mora Loro M, et al. Good Metabolic Control in Children with Type 1 Diabetes Mellitus: Does Glycated Hemoglobin Correlate with Interstitial Glucose Monitoring Using FreeStyle Libre? *J Clin Med.* 2021;10(21).
388. Prabhu Navis J, Leelarathna L, Mubita W, et al. Impact of COVID-19 lockdown on flash and real-time glucose sensor users with type 1 diabetes in England. *Acta Diabetol.* 2021;58(2):231-237.
389. Preau Y, Armand M, Galie S, Schaepelynck P, Raccah D. Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices. *Diabetes Technol Ther.* 2021;23(4):259-267.
390. Preau Y, Galie S, Schaepelynck P, Armand M, Raccah D. Benefits of a Switch from Intermittently Scanned Continuous Glucose Monitoring (isCGM) to Real-Time (rt) CGM in Diabetes Type 1 Suboptimal Controlled Patients in Real-Life: A One-Year Prospective Study (section sign). *Sensors (Basel).* 2021;21(18).

391. Predieri B, Leo F, Candia F, et al. Glycemic Control Improvement in Italian Children and Adolescents With Type 1 Diabetes Followed Through Telemedicine During Lockdown Due to the COVID-19 Pandemic. *Front Endocrinol (Lausanne).* 2020;11:595735.
392. Preiser JC, Lheureux O, Thooft A, Brimioulle S, Goldstein J, Vincent JL. Near-Continuous Glucose Monitoring Makes Glycemic Control Safer in ICU Patients. *Crit Care Med.* 2018;46(8):1224-1229.
393. Prentice JC, Mohr DC, Zhang L, et al. Increased Hemoglobin A1c Time in Range Reduces Adverse Health Outcomes in Older Adults With Diabetes. *Diabetes Care.* 2021;44(8):1750-1756.
394. Price DA, Deng Q, Kipnes M, Beck SE. Episodic Real-Time CGM Use in Adults with Type 2 Diabetes: Results of a Pilot Randomized Controlled Trial. *Diabetes Ther.* 2021;12(7):2089-2099.
395. Puhr S, Calhoun P, Welsh JB, Walker TC. The Effect of Reduced Self-Monitored Blood Glucose Testing After Adoption of Continuous Glucose Monitoring on Hemoglobin A1c and Time in Range. *Diabetes Technol Ther.* 2018;20(8):557-560.
396. Puhr S, Derdzinski M, Welsh JB, Parker AS, Walker T, Price DA. Real-World Hypoglycemia Avoidance with a Continuous Glucose Monitoring System's Predictive Low Glucose Alert. *Diabetes Technol Ther.* 2019;21(4):155-158.
397. Pulkkinen MA, Tuomaala AK, Hero M, Gordin D, Sarkola T. Motivational Interview to improve vascular health in Adolescents with poorly controlled type 1 Diabetes (MIAD): a randomized controlled trial. *BMJ Open Diabetes Res Care.* 2020;8(1).
398. Rachmiel M, Lebenthal Y, Mazor-Aronovitch K, et al. Glycaemic control in the paediatric and young adult population with type 1 diabetes following a single telehealth visit - what have we learned from the COVID-19 lockdown? *Acta Diabetol.* 2021;58(6):697-705.
399. Rama Chandran S, Jacob P, Choudhary P. Baseline Glucose Variability and Interweek Variability Affects the Time to Stability of Continuous Glucose Monitoring-Derived Glycemic Indices. *Diabetes Technol Ther.* 2020;22(12):937-942.
400. Rama Chandran S, Zaremba N, Harrison A, et al. Disordered eating in women with type 1 diabetes: Continuous glucose monitoring reveals the complex interactions of glycaemia, self-care behaviour and emotion. *Diabet Med.* 2021;38(2):e14446.
401. Ramirez-Mendoza F, Gonzalez JE, Gasca E, et al. Time in range and HbA1C after 6 months with a multidisciplinary program for children and adolescents with diabetes mellitus, real world data from Mexico City. *Pediatr Diabetes.* 2020;21(1):61-68.
402. Ramkissoon CM, Bertachi A, Beneyto A, Bondia J, Vehi J. Detection and Control of Unannounced Exercise in the Artificial Pancreas Without Additional Physiological Signals. *IEEE J Biomed Health Inform.* 2020;24(1):259-267.
403. Ranjan A, Rosenlund S, Hansen TW, Rossing P, Andersen S, NØRgaard K. 28-LB: Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pump–Treated Type 1 Diabetes. *Diabetes.* 2020;69(1).
404. Ranjan AG, Rosenlund SV, Hansen TW, Rossing P, Andersen S, Norgaard K. Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes. *Diabetes Care.* 2020;43(11):2882-2885.
405. Ravi SJ, Coakley A, Vigers T, Pyle L, Forlenza GP, Alonso T. Pediatric Medicaid Patients With Type 1 Diabetes Benefit From Continuous Glucose Monitor Technology. *J Diabetes Sci Technol.* 2021;15(3):630-635.
406. Ravi SJ, Coakley A, Vigers T, Pyle L, Forlenza GP, Alonso T. Pediatric Medicaid Patients With Type 1 Diabetes Benefit From Continuous Glucose Monitor Technology. *J Diabetes Sci Technol.* 2021;15(3):630-635.
407. Reddy R, Wittenberg A, Castle JR, et al. Effect of Aerobic and Resistance Exercise on Glycemic Control in Adults With Type 1 Diabetes. *Can J Diabetes.* 2019;43(6):406-414 e401.
408. Renard E, Tubiana-Rufi N, Bonnemaison E, et al. Outcomes of hybrid closed-loop insulin delivery activated 24/7 versus evening and night in free-living prepubertal children with type 1 diabetes: A multicentre, randomized clinical trial. *Diabetes Obes Metab.* 2021;24(3):511-521.
409. Renard E, Tubiana-Rufi N, Bonnemaison E, et al. Outcomes of hybrid closed-loop insulin delivery activated 24/7 versus evening and night in free-living prepubertal children with type 1 diabetes: A multicentre, randomized clinical trial. *Diabetes Obes Metab.* 2021;24(3):511-521.
410. Ribeiro RT, Andrade R, Nascimento do OD, Lopes AF, Raposo JF. Impact of blinded retrospective continuous glucose monitoring on clinical decision making and glycemic control in

persons with type 2 diabetes on insulin therapy. *Nutr Metab Cardiovasc Dis.* 2021;31(4):1267-1275.
411. Rickels MR, Evans-Molina C, Bahnson HT, et al. High residual C-peptide likely contributes to glycemic control in type 1 diabetes. *J Clin Invest.* 2020;130(4):1850-1862.
412. Riddell MC, Li Z, Beck RW, et al. More Time in Glucose Range During Exercise Days than Sedentary Days in Adults Living with Type 1 Diabetes. *Diabetes Technol Ther.* 2021;23(5):376-383.
413. Righy Shinotsuka C, Brasseur A, Fagnoul D, So T, Vincent JL, Preiser JC. Manual versus Automated moNitoring Accuracy of GlucosE II (MANAGE II). *Crit Care.* 2016;20(1):380.
414. Rodbard D. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. *Diabetes Technol Ther.* 2017;19(S3):S25-S37.
415. Rodbard D. Metrics to Evaluate Quality of Glycemic Control: Comparison of Time in Target, Hypoglycemic, and Hyperglycemic Ranges with "Risk Indices". *Diabetes Technol Ther.* 2018;20(5):325-334.
416. Rodbard D. Glucose Time In Range, Time Above Range, and Time Below Range Depend on Mean or Median Glucose or HbA1c, Glucose Coefficient of Variation, and Shape of the Glucose Distribution. *Diabetes Technol Ther.* 2020;22(7):492-500.
417. Rodbard D. Quality of Glycemic Control: Assessment Using Relationships Between Metrics for Safety and Efficacy. *Diabetes Technol Ther.* 2021;23(10):692-704.
418. Rodbard D. The Ambulatory Glucose Profile: Opportunities for Enhancement. *Diabetes Technol Ther.* 2021;23(5):332-341.
419. Rodrigues R, Rossi ICB, Rossi BF, Gomes DC, Penha-Silva N. New glycemic metrics and traditional clinical and laboratory profiles of children and adolescents with type 1 diabetes mellitus in an outpatient follow-up. *Diabetes Res Clin Pract.* 2021;173:108680.
420. Rosenstock J, Marquard J, Laffel LM, et al. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials. *Diabetes Care.* 2018;41(12):2560-2569.
421. Rossetti P, Quiros C, Moscardo V, et al. Closed-Loop Control of Postprandial Glycemia Using an Insulin-on-Board Limitation Through Continuous Action on Glucose Target. *Diabetes Technol Ther.* 2017;19(6):355-362.
422. Roversi C, Vettoretti M, Del Favero S, Facchinetti A, Choudhary P, Sparacino G. Impact of Carbohydrate Counting Error on Glycemic Control in Open-Loop Management of Type 1 Diabetes: Quantitative Assessment Through an in silico Trial. *J Diabetes Sci Technol.* 2021:19322968211012392.
423. Rowe CW, Watkins B, Brown K, et al. Efficacy and safety of the pregnancy-IVI, an intravenous insulin protocol for pregnancy, following antenatal betamethasone in type 1 and type 2 diabetes. *Diabet Med.* 2021;38(4):e14489.
424. Ruan Y, Zhong J, Chen R, et al. Association of Body Fat Percentage with Time in Range Generated by Continuous Glucose Monitoring during Continuous Subcutaneous Insulin Infusion Therapy in Type 2 Diabetes. *J Diabetes Res.* 2021;2021:5551216.
425. Runge A, Kennedy L, Brown A, et al. Does Time-in-Range Matter? Perspectives from People with Diabetes on the Success of Current Therapies and Drivers of Improved Outcomes. 2017;66.
426. Runge AS, Kennedy L, Brown AS, et al. Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes. *Clin Diabetes.* 2018;36(2):112-119.
427. Saboo B, Kesavadev J, Shankar A, et al. Time-in-range as a target in type 2 diabetes: An urgent need. *Heliyon.* 2021;7(1):e05967.
428. Sakai T, Aoyama K, Inazumi K, et al. Time in range correlates glycated albumin measured immediately after 2weeks of continuous glucose monitoring. *J Diabetes Complications.* 2021;35(8):107962.
429. Salehi P, Roberts AJ, Kim GJ. Efficacy and Safety of Real-Life Usage of MiniMed 670G Automode in Children with Type 1 Diabetes Less than 7 Years Old. *Diabetes Technol Ther.* 2019;21(8):448-451.
430. Sampaio CR, Franco DR, Goldberg DJ, Baptista J, Eliaschewitz FG. Glucose control in acute myocardial infarction: a pilot randomized study controlled by continuous glucose monitoring system comparing the use of insulin glargine with standard of care. *Diabetes Technol Ther.* 2012;14(2):117-124.

431. Sanchez Conejero M, Gonzalez de Buitrago Amigo J, Tejado Bravo ML, de Nicolas Jimenez JM. [Impact of COVID-19 lockdown on glucemic control in children and adolescents with type 1 diabetes mellitus]. *An Pediatr (Engl Ed).* 2021.
432. Sanchez P, Ghosh-Dastidar S, Tweden KS, Kaufman FR. Real-World Data from the First U.S. Commercial Users of an Implantable Continuous Glucose Sensor. *Diabetes Technol Ther.* 2019;21(12):677-681.
433. Sandig D, Grimsmann J, Reinauer C, et al. Continuous Glucose Monitoring in Adults with Type 1 Diabetes: Real-World Data from the German/Austrian Prospective Diabetes Follow-Up Registry. *Diabetes Technol Ther.* 2020;22(8):602-612.
434. Schoelwer MJ, Kanapka LG, Wadwa RP, et al. Predictors of Time-in-Range (70-180 mg/dL) Achieved Using a Closed-Loop Control System. *Diabetes Technol Ther.* 2021;23(7):475-481.
435. Schoelwer MJ, Robic JL, Gautier T, et al. Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type 1 Diabetes. *Diabetes Technol Ther.* 2020;22(8):594-601.
436. Secher AL, Pedersen-Bjergaard U, Svendsen OL, et al. Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26 week randomised, controlled, multicentre trial. *Diabetologia.* 2021;64(12):2713-2724.
437. Sehgal S, De Bock M, Williman J, et al. Study protocol: Safety and efficacy of smart watch integrated do-it-yourself continuous glucose monitoring in adults with Type 1 diabetes, a randomised controlled trial. *J Diabetes Metab Disord.* 2021;20(2):2103-2113.
438. Sekiguchi S, Yamada E, Nakajima Y, et al. The Optimal "Time in Range" and "Time below Range" are Difficult to Coordinate in Patients with Type 1 Diabetes. *Tohoku J Exp Med.* 2021;255(3):221-227.
439. Selvin E. The Prognostic Value of Time in Range in Type 2 Diabetes. *Diabetes Care.* 2021;44(2):319-320.
440. Selvin E, Wang D, Tang O, Minotti M, Echouffo-Tcheugui JB, Coresh J. Glucose Patterns in Very Old Adults: A Pilot Study in a Community-Based Population. *Diabetes Technol Ther.* 2021;23(11):737-744.
441. Senior P, Lam A, Farnsworth K, Perkins B, Rabasa-Lhoret R. Assessment of Risks and Benefits of Beta Cell Replacement Versus Automated Insulin Delivery Systems for Type 1 Diabetes. *Curr Diab Rep.* 2020;20(10):52.
442. Shah NA, Levy CJ. Emerging technologies for the management of type 2 diabetes mellitus. *J Diabetes.* 2021;13(9):713-724.
443. Shah VN, Akturk HK, Joseph H, Schneider N, Snell-Bergeon JK. A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec. *Diabetes Obes Metab.* 2021;23(8):1936-1941.
444. Shah VN, Snell-Bergeon JK, Demmitt JK, et al. Relationship Between Time-in-Range, HbA1c, and the Glucose Management Indicator in Pregnancies Complicated by Type 1 Diabetes. *Diabetes Technol Ther.* 2021;23(12):783-790.
445. Shamanna P, Saboo B, Damodharan S, et al. Reducing HbA1c in Type 2 Diabetes Using Digital Twin Technology-Enabled Precision Nutrition: A Retrospective Analysis. *Diabetes Ther.* 2020;11(11):2703-2714.
446. Shen Y, Fan X, Zhang L, et al. Thresholds of Glycemia and the Outcomes of COVID-19 Complicated With Diabetes: A Retrospective Exploratory Study Using Continuous Glucose Monitoring. *Diabetes Care.* 2021;44(4):976-982.
447. Sheng T, Offringa R, Kerr D, et al. Diabetes Healthcare Professionals Use Multiple Continuous Glucose Monitoring Data Indicators to Assess Glucose Management. *J Diabetes Sci Technol.* 2020;14(2):271-276.
448. Sheng T, Offringa R, Kerr D, et al. Diabetes Healthcare Professionals Use Multiple Continuous Glucose Monitoring Data Indicators to Assess Glucose Management. *J Diabetes Sci Technol.* 2020;14(2):271-276.
449. Sheng X, Xiong GH, Yu PF, Liu JP. The Correlation between Time in Range and Diabetic Microvascular Complications Utilizing Information Management Platform. *Int J Endocrinol.* 2020;2020:8879085.

450. Sherrill CH, Houpt CT, Dixon EM, Richter SJ. Professional continuous glucose monitoring: A retrospective cohort study comparing one vs two pharmacist-driven encounters. *Jaccp: Journal of the American College of Clinical Pharmacy.* 2021;4(7):785-792.
451. Shoda K, Kubota T, Ushigome E, et al. Dynamics of glucose levels after Billroth I versus Roux-en-Y reconstruction in patients who undergo distal gastrectomy. *Surg Today.* 2021;52(6):889-895.
452. Siegmund T, Ampudia-Blasco FJ, Schnell O. Two clinical cases of adjunctive use of a SGLT-2 inhibitor in type 1 diabetes. *Diabetes Res Clin Pract.* 2020;162:108131.
453. Simonson GD, Bergenstal RM, Johnson ML, Davidson JL, Martens TW. Effect of Professional CGM (pCGM) on Glucose Management in Type 2 Diabetes Patients in Primary Care. *J Diabetes Sci Technol.* 2021;15(3):539-545.
454. Singh LG, Satyarengga M, Marcano I, et al. Reducing Inpatient Hypoglycemia in the General Wards Using Real-time Continuous Glucose Monitoring: The Glucose Telemetry System, a Randomized Clinical Trial. *Diabetes Care.* 2020;43(11):2736-2743.
455. Slattery D, Choudhary P. Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes. *Diabetes Technol Ther.* 2017;19(S2):S55-S61.
456. Smith TA, Marlow AA, King BR, Smart CE. Insulin strategies for dietary fat and protein in type 1 diabetes: A systematic review. *Diabet Med.* 2021;38(11):e14641.
457. Sofizadeh S, Imberg H, Olafsdottir AF, et al. Effect of Liraglutide on Times in Glycaemic Ranges as Assessed by CGM for Type 2 Diabetes Patients Treated With Multiple Daily Insulin Injections. *Diabetes Ther.* 2019;10(6):2115-2130.
458. Sofizadeh S, Pehrsson A, Olafsdottir AF, Lind M. Evaluation of Reference Metrics for Continuous Glucose Monitoring in Persons Without Diabetes and Prediabetes. *J Diabetes Sci Technol.* 2021;16(2):373-382.
459. Soto-Mota A, Norwitz NG, Evans R, Clarke K, Barber TM. Exogenous ketosis in patients with type 2 diabetes: Safety, tolerability and effect on glycaemic control. *Endocrinol Diabetes Metab.* 2021;4(3):e00264.
460. Soupal J, Petruzelkova L, Grunberger G, Haskova A, Prazny M. Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study. 2020;43.
461. Stone JY, Bailey TS. Benefits and limitations of continuous glucose monitoring in type 1 diabetes. *Expert Rev Endocrinol Metab.* 2020;15(1):41-49.
462. Stone MP, Agrawal P, Chen X, et al. Retrospective Analysis of 3-Month Real-World Glucose Data After the MiniMed 670G System Commercial Launch. *Diabetes Technol Ther.* 2018;20(10):689-692.
463. Strategies to Enhance New CGMUiECSG. A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes. *Diabetes Care.* 2021;44(2):464-472.
464. Street TJ. Review of Self-Reported Data from UK Do-It-Yourself Artificial Pancreas System (DIYAPS) Users to Determine Whether Demographic of Population Affects Use or Outcomes. *Diabetes Ther.* 2021;12(7):1839-1848.
465. Suzuki D, Yamada H, Yoshida M, et al. Sodium-glucose cotransporter 2 inhibitors improved time-in-range without increasing hypoglycemia in Japanese patients with type 1 diabetes: A retrospective, single-center, pilot study. *J Diabetes Investig.* 2020;11(5):1230-1237.
466. Suzuki J, Urakami T, Yoshida K, et al. Association between scanning frequency of flash glucose monitoring and continuous glucose monitoring-derived glycemic makers in children and adolescents with type 1 diabetes. *Pediatr Int.* 2021;63(2):154-159.
467. Sylvetsky AC, Moore HR, Kaidbey JH, et al. Rationale and design of DRINK-T1D: A randomized clinical trial of effects of low-calorie sweetener restriction in children with type 1 diabetes. *Contemp Clin Trials.* 2021;106:106431.
468. Tan FHS, Tong CV, Tiong XT, et al. The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin. *J ASEAN Fed Endocr Soc.* 2021;36(2):167-171.

469. Tan FHS, Tong CV, Tiong XT, et al. The Effect of DPP4 Inhibitor on Glycemic Variability in Patients with Type 2 Diabetes treated with twice-daily Premixed Human Insulin. *J ASEAN Fed Endocr Soc.* 2021;36(2):167-171.
470. Thabit H, Prabhu JN, Mubita W, et al. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1c in a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study. *Diabetes Care.* 2020;43(10):2537-2543.
471. Thabit H, Prabhu JN, Mubita W, Fullwood C, Leelarathna L. Use of Factory-Calibrated Real-time Continuous Glucose Monitoring Improves Time in Target and HbA1cin a Multiethnic Cohort of Adolescents and Young Adults With Type 1 Diabetes: The MILLENNIALS Study. 2020;43.
472. Thewjitcharoen Y, Yenseung N, Malidaeng A, et al. Effectiveness of Insulin Degludec in Thai Patients with Diabetes Mellitus: Real-World Evidence From a Specialized Diabetes Center. *Exp Clin Endocrinol Diabetes.* 2021;129(9):666-673.
473. Thivolet C, Gaudilliere M, Villar Fimbel S, et al. Hybrid closed Loop improved glucose control compared to sensor-augmented pumps in outpatients with type 1 diabetes in real-life conditions with telehealth monitoring. *Acta Diabetol.* 2021;59(3):395-401.
474. Tinti D, Savastio S, Grosso C, et al. Impact of lockdown during COVID-19 emergency on glucose metrics of children and adolescents with type 1 diabetes in Piedmont, Italy. *Acta Diabetol.* 2021;58(7):959-961.
475. Tokutsu A, Okada Y, Mita T, et al. Relationship between blood glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics: Subanalysis of a prospective cohort study. *Diabetes Obes Metab.* 2021;24(1):82-93.
476. Tokutsu A, Okada Y, Torimoto K, Tanaka Y. Relationship between interstitial glucose variability in ambulatory glucose profile and standardized continuous glucose monitoring metrics; a pilot study. *Diabetol Metab Syndr.* 2020;12:70.
477. Tornese G, Ceconi V, Monasta L, Carletti C, Faleschini E, Barbi E. Glycemic Control in Type 1 Diabetes Mellitus During COVID-19 Quarantine and the Role of In-Home Physical Activity. *Diabetes Technol Ther.* 2020;22(6):462-467.
478. Tsuchiya T, Saisho Y, Murakami R, Watanabe Y, Inaishi J, Itoh H. Relationship between daily and visit-to-visit glycemic variability in patients with type 2 diabetes. *Endocr J.* 2020;67(8):877-881.
479. Tsuchiya T, Saisho Y, Murakami R, Watanabe Y, Inaishi J, Itoh H. Relationship between daily and visit-to-visit glycemic variability in patients with type 2 diabetes. *Endocr J.* 2020;67(8):877-881.
480. Tundidor D, Meek CL, Yamamoto J, et al. Continuous Glucose Monitoring Time-in-Range and HbA1c Targets in Pregnant Women with Type 1 Diabetes. *Diabetes Technol Ther.* 2021;23(10):710-714.
481. Tuomaala AK, Hero M, Tuomisto MT, et al. Motivational Interviewing and Glycemic Control in Adolescents With Poorly Controlled Type 1 Diabetes: A Randomized Controlled Pilot Trial. *Front Endocrinol (Lausanne).* 2021;12:639507.
482. Tweden KS, Deiss D, Rastogi R, Addaguduru S, Kaufman FR. Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor over Multiple Sensor Insertion and Removal Cycles. *Diabetes Technol Ther.* 2020;22(5):422-427.
483. Uemura F, Okada Y, Torimoto K, Tanaka Y. Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring. *Sci Rep.* 2021;11(1):4875.
484. Urai S, Hashimoto N, Takabe M, et al. Dynamic changes in insulin requirements with post-operative time using bedside artificial pancreas to maintain normoglycemia without hypoglycemia after cardiac surgery. *J Artif Organs.* 2021;25(1):72-81.
485. Urakami T, Yoshida K, Kuwabara R, et al. Significance of "Time below Range" as a Glycemic Marker Derived from Continuous Glucose Monitoring in Japanese Children and Adolescents with Type 1 Diabetes. *Horm Res Paediatr.* 2020;93(4):251-257.
486. Urakami T, Yoshida K, Kuwabara R, et al. Individualization of recommendations from the international consensus on continuous glucose monitoring-derived metrics in Japanese children and adolescents with type 1 diabetes. *Endocr J.* 2020;67(10):1055-1062.

487. Valenzano M, Cibrario Bertolotti I, Valenzano A, Grassi G. Time in range-A1c hemoglobin relationship in continuous glucose monitoring of type 1 diabetes: a real-world study. *BMJ Open Diabetes Res Care.* 2021;9(1).
488. van der Linden J, Welsh JB, Hirsch IB, Garg SK. Real-Time Continuous Glucose Monitoring During the Coronavirus Disease 2019 Pandemic and Its Impact on Time in Range. *Diabetes Technol Ther.* 2021;23(S1):S1-S7.
489. van der Linden J, Welsh JB, Walker TC. Sustainable Use of a Real-Time Continuous Glucose Monitoring System from 2018 to 2020. *Diabetes Technol Ther.* 2021;23(7):508-511.
490. Varghese JS, Ho JC, Anjana RM, et al. Profiles of Intraday Glucose in Type 2 Diabetes and Their Association with Complications: An Analysis of Continuous Glucose Monitoring Data. *Diabetes Technol Ther.* 2021;23(8):555-564.
491. Varimo T, Pulkkinen MA, Hakonen E, Hero M, Miettinen PJ, Tuomaala AK. First year on commercial hybrid closed-loop system-experience on 111 children and adolescents with type 1 diabetes. *Pediatr Diabetes.* 2021;22(6):909-915.
492. Vetrani C, Calabrese I, Cavagnuolo L, et al. Dietary determinants of postprandial blood glucose control in adults with type 1 diabetes on a hybrid closed-loop system. *Diabetologia.* 2021;65(1):79-87.
493. Vetrani C, Calabrese I, Di Rienzo S, et al. Dietary Changes During COVID-19 Lockdown in Adults With Type 1 Diabetes on a Hybrid Artificial Pancreas. *Front Public Health.* 2021;9:752161.
494. Vianna AGD, Lacerda CS, Pechmann LM, et al. Improved glycaemic variability and time in range with dapagliflozin versus gliclazide modified release among adults with type 2 diabetes, evaluated by continuous glucose monitoring: A 12-week randomized controlled trial. *Diabetes Obes Metab.* 2020;22(4):501-511.
495. Vigersky R. Escaping the A1c-Centric Role of Assessing Glycemic Control in Diabetes. *Diabetes Technol Ther.* 2016;18 (1):A1-139.
496. Vigersky RA. Going beyond HbA1c to understand the benefits of advanced diabetes therapies. *J Diabetes.* 2019;11(1):23-31.
497. Vigersky RA, McMahon C. The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes. *Diabetes Technol Ther.* 2019;21(2):81-85.
498. Visser MM, Charleer S, Fieuws S, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. *Lancet.* 2021;397(10291):2275-2283.
499. Vogt L, Thomas A, Fritzsche G, Heinke P, Kohnert KD, Salzsieder E. Model-Based Tool for Personalized Adjustment of Basal Insulin Supply in Patients With Intensified Conventional Insulin Therapy. *J Diabetes Sci Technol.* 2019;13(5):928-934.
500. Volcansek S, Lunder M, Janez A. Acceptability of Continuous Glucose Monitoring in Elderly Diabetes Patients Using Multiple Daily Insulin Injections. *Diabetes Technol Ther.* 2019;21(10):566-574.
501. Wang H, Zhou Y, Zhai X, et al. Evaluating Glycemic Control During Basalin or Lantus Administration in Adults With Controlled Type 2 Diabetes Mellitus Using Continuous Glucose Monitoring. *Front Endocrinol (Lausanne).* 2021;12:754820.
502. Wang L, Shi C, Yan H, et al. Acute Effects of Sleeve Gastrectomy on Glucose Variability, Glucose Metabolism, and Ghrelin Response. *Obes Surg.* 2021;31(9):4005-4014.
503. Welsh JB, Derdzinski M, Parker AS, Puhr S, Jimenez A, Walker T. Real-Time Sharing and Following of Continuous Glucose Monitoring Data in Youth. *Diabetes Ther.* 2019;10(2):751-755.
504. Wilhelm-Benartzi CS, Miller SE, Bruggraber S, et al. Study protocol: Minimum effective low dose: anti-human thymocyte globulin (MELD-ATG): phase II, dose ranging, efficacy study of antithymocyte globulin (ATG) within 6 weeks of diagnosis of type 1 diabetes. *BMJ Open.* 2021;11(12):e053669.
505. Wolnik B, Orlowska-Kunikowska E, Blaszkowska M, et al. The phenomenon of HbA1c stability and the risk of hypoglycemia in long-standing type 1 diabetes. *Diabetes Res Clin Pract.* 2019;152:96-102.
506. Wright EE, Jr., Morgan K, Fu DK, Wilkins N, Guffey WJ. Time in Range: How to Measure It, How to Report It, and Its Practical Application in Clinical Decision-Making. *Clin Diabetes.* 2020;38(5):439-448.

507. Wright LA, Hirsch IB. Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters. *Diabetes Technol Ther.* 2017;19(S2):S16-S26.
508. Wu X, Luo S, Zheng X, et al. Glycemic control in children and teenagers with type 1 diabetes around lockdown for COVID-19: A continuous glucose monitoring-based observational study. *J Diabetes Investig.* 2021;12(9):1708-1717.
509. Wu Z, Luo S, Zheng X, et al. Use of a do-it-yourself artificial pancreas system is associated with better glucose management and higher quality of life among adults with type 1 diabetes. *Ther Adv Endocrinol Metab.* 2020;11:2042018820950146.
510. Wylie TAF, Shah C, Burgess L, et al. Optimizing the use of technology to support people with diabetes: research recommendations from Diabetes UK's 2019 diabetes and technology workshop. *Diabet Med.* 2021;38(11):e14647.
511. Xu SY, KeLi, Zhang Z, et al. Association between time in range, a novel measurement of glycemic control and islet secretory function in chinese patients with type 2 diabetes mellitus-An observational study. *Diabetes Res Clin Pract.* 2021;173:108684.
512. Yamada E, Sekiguchi S, Nakajima Y, Uehara R, Okada S, Yamada M. Pitfalls of intermittent continuous glucose monitoring in patients with steroid diabetes. *Endocr J.* 2021;68(11):1367-1372.
513. Yamamoto JM, Corcoy R, Donovan LE, et al. Maternal glycaemic control and risk of neonatal hypoglycaemia in Type 1 diabetes pregnancy: a secondary analysis of the CONCEPTT trial. *Diabet Med.* 2019;36(8):1046-1053.
514. Yang J, Yang X, Zhao D, Wang X, Wei W, Yuan H. Association of time in range, as assessed by continuous glucose monitoring, with painful diabetic polyneuropathy. *J Diabetes Investig.* 2021;12(5):828-836.
515. Yeoh E, Png D, Koh PL, et al. Glucose Awareness to Motivate and Enable Solutions (GAMES) in diabetes mellitus using flash glucose monitoring: A clinical programme. *Diabet Med.* 2021;39(1):e14733.
516. Yesiltepe-Mutlu G, Capaci M, Can E, et al. A comparison of glycemic parameters and their relationship with C-peptide and Proinsulin levels during partial remission and non-remission periods in children with type 1 diabetes mellitus - a cross-sectional study. *BMC Endocr Disord.* 2021;21(1):18.
517. Yin J, Han M, Li L, et al. To Assess Liraglutide's Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System. *Diabetes Metab Syndr Obes.* 2021;14:4399-4407.
518. Ying L, Ma X, Lu J, et al. Fulminant type 1 diabetes: The clinical and continuous glucose monitoring characteristics in Chinese patients. *Clin Exp Pharmacol Physiol.* 2019;46(9):806-812.
519. Yoo JH, Choi MS, Ahn J, et al. Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes. *Diabetes Technol Ther.* 2020;22(10):768-776.
520. Yoo JH, Kim JH. Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control. *Diabetes Metab J.* 2020;44(6):828-839.
521. Yoo JH, Kim JH. Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control. *Diabetes Metab J.* 2021;45(5):795.
522. Zaharieva DP, McGaugh S, Pooni R, Vienneau T, Ly T, Riddell MC. Improved Open-Loop Glucose Control With Basal Insulin Reduction 90 Minutes Before Aerobic Exercise in Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion. *Diabetes Care.* 2019;42(5):824-831.
523. Zanfardino A, Confetto S, Curto S, et al. Demystifying the Pizza Bolus: The Effect of Dough Fermentation on Glycemic Response-A Sensor-Augmented Pump Intervention Trial in Children with Type 1 Diabetes Mellitus. *Diabetes Technol Ther.* 2019;21(12):721-726.
524. Zhang J, Yang J, Liu L, et al. Significant abnormal glycemic variability increased the risk for arrhythmias in elderly type 2 diabetic patients. *BMC Endocr Disord.* 2021;21(1):83.
525. Zhang W, Liu Y, Sun B, et al. Improved HbA1c and reduced glycaemic variability after 1-year intermittent use of flash glucose monitoring. *Sci Rep.* 2021;11(1):23950.
526. Zhao X, Zhang W, Xin S, Yu X, Zhang X. Effect of CPAP on blood glucose fluctuation in patients with type 2 diabetes mellitus and obstructive sleep apnea. *Sleep Breath.* 2021.

527. Zheng X, Qi Y, Bi L, et al. Effects of Exercise on Blood Glucose and Glycemic Variability in Type 2 Diabetic Patients with Dawn Phenomenon. *Biomed Res Int.* 2020;2020:6408724.
528. Zhu X, Zhao L, Chen J, et al. The Effect of Physical Activity on Glycemic Variability in Patients With Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Front Endocrinol (Lausanne).* 2021;12:767152.
529. Zisser H, Dassau E, Lee JJ, Harvey RA, Bevier W, Doyle FJ, 3rd. Clinical results of an automated artificial pancreas using technosphere inhaled insulin to mimic first-phase insulin secretion. *J Diabetes Sci Technol.* 2015;9(3):564-572.
530. Zisser HC, Dassau E, Harvey R, et al. Abstracts Clinical evaluation of an automated artificial pancreas using zone-model predictive control and health monitoring system. *Diabetes Technol Ther.* 2014;16(6): 348-357
531. Zueger T, Gloor M, Lehmann V, et al. White coat adherence effect on glucose control in adult individuals with diabetes. *Diabetes Res Clin Pract.* 2020;168:108392.

List of Included Conference Abstracts

1. Aanstoot HJ, Winterdijk P, Bovenberg S, et al. "Switching to a new advanced hybrid closed-loop system: improved time in range, sustained auto mode and better average glucose levels". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
2. Abraham M, Smith G, Fairchild J, et al. Predictors of glycaemic control and quality of life in adolescents with type 1 diabetes on contemporary management. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
3. Abraham MB, Smith G, DeBock M, et al. Optimization of data collection for accuracy of metrics used in continuous glucose monitoring to characterize glycemic outcomes. *Pediatr Diabetes.* 2021;22:4-105.
4. Abraham MB, Smith GJ, De Bock M, et al. Glycemic patterns derived from masked continuous glucose monitoring in adolescents with type 1 diabetes on contemporary management. *Diabetes.* 2019;68(Supplement_1).
5. Acciaroli G, Welsh J, Parker AS. Integration of a cgm system and a voicecontrolled virtual assistant. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
6. Adolfsson P, Hartvig NV, Kaas A, Knudsen NN, Ann-Charlotte M, Hellman J. Increased Time-in-Range (TIR) Observed after Introduction of a Connected Insulin Pen. *Diabetes.* 2019;68(Supplement_1).
7. Adolfsson P, Ogionwo-Lange E, Fredlund J, Björnsson V, Holmgren A, Helm N. Telemedicine as a supplement to regular visits - Evaluation via a multicenter randomized controlled study. *Pediatr Diabetes.* 2019;20(S28):232-254.
8. Agrawal P, Stone M, Cordero T, Lee S, Shin J, Kaufman F. Real-world use of the Minimed™ 670G hybrid closed-loop system. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
9. Akturk HK, Giordano DA, Joseph H, Garg SK, Snell-Bergeon JK. Improvement in Time-in-Range (TIR) with Real-Life Use of Hybrid Closed-Loop System in Patients with Type 1 Diabetes (T1D). *Diabetes.* 2019;68(Supplement_1).
10. Akturk HK, Snell-Bergeon JK, Beck EA, et al. Improved post-prandial blood glucose excursions with Technosphere inhaled insulin compared to aspart in adult patients with type 1 diabetes: STAT study intention to treat analysis. *Diabetologia.* 2018;61(Suppl 1):1-620.
11. Akturk HK, Snell-Bergeon JK, Rewers A, et al. Improved postprandial blood glucose (PPBG) excursions with technosphere inhaled insulin (TI) compared with aspart in T1D patients-stat study. 2018;67.
12. Al-Harbi M, Dunn T, Kao K, Brandner L, El Jammal M. Frequency of flash glucose monitoring in relation to glucose metrics: Real-world data from Saudi Arabia. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
13. Alamoudi R, Khogeer GS, Qarni AA, et al. Glargine timing during fasting ramadan in patients with type 1 diabetes: A randomized controlled trial. *Diabetes.* 2021;70(Supplement_1).
14. Aleppo G. Clinical Application of Time in Range and Other Metrics. *Diabetes Spectr.* 2021;34(2):109-118.
15. Allen NA, Litchman ML, Chamberlain J, Grigorian E, Iacob E, Berg C. Continuous glucose monitoring data sharing in older adults with type 1 diabetes and their care partners. *Diabetes.* 2021;70(Supplement_1).
16. Alobaid A, Dingena C, Marsh A, et al. Interrupted sitting improves acute postprandial glucose control without increasing risk of hypoglycaemia in people with type 1 diabetes. *Diabetologia.* 2020;63(Suppl 1):1-485.
17. Alonso Rubio P, Bahillo Curieses P, Murillo Vallés M, et al. Differences in glucose monitoring data and health-related quality of life in children and teenagers with type 1 diabetes according to glycemic control. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
18. Alwazeer MR, De Salvo DJ, McKay SV, et al. Daily consumption of almonds does not improve postprandial glucose excursion in pediatric type 1 diabetes (T1D). 2016;37.
19. Alzohaili O, Whelan S, Solaiman AY, Aldhalimy N, Abbott S, Shi L. Improved glycemic control in patients with type 2 diabetes switching to the v-go® insulin delivery device: A prospective study utilizing continuous glucose monitoring. *Diabetes.* 2016;65(Supplement_1):A221-A360.

20. Amadou C, Franc S, Benhamou PY, et al. "Diabeloop closed-loop system allows patients with type 1 diabetes (T1D) to significantly improve their glycemic control in real-life situation, without serious adverse events: A 6-month follow-up". *Diabetes.* 2020;69(Supplement_1).
21. Ambrojo-López A, Gallego-Gamero F, Fernandez-Bueso MM, Arroyo-Díez F, Romero-Pérez MDM, Beato-Víbora P. Sustained benefit of hybrrid closed loop system on glycaemic control after one year of use in children and adults with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
22. Ambrosino JM, McElwee-Malloy M, Habif S. Improvement in hypoglycemia outcomes in pediatric population using predictive low-glucose suspend (PLGS): Basal-IQ system real-world data. *Pediatr Diabetes.* 2019;20(S28):41-231.
23. Amuedo-Domínguez S, Guerrero-Vázquez R, Gros-Herguido N, et al. Clinical impact in real life of flash glucose monitoring in adolescents with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
24. Aronson R, Brown RE, Abitbol A, et al. Current state of type 1 diabetes in adults: Data from The Canadian LMC diabetes registry. *Diabetes.* 2019;68(Supplement_1).
25. Aronson R, Li A, Brown RE, McGaugh S, Yavelberg L, Riddell M. Flexible insulin therapy: Untethered insulin regimen using insulin degludec and continuous subcutaneous insulin infusion (CSII) in avidly exercising patients with T1D: Fit untethered study. *Diabetes.* 2019;68(Supplement_1).
26. Arroyo Ruiz R, Alonso Diez C, Roux Rodriguez A, Prieto Matos P, Bajo Delgado AF, Martin Alonso M. Effectiveness and security of advanced hybrid closed loop system. *Pediatric Diabetes.* 2021;22(S30):33-165.
27. Arunachalam S, Zhong A, Agrawal P, Velado K, Cordero TL, Vigersky RA. Hypoglycemia rate during real-world use of the iqcast feature in the guardian™ connect cgm system. *Journal of Diabetes Science and Technology.* 2020;14(2):361-492.
28. Ata A, Ar G, I??klar H, et al. The effect of diabetes camp on glycemic variability in children and adolescents with type 1 diabetes mellitus. *The Journal of Pediatric Research.* 2021;8(3):303-308.
29. Autoren Edwards SS, He X, Johnson J, et al. "Key differences with hypoglycaemic fear in people using insulin: the association with missed bolus doses exists for T2 D, but not T1D". 2021;16.
30. Autoren Moser O, Weilguni B, Tauschmann M, Aziz F, Sourij H, Eckstein M. Comparison of time in range for closed-loop systems versus current care during physical exercise in type 1 diabetes: A systematic review and meta-analysis. 2021;16.
31. Avari P, Leal Y, Wos M, et al. Efficacy and safety of the patient empowerment through predictive personalised decision support (PEPPER) system: An open-label randomised controlled trial. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
32. Avari P, Leal Y, Wos M, et al. Feasibility of safety system within a novel personalised decision support tool for insulin dosing. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
33. Avari P, Moscardo V, Jugnee N, Reddy M, Oliver N. Ambulatory glucose profiling and glycaemic outcomes when switching flash to continuous glucose monitoring: The i-hart cgm study. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
34. Avari P, Unsworth R, Rilstone S, et al. Higher levels of social deprivation associated with increased percentage time in range in people with type 1 diabetes during COVID-19 lockdown. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
35. Avari P, Unsworth R, Uduku C, et al. Improved glycaemia during the COVID-19 lockdown is sustained in adults with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
36. Axelrod C, Castorino KN, Bevier WC, et al. Comparison of two approaches to basal insulin management for adults with type 1 diabetes flying across multiple time zones. *Diabetes.* 2020;69(Supplement_1).
37. Babikian S, Singh V, Clements M. Insulin pump usage patterns among persons with diabetes (PWD) predict deteriorating sensor-based glucose control 2-4 weeks following clinic visits: A machine learning model. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
38. Baidal D, Alvarez Gil AM, Padilla N, Ricordi C, Alejandro R. Continuous glucose monitoring metrics in islet transplant recipients with long-term insulin independence. *Diabetes.* 2019;68(Supplement_1).

39. Bajaj H, Chu L, Bansal N, et al. 65 - Randomized Comparison of Initiating Insulin Glargine or Iglarlixi in South Asian Canadians With Type 2 Diabetes: VARIATION 2 SA Trial. *Canadian Journal of Diabetes.* 2020;44(7).
40. Bajaj H, Isendahl J, Gowda A, Stachlewska K, Rosenstock J. "Efficacy and safety of switching to insulin icodec, a once-weekly basal insulin, vs insulin glargine U100 in patients with type 2 diabetes inadequately controlled on OADs and basal insulin". *Diabetologia.* 2020;63(Suppl 1):1-485.
41. Bajaj HS, Beck Bang R, Gowda A, Koefoed MM, Senior PA, Bergenstal RM. CGM-based measurements for once-weekly insulin Icodec vs. Once-daily insulin glargine U100 in insulin-treated patients with T2D: A post-hoc analysis. *Diabetes.* 2021;70(Supplement_1).
42. Barsamyan G, Da Silva A, Whyte L, Amole M, Ghayee H, Leey JA. Utilization of continuous glucose monitoring (CGM) and its impact on the care of veterans. *Diabetes.* 2020;69(Supplement_1).
43. Bartee A, Brazg RL, Katz M, Lalonde A, Wolpert H, Jones R. Automated insulin delivery (AID) system performance with and without meal announcement: Effect of meal macronutrient content. *Diabetes.* 2020;69(Supplement_1).
44. Bartee A, Lalonde A, Katz M, et al. Performance of the lilly automated insulin delivery (AID) system: Results of early phase feasibility study. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
45. Bashir B, Urwin A, Chapman A, et al. Transitioning from basal IQ predictive low glucose suspend to control IQ hybrid closed-loop therapy increases time in range and reduces hypoglycaemia burden in adults with type 1 diabetes: A real-world observational study. *Diabetic Medicine.* 2021;38(S1).
46. Basson-Shleymovich Y, Cukierman-Yaffe T, Yahalom-Peri T, Azmon M, Peltz-Sinvani N. "The association between time-in-range %, measured by continuous glucose monitoring (CGM) and physical and functional indices amongst older people with type 2 diabetes: A crosssectional study". *Diabetes.* 2021;70(Supplement_1).
47. Basson-Shleymovich Y, Cukierman-Yaffe T, Yahalom-Peri T, Azmon M, Peltz-Sinvani N. "The association between time in range %, measured by continuous glucose monitoring (CGM) and physical & functional indices amongst older people with type 2 diabetes". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
48. Battelino T, Danne T, Phillip M. CGM-based clinical targets: Recommendations from the international consensus on time-in-range (TIR). *Diabetes.* 2019;68(Supplement_1).
49. Bazdarska Y, Iotova V, Galcheva S, et al. "Connections between time in range, hyperglycemia, estimated HbA1c and laboratory conventionally measured HbA1c in children with type 1 diabetes (T1D) on sensor-augmented pump treatment". *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
50. Bazdarska Y, Iotova V, Mladenov V, Boyadzhiev V, Stoicheva R, Galcheva S. Advantages from "do-it-yourself" loops among children and adolescents at Varna's diabetes center. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
51. Beato Ví-bora PI, Gallego-Gamero F, Lázaro-Martín L, Romero-Pérez M, Arroyo-Díez F. "Prospective evaluation of the impact of hybrid closed-loop system on glycaemic control, glycaemic variability and patient-related outcomes in children and adults in spain". *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
52. Beato Vibora PI, Gallego-Gamero F, Lázaro-Martín L, Romero-Pérez M, Arroyo-Díez F. Clinical outcomes after 6 months of use of hybrid closed loop system in children and adults. *Diabetologia.* 2020;63(Suppl 1):1-485.
53. Beato-Víbora P, Lázaro-Martín L, Gallego-Gamero F. Glycaemic variability and time in range in type 1 diabetes patients on real time continuous glucose monitoring and insulin injections versus sensoraugmented insulin pump therapy. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
54. Beato-Víbora P, Quirós-López C, Lázaro-Martín L, et al. Predictors of an increased time in range in type 1 diabetes patients on sensoraugmented insulin pump with predictive low-glucose suspend function: A realworld data analysis. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
55. Beato-Víbora PI, Gallego-Gamero F, Ambrojo-López A, et al. Rapid improvement in time in range after advanced hybrid closed-loop system initiation. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.

56. Beck R. Time in range as an outcome in clinical trials. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
57. Beck R. Time in range and diabetes complications. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
58. Benido Silva V, Fonseca L, Borges Duarte D, et al. Metabolic impact of SGLT2 inhibitors in individuals with type 1 diabetes under csii therapy. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
59. Berard L, Brandner L. Canadian real-world analysis of flash glucose monitoring and glycemic control. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
60. Berard L, Brandner L. 27 - Canadian Real-World Analysis of Flash Glucose Monitoring and Glycemic Control. *Canadian Journal of Diabetes.* 2020;44(7).
61. Berard L, Virdi N, Dunn T. Canada Real-World Analysis of Flash Glucose Monitoring and Impact on Time-in-Range and Hypoglycemia. *Diabetes.* 2019;68(Supplement_1).
62. Bergenstal R, Hachmann-Nielsen E, Kaas A, Kvist K. Reducing glycaemic variability decreases time in hypoglycaemia independent of mean glucose: Data from real-world continuous glucose monitoring in type 1 diabetes patients. *Diabetologia.* 2018;61(Suppl 1):1-620.
63. Bergenstal R, Hachmann-Nielsen E, Kvist K, Buse JB. Derived time-in-range is associated with MACE in type 2 diabetes: data from the DEVOTE trial. 2020;63.
64. Bergenstal RM, Dunn T, Xu Y, Jangam S, Hayter G. Real-world improvement in above-target estimated a1c with sequential use of professional flash continuous glucose monitoring for individuals with diabetes. 2018;67.
65. Bergenstal RM, Hachmann-Nielsen E, Kvist K, Buse JB. Derived time-in-range is associated with mace in T2D: Data from the devote trial. *Diabetes.* 2020;69(Supplement_1).
66. Bergenstal RM, Hachmann-Nielsen E, Tarp J, Kvist K, Buse JB. "Real-World Continuous Glucose Monitoring Data on Time-in-Range from a US Population, 2015-2019". *Diabetes.* 2021;70(Supplement_1).
67. Bergenstal RM, Hachmann-Nielsen E, Tarp J, Kvist K, Buse JB. "Real-world continuous glucose monitoring data on timein-range from a u.s. population, 2015-2019". *Diabetes.* 2021;70(Supplement_1).
68. Bergenstal RM, Strock E, Thompson K, et al. A comparison of utilising SMBG vs CGM data to optimise glycaemic profiles and glucose control in patients with type 2 diabetes. *Diabetologia.* 2013;56:1-566.
69. Berget C, Messer LH, Dong F, et al. Increased time in range in the first month of Control IQ use in a clinical sample of youth with T1D. *Pediatric Diabetes.* 2021;22(S29):25-105.
70. Berget C, Messer LH, Vigers T, et al. Hybrid closed loop therapy in the real world: 6 month clinical observation of youth with type 1 diabetes. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
71. Biester T, Hermann J, Heidtmann B, et al. "Intermittent scanned glucose (FGM) in pediatrics with typ 1 diabetes: Correlation with traditional metabolic control parameters, a multi centre DPV analysis of 476 patients". *Diabetologia.* 2017;60(Suppl 1):1-608.
72. Biester T, Nieswandt A, Biester S, et al. Add-on therapy with dapagliflozin improves full closed loop post prandial glycaemic control in type 1 diabetic young adults-the dapadream. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
73. Biester T, Nieswandt A, Biester S, et al. Adjunctive therapy with dapagliflozin improves full closed loop post prandial glycaemic control in type 1 diabetic young adults-the DAPADream. *Pediatr Diabetes.* 2017;18:47-137.
74. Biester T, Nieswandt AK, Biester S, et al. DAPADream: Improvement of time in range after SGLT2-add-onmedication in youth and young adults with type 1 diabetes during unannounced meals under full closed loop CSII. *Diabetologia.* 2018;61(Suppl 1):1-620.
75. Biester T, Remus K, Biester S, et al. Improved glycemic control without increasing risk of hypoglycemia: Eversense use in a pediatric populationthe fear no hypo study. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
76. Biester T, Von Dem Berge T, Cohen A, et al. DAPAgliflozin add-on therapy improves glycemic control with full closed loop insulin administration in adolescents-DAPADream. *Pediatric Diabetes.* 2018;19:14-40.
77. Biester T, Von Dem Berge T, Remus K, et al. 670g in children smaller than labelled: The hannover smarthome study. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.

78. Billion L, Charleer S, Verbraeken L, et al. Glucose control using fast-acting insulin aspart in a real-world setting: A one-year multicenter study in people with type 1 diabetes using continuous glucose monitoring. *Diabetes.* 2021;70(Supplement_1).
79. Billion L, De Block C, Verbraeken L, et al. Fast-acting insulin aspart improves glucose control in a real-world setting: A 1-year multicenter study in people with type 1 diabetes using continuous glucose monitoring. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
80. Blauw H, Onvlee AJ, Klaassen M, Van Bon AC, Devries H. Clinical validation of a bihormonal artificial pancreas. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
81. Bleichner E, Guenego A, Moreau B, Derrien C, Guilhem I. Time in range : How many patients achieve attd recommendations ? Results in a cohort of diabetic patients using freestyle libre. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
82. Bode B, Levy C, Brown S, et al. Performance of omnipod® 5 automated insulin delivery system at specific glucose targets from 110-150mg/dl over three months in adults and adolescents with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
83. Bode BW, Cao D, Liu R, Hardy T, Bue-Valleskey JM. Ultra Rapid Lispro (URLi) Improves Postprandial Glucose (PPG) Control and Time in Range (TIR) in T1D Compared with Humalog (Lispro): PRONTO-T1D Continuous Glucose Monitoring (CGM) Substudy. *Diabetes.* 2019;68(Supplement_1).
84. Bode BW, Clarke JG. Evaluating the impact of glucommander on improvement in time-in-range (TIR) in type 2 diabetes using continuous glucose monitoring. *Diabetes.* 2020;69(Supplement_1).
85. Bolinder J. Review of flash glucose monitoring-benefits vs capillary and vs CGM. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
86. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Kroeger J, Weitgasser R. Novel flash glucose-sensing technology reduces hypoglycaemia in individuals with type 1 diabetes using multiple daily injections (MDI). *Diabetes Technol Ther.* 2017;19(S1):A1-A133.
87. Bolinder J, Antuna R, Geelhoed-Duijvestijn P, Matthaei S, Weitgasser R. Using novel flash glucose-sensing technology for 6months results in a high rate of concordance by young adults with type 1 diabetes. *Diabetologia.* 2016;59:1-581.
88. Boonin A, Martinez J, Abbott S, Davis N, Balinski B, Sauter J. Initial experience with the V-Go® disposable insulin delivery device in long-term care. 2015;64.
89. Borges Duarte D, Fonseca L, Santos T, et al. Patient satisfaction and clinical efficacy of intermittently scanned continuous glucose monitoring: A 12-month real life study. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
90. Brandt R, Park M, Quinn LT, et al. Characteristics of overnight blood glucose levels are related to sleep quality in people with type 1 diabetes. *Diabetes.* 2020;69(Supplement_1).
91. Braune K, Boss K, Schmidt-Herzel J, Schulze L, Posern B, Raile K. Shaping workflows in digital and remote diabetes care during the COVID-19 pandemic: A service design approach. *Pediatric Diabetes.* 2021;22(S29):25-105.
92. Breton MD, Beck R, Bergenstal RM, Kovatchev B. Cross-study comparisons done right: An illustration using two pivotal trials of closed-loop systems. *Diabetes.* 2020;69(Supplement_1).
93. Briganti SI, Strollo R, Maggi D, Kyanvash S, Pozzilli P, Manfrini S. Time in range and glucose control in patients with type 1 diabetes using a mobile app-assisted carbohydrate counting. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
94. Brown S, Raghinaru D, Buckingham B, et al. "Glycemic outcomes of use of CLC vs PLGS in type 1 diabetes (T1D): A randomized, controlled trial". *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
95. Brown SA, Raghinaru D, Buckingham BA, et al. "Eighteen-month use of closed-loop control (CLC): A randomized, controlled trial". *Diabetes.* 2020;69(Supplement_1).
96. Buckingham B, Norlander L, Hirsch I, et al. Comparing use of the omnipod® 5 system with 3 months of automated insulin delivery to 3 months in manual mode: A post-hoc crossover analysis. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
97. Buckingham B, Pinsker J, Christiansen M, et al. Feasibility of omnipod hybrid closed-loop control in adults with type 1 diabetes using a personalized model predictive control algorithm. *Diabetes Technol Ther.* 2017;19(S1):A1-A133.
98. Buckingham B, Pinsker J, Forlenza G, et al. Prolog: A randomized clinical trial to assess the efficacy of predictive low glucose suspend versus sensor-augmented pump therapy in the management of type 1 diabetes. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.

99. Buckingham BA, Li Z, Pinsker JE, et al. "Decreased time <70 mg/dl for patients previously using pumps, multiple daily injections, CGMor no CGMbefore using a predictive low glucose suspend system: The PROLOG study". *Diabetologia.* 2018;61(Suppl 1):1-620.
100. Bue-Valleskey J, Bode B, Ma?ecki M, Cao D, Liu R, Hardy T. Ultra rapid lispro (URLI) improves postprandial glucose (PPG) control and time in range (TIR) in T1D compared to lispro: Pronto-T1D continuous glucose monitoring (CGM) sub-study. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
101. Buse JB, Klein K, Freeman JL, Dunn I, Valcarce C. The simplici-T1 trial: Glucokinase activator TTP399 improves glycemic control in patients with type 1 diabetes. *Diabetes.* 2020;69(Supplement_1).
102. Calhoun P, Johnson T, Welsh J, Walker TC, Price DA. Associations between A1c and continuous glucose monitoring- derived glycemic parameters. 2018;67.
103. Calhoun P, Price DA, Beck R. Baseline time-in-range association with glycemic improvement in adults with type 1 diabetes (T1D). *Diabetes.* 2020;69(Supplement_1).
104. Calliari LEP, Xu Y, Jangam S, Hayter G, Dunn T. Real-world flash glucose monitoring in a developing country. 2018;67.
105. Calvo J, Sr. Time in hypoglycemia recorded by continuous glucose monitoring in subjects with type 1 diabetes in a single center in Costa Rica. *Diabetes.* 2019;68(Supplement_1).
106. Camerlingo N, Vettoretti M, Cappon G, De Lfavero S, Sparacino G, Facchinetti A. A new real-time algorithm for preventive hypotreatments generation allows reducing frequency and duration of hypoglycemia. *Journal of Diabetes Science and Technology.* 2020;14(2):361-492.
107. Camerlingo N, Vettoretti M, Cigler M, et al. Limits of correlation coefficient analysis in determining the minimal duration of CGM data needed to estimate time below range. *Diabetes.* 2020;69(Supplement_1).
108. Camerlingo N, Vettoretti M, Sparacino G, et al. A Mathematical Formula to Determine the Minimum Continuous Glucose Monitoring Duration to Assess Time-in-ranges: Sensitivity Analysis Over the Parameters. *Annu Int Conf IEEE Eng Med Biol Soc.* 2021;2021:1435-1438.
109. Campbell F, Bolinder J. Freestyle libre™ use for self-management of diabetes in teenagers and young adults. 2018;67.
110. Campbell F, Kordonouri O, Murphy N, Stewart C. FreeStyle Libre use for self-management of diabetes in children and adolescents. *Diabetologia.* 2017;60(Suppl 1):1-608.
111. Cardona-Hernandez R, Suárez-Ortega L. Comparison of estimated HbA1c assessed through abbott freestyle libre software® and siemens DCA Vintage® HbA1c in a sample of children and adolescents with type 1 diabetes. *Pediatr Diabetes.* 2017;18:47-137.
112. Carlson AL. Systems-lessons learnt from clinical studies performance of studies on advance hybrid closed-loop 780g. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
113. Carr A, Oram RA, Narendran P, Andrews RC. Measurement of c-peptide at diagnosis informs glycemic control but not hypoglycemic risk in type 1 diabetes. *Diabetes.* 2021;70(Supplement_1).
114. Chawla M. Time in range: How to measure its practical application in clinical decision making. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
115. Chawla M, Chawla P, Saboo B, et al. Insights to the time in range (TIR) in patients on flash glucose monitoring (FGM) in patients with type 2 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
116. Chawla M, Chawla PM, Shah A. Evaluation of utility of flash glucose monitoring (FGM) in people with type 2 diabetes in an urban Indian setting. *Diabetes.* 2019;68(Supplement_1).
117. Cherubini V, Bonfanti R, Favalli V, et al. Time in range in a large cohort of children with type 1 diabetes using glucose sensor and multiple daily injection or insulin pump treatment. *Pediatr Diabetes.* 2019;20(S28):41-231.
118. Cherubini V, Bonfanti R, Scaramuzza A, et al. Glucose metrics in a large group of children with type 1 diabetes using CGM in real life. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
119. Cherubini V, Gesuita R, Bonfanti R, et al. Virtual camp effectiveness to start new technologies in families with children living with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
120. Cherubini V, Rabone I, Bonfanti R, et al. Optimal predictive low glucose management settings during physical exercise. *Pediatric Diabetes.* 2017;18:18-46.

121. Chetty T, Burckhardt MA, Smith G, et al. Use of continuous glucose monitoring (CGM) trends to prevent hypoglycaemia during exercise in young children with type 1 diabetes. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
122. Chiba K, Cho K, Kameda H, et al. SGLT2 inhibitors improve day-to-day glucose variability in patients with type 1 diabetes. *Diabetes.* 2020;69(Supplement_1).
123. Chico A, Ampudia FJ, Climent E, et al. The ACCU-chek® solo tubeless micropump improves glycemic control and quality of life in adult and pediatric patients with type 1 diabetes: A pilot study. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
124. Cho K, Nomoto H, Kawata S, et al. Prominent effects of SGLT2 inhibitor canagliflozin combined with DPP-4 teneligliptin on postprandial hyperglycaemia at breakfast and dinner. *Diabetologia.* 2020;63(Suppl 1):1-485.
125. Chrzanowski J, Wielgus A, Grabia S, et al. GlyCulator 3.0: A web-based platform for continuous glucose monitoring analysis and center benchmarking. *Pediatric Diabetes.* 2021;22(S30):33-165.
126. Clark C, Hart B. Twenty-eight days of meal delivery improves time-inrange for people with type 2 diabetes. *Diabetes.* 2021;70(Supplement_1).
127. Cobry E, Berget C, Messer L, et al. Sleep mode use in pediatric patients with type 1 diabetes using Control-IQ. *Pediatric Diabetes.* 2021;22(S29):25-105.
128. Cobry E, Berget C, Messer L, et al. Hypoglycemia fear and diabetes distress: What we have learned from 1 year of hybrid closed-loop therapy in youth and young adults with type 1 diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
129. Colmegna P, Bisio A, McFadden R, et al. Bringing simulation technologies to people with T1D: A pilot study. *Diabetes.* 2021;70(Supplement_1).
130. Comsa M, Dumitrescu A. The performance of minimed 670g hybridclosed loop during real-life prolonged competitional trail races (mountain marathons and half-marathons). *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
131. Constantin A, Habif S, Singh H. Significant improvement in sensor time in range and hyperglycemia outcomes in 6 to 13-year-old children with type 1 diabetes using Control-IQ technology in the real-world. *Pediatr Diabetes.* 2021;22:4-105.
132. Costa C, Caetano J, Bastos F, et al. The effect of the ultra-rapid insulin analog FIASP® in pediatric type 1 diabetes patients under continuos subcutaneous insulin infusion (CSII). *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
133. Cristello A, Kahkoska AR, Smart CE, et al. Preliminary evidence that “structured eating” (SE) may be acceptable and promote glycemic control in type 1 diabetes (T1D). *Diabetes.* 2020;69(Supplement_1).
134. Crowder CM, Jelley D, Condren M, Chalmers L, Graef JL. "The T1dlocho study: Effects of a low-carbohydrate, nonketogenic diet vs. standard diabetes diet on glycemic control in young adults with type 1 diabetes". *Diabetes.* 2019;68(Supplement_1).
135. Cusinato M, Bottesi G, Martino M, et al. Intolerance of uncertainty is associated with lower time in hyperglycemia in adolescents with type 1 diabetes treated with continuous subcutaneous insulin infusion. *Pediatric Diabetes.* 2021;22(S29):25-105.
136. Cutruzzolà A, Assaloni R, Citro G, et al. Implantable continuous glucose monitoring and glucometric parameters: preliminary data from real-life. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
137. Cutruzzola A, Parise M, Tartaglione L, et al. Teleassistance in patients with type 1 diabetes during COVID-19 pandemic. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
138. Da Silva A, Leey J, Whyte L. Utilization of Continuous Glucose Monitoring (CGM) and its impact on Veteran care. 2020;26.
139. Da Silva J, Arrieta A, Castaneda J, Grosman B, Cohen O. Real-world performance of the minimed™780g system: Impact of initiating automated basal and correction boluses. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
140. Daghero A, Iglesias M, Oliva F, et al. Telehealth during COVID-19: Patient satisfaction of virtual training on the minimed 670g system in people with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
141. Danne T. Beyond A1C: Consensus on CGM outcomes. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.

142. Danne T, Cariou B, Buse JB, et al. "Increased time in range with sotagliflozin as adjunct therapy to insulin in adults with type 1 diabetes demonstrated by 24-week continuous glucose monitoring (intandem1, intandem2)". *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
143. Danne T, Cariou B, Buse JB, et al. inTandem1 and inTandem2: Increased time in range with sotagliflozin as adjunct therapy to insulin in adults with type 1 diabetes by 24-week continuous glucose monitoring. *Diabetologia.* 2018;61(Suppl 1):1-620.
144. Danne T, Cariou B, Buse JB, et al. "Increased Time-in-Range with Sotagliflozin as Adjunct Therapy to Insulin in Adults with Type 1 Diabetes as Demonstrated by 24-Week Continuous Glucose Monitoring (inTandem1, inTandem2)". *Diabetes.* 2018;67(Supplement_1).
145. Danne T, Frias J, Ampudia-Blasco J, et al. "Sotagliflozin (SOTA), a dual sodium glucose cotransporter (SGLT)1 and SGLT2 inhibitor, in overweight/obese patients with type 1 diabetes (T1D): Addressing unmet needs as adjunct therapy to insulin". *Pediatr Diabetes.* 2019;20(S28):41-231.
146. Danne T, Schweitzer MA, Keuthage W, et al. Gobolus study: Impact of faster aspart on glycemic control in a real-world population with type 1 diabetes on basal-bolus therapy as multiple daily injections using flash glucose monitoring. *Diabetes.* 2020;69(Supplement_1).
147. Danne T, Strumph P. Increased time in range and improved glycemic variability with sotagliflozin in combination with insulin in adults with type 1 diabetes: A pooled analysis of 24-week continuous glucose monitoring data. 2019;13.
148. Darukhanavala A, Dinunno KV, Puhr S, et al. Diabetes camp experience associated with improved glycemia and treatment satisfaction. *Diabetes.* 2020;69(Supplement_1).
149. Dassau E, Brown SA, Basu A, et al. Multicenter outpatient randomized crossover trial of zone-MPC artificial pancreas in type 1 diabetes: Effects of initialization strategies. 2015;64.
150. Dassau E, Zisser H, Percival MW, Grosman B, Jovanovic L, Doyle Iii FJ, III. Clinical results of automated artificial pancreatic ?-cell system with unannounced meal using multi-parametric mpc and insulin-on-board. 2010.
151. Davis NA, Jelley DH. The relationship between patient-driven input and glycemic control in youth with type 1 diabetes mellitus in the star 3 study. *Diabetes.* 2016;65(Supplement_1):A221-A360.
152. De Carvalho Vaz A, Da Silva Cardoso J, Vieira PM, et al. Can dietary carbohydrate content influence the glycemic control in children and adolescents with type 1 diabetes? *Pediatric Diabetes.* 2021;22(S30):33-165.
153. De Oliveira CP, Dellva MA, Bue-Valleskey JM, Chang AM, Chigutsa FB, Liao B. Relative contribution of fasting plasma and postprandial glucose to HbA1c and tir in people with T1D on basal-bolus insulin therapy. *Diabetes.* 2021;70(Supplement_1).
154. De Valk HW, Oosterwijk L, Kaasjager K. Fetal growth acceleration is still common in well-controlled pregnant women with type 1 diabetes using real-time glucose monitoring. *Diabetes.* 2020;69(Supplement_1).
155. Deb B, Manduca A, Kudva YC, Bharucha AE. Predicting Post-Prandial Glycemia From Gastric Emptying In Type 1 Dm Patients. *Gastroenterology.* 2021;160(6).
156. DeBoer MD, Chernavvsky DR, Breton MD, Kovatchev BP. Use of an artificial pancreas among adolescents to minimize extreme hyperglycemia in the setting of insulin omission for food. 2014;35.
157. Derdzinski M, Puhr S, Welsh J, et al. Hypoglycemia avoidance after adoption of a next-gen CGM system including a predictive low glucose alert. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
158. Desborough L, Levin P, Bromberger LA. Inhaled insulin improves daytime time-in-range in people with type 2 diabetes. *Diabetes.* 2021;70(Supplement_1).
159. Deshmukh H, Wilmot EG, Herring R, et al. Effect of time-in-range over 14 days on glycaemic controls and hypoglycaemia unawareness in patients using freestyle libre. *Diabetes.* 2020;69(Supplement_1).
160. Diamond T, Wayne Bequette B, Cameron F. "Assessment of a ""dIY looping™ algorithm using the UVa/padova metabolic simulator". *Journal of Diabetes Science and Technology.* 2020;14(2):361-492.
161. Diaz Soto G, Gomez Hoyos E, Jimenez R, et al. "Relationship between hemoglobin A1c, time-in-range and glycemic variability in type 1 diabetes patients under intermittently scanned continuous glucose monitoring". *Diabetes Technol Ther.* 2020;22(S1):A1-A250.

162. Disoteo O, Grassi G, Robuffo F, et al. Professional continuous glucose monitoring in haemodialyzed diabetic patients. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
163. Dixon RF, Miller DP, Majithia A, et al. Does HBA1C accurately predict time-in-range? *Diabetes.* 2019;68(Supplement_1).
164. Dovc K, Lanzinger S, Cardona Hernandez R, et al. Real-world data on time in range among children and adolescents with type 1 diabetes: Data from the international sweet registry. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
165. Dovc K, Van Name M, Rusak E, et al. Continuous glucose monitoring use and glucose variability in very young children with type 1 diabetes: the vibrate study. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
166. Dowd R, Derdzinski M, Puhr S, Welsh J. Time-in-range is impacted more by high threshold alerts than by screen view frequency for users of a real-time cgm system. *Diabetes.* 2021;70(Supplement_1).
167. Dowd R, Norman G, Welsh JB, Walker T, Parker A. Real-time CGM usage and estimates of glycaemic control among individuals with type 1 or type 2 diabetes. *Diabetologia.* 2020;63(Suppl 1):1-485.
168. Dowden S, Hudson B, Li M. Paris-brest-paris: ultra endurance cycling with type 1 diabetes using an open source artificial pancreas system. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
169. Dreval A, Barsukov I, Slesareva E, Dreval O. The frequency of unlimited flash glycemia scans by patients with type 1 diabetes on pump insulin therapy. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
170. Dubose S, Li Z, Shah VN, et al. Frequency of Hypoglycemia by Gender in Healthy Individuals without Diabetes-Not So Different After All. *Diabetes.* 2019;68(Supplement_1).
171. Dunn T, Xu Y, Hayter G. Evidence of a strong association between frequency of flash glucose monitoring and glucose control measures during real-world usage. *Diabetes Technol Ther.* 2017;19(S1):A1-A133.
172. Dunn T, Xu Y, Hayter G. Impact of national reimbursement status on real world flash glucose monitoring use and glycemic control measures. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
173. Edelman S, Bosnyak Z, Bailey T, Bergenstal R, Cheng A, Battelino T. InRange: A randomized controlled trial comparing Gla-300 vs IDeg-100 in people with type 1 diabetes (T1D) using continuous glucose monitoring (CGM). *Pediatr Diabetes.* 2019;20(S28):41-231.
174. Edelman S, Bosnyak Z, Bailey T, Bergenstal R, Cheng A, Battelino T. Inrange: A randomized controlled trial comparing GLA-300 vs IDeg-100 in people with type 1 diabetes (T1D) using continuous glucose monitoring (CGM). *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
175. Edwards SS, He X, Johnson J, et al. Missed bolus doses (MBDS) are associated with reduced time-in-range (TIR): The influence of hypoglycemic fear. *Diabetes.* 2020;69(Supplement_1).
176. Edwards SS, He X, Johnson J, et al. "Key differences with hypoglycaemic fear in people using insulin: The association with missed bolus doses exists for type 2 diabetes, but not type 1 diabetes". *Diabetologia.* 2020;63(Suppl 1):1-485.
177. Ehrmann D, Heinemann L, Freckmann G, Waldenmaier D, Hermanns N. Directness and sustainability of rtcgm effects on hypoglycemia: A secondary analysis of the hypode study. *Diabetes.* 2019;68(Supplement_1).
178. Ehrmann D, Kulzer B, Hermanns N. Better skills in carbohydrate estimation is associated with higher time in range. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
179. Ehrmann D, Schipfer M, Haak T, Kulzer B, Hermanns N. Comparison of glycemic control between experienced users of flash glucose monitoring vs. Flash-naïve patients. 2018;67.
180. Ehrmann D, Schmitt A, Priesterroth L, Knoll C, Hermanns N. Diabetes technology and alarms: Subjective distress is not associated with glucose parameters. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
181. Ehrmann D, Schmitt AJ, Priesterroth L, Kulzer B, Hermanns N. Predictors of daily diabetes distress in type 1 diabetes. *Diabetes.* 2021;70(Supplement_1).
182. Ehrmann D, Schmitt AJ, Rubertus P, Kulzer B, Hermanns N. Can mood and energy levels be predicted by preceding glucose values? Combining ecological momentary assessment (EMA) and continuous glucose monitoring (CGM). *Diabetes.* 2020;69(Supplement_1).

183. Ekberg NR, Hartvig NV, Kaas A, Moller J, Mårdby A-CM, Adolfsson P. The association between missed basal insulin injections and glycemic control in adults with type 1 diabetes mellitus. *Diabetes.* 2021;70(Supplement_1).
184. Ekhlaspour L, Raghinaru D, Forlenza GP, et al. Outcomes in pump- and CGM-naïve subgroups in the international diabetes closed-loop (iDCL) trial. *Journal of Diabetes Science and Technology.* 2020;14(2):361-492.
185. Ekhlaspour L, Raghinaru D, Lum J, Brown SA, Buckingham BA. Glycemic outcomes in baseline hemoglobin A1c subgroups in the international diabetes closed-loop (idcl) trial. *Diabetes.* 2020;69(Supplement_1).
186. Ekhlaspour L, Wadwa P, Chernavvsky D, et al. Artificial Pancreas (AP) Ski Camp 2018: Successful use of the Tandem Control-IQ AP system in adolescents and children during winter sports and at home. *Pediatric Diabetes.* 2018;19:14-40.
187. El Malahi A, Van Elsen M, Charleer S, et al. "Chronic complications versus glycaemic variability, time in range and HbA(1c) in people with type 1 diabetes: sub study of the RESCUE-trial". 2020;63.
188. Elbalshy M, Styles S, Haszard JJ, et al. The effect of do-it-yourself real-time continuous glucose monitoring on psychological and glycaemic variables in children with type 1 diabetes: A randomised crossover trial. *Diabetes.* 2021;70(Supplement_1).
189. Eldib AH, Tomah S, Dhaver SE, et al. Evaluation of hybrid closed-loop insulin delivery system for patients with type 1 diabetes in real-world clinical practice: A one-year qualitative observational study. *Diabetes.* 2020;69(Supplement_1).
190. Eren E, Ongen YD, Demirbas O, Tarim O. Evaluation of AGP reports in patients with type 1 diabetes using intermittently viewed continuous glucose measurement system (ICGM). *Hormone Research in Paediatrics.* 2019;91(1):1-682.
191. Evans M, Jeffs A, Lavender M, et al. Hybrid closed loop improves glycaemic control in gastroparesis in type 1 diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
192. Evin F, Ata A, Er E, et al. Predictive low-glucose suspend system and glycemic variability. *International Journal of Diabetes in Developing Countries.* 2021;42(2):276-282.
193. Evin F, Demir G, Çetin H, Özen S, Darcan, Goksen D. Sensor augmented pump therapy effects glycemic variability. *Pediatr Diabetes.* 2019;20(S28):41-231.
194. Evin F, Demir G, Cetin H, Ozen S, Darcan S, Goksen D. Sensor augmented pump therapy effects glycemic variability. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
195. Fabris C, Beck R, Kovatchev B. Tracking haemoglobin A1c from CGM data via personalised model of haemoglobin glycation and clearance. *Diabetologia.* 2020;63(Suppl 1):1-485.
196. Fabris C, Beck R, Kovatchev B. Daily tracking of hemoglobin A1c through personalized glycation model. *Diabetes.* 2020;69(Supplement_1).
197. Fall Mostaine F, Amoura L, Bounyar L, et al. Pilot evaluation of continuous glucose monitoring by guardian connect for hospitalized patients with diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
198. Faradji R, Antonio-Villa N, Garcia-Tuomola A, et al. Does time in range predict HbA1c? *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
199. Ferreira-Hermosillo A, Mena-Ureta T. Assessment of glycemic variability in Mexican patients with type 1 diabetes with HbA1c below 7 percent and among 7 to 8 percent. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
200. Filho FFR, Dos Santos FL, Ostuzzi LG, Cunha RA. Impact of the structured care program for individuals with diabetes mellitus type 1 using a continuous subcutaneous insulin infusion (CSII) in Brazilian unified health system (SUS): 6 month follow up. *Diabetology & Metabolic Syndrome.* 2019;11(S1).
201. Florissi C, Gowen R, Pang C, Wood R. Patient perspectives: Linking the use of diabetes technology to self-reported evaluations of burden of care and glycemic control. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
202. Flowers K, Kirk A, Turner L, Cranston I. "Improving the understanding of glucose-related risks in haemodialysis patients, using continuous glucose monitoring (CGM) and the ambulatory glucose profile (AGP): An observational study with important clinical implications". *Diabetic Medicine.* 2021;38(S1).

203. Fonseca L, Duarte D, Santos T, et al. Flash glucose monitoring decreases time spent in hypoglycemia in type 1 diabetes mellitus: Real world data. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
204. Forbes S, Olateju TO, Lam A, et al. "CGM Shows Islet Transplantation Prevents Hypoglycemia, Correcting Time in Range and Reducing Glycemic Variability, Despite Subnormal Beta-Cell Function". *Diabetes.* 2018;67(Supplement_1).
205. Foreman YD, van Doorn WPTM, Schaper NC, et al. Greater daily glucose variability and lower time in range assessed with continuous glucose monitoring are associated with greater aortic stiffness: The Maastricht Study. *Diabetologia.* 2021;64(8):1880-1892.
206. Forlenza G, Buckingham B, Christiansen M, et al. Performance of omnipod personalized model predictive control algorithm with moderate intensity exercise and variable setpoints in adults with type 1 diabetes. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
207. Forlenza G, Chernavvsky D, DeBoer M, et al. The artificial pancreas (AP) improves glycemic control during extended exercise at ski camp in adolescents with type 1 diabetes (T1D). *Diabetes Technol Ther.* 2017;19(S1):A1-A133.
208. Forlenza GP, DeSalvo DJ, Hadjiyianni I, et al. "Glycemic profiles and treatment patterns in 1,464 children and adolescents with type 1 diabetes using the Omnipod DASH® Insulin Management System with continuous glucose monitoring and cloud-based data management". *Pediatric Diabetes.* 2021;22(S30):33-165.
209. Fortmann AL, Bastian A, Bagsic SRS, et al. Feasibility and preliminary effectiveness of continuous glucose monitoring for diabetes prevention. *Diabetes.* 2020;69(Supplement_1).
210. Fortmann AL, Bastian A, Lensing CJ, et al. Integration of continuous glucose monitoring in diabetes self-management education for type 2 diabetes improves glycemic control. *Diabetes.* 2020;69(Supplement_1).
211. Franc S, Benhamou PY, Amadou C, et al. "Diabeloop closed loop system allows patients with diabetes type 1 (T1D) to largely improve their glycemic control in real life situation, without serious adverse events". *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
212. Franc S, Benhamou PY, Borot S, et al. Diabeloop closed loop system allows patients with diabetes type 1 (DT1) to practice physical activity (PA) without increasing hypoglycaemic risk. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
213. Franc S, Benhamou PY, Borot S, et al. Twelve-week home use of hybrid closed-loop insulin delivery system vs. sensor-assisted pump therapy in adults with type 1 diabetes-intermediate results of the multicenter randomised crossover diabeloop WP7 trial. 2018;67.
214. Franc S, Borot S, Benhamou PY, et al. Diabeloop closed-loop does better than sensor-augmented-pump on blood glucose during 3 days with intensive physical exercises: A randomized crossover trial. *Diabetes Technol Ther.* 2017;19(S1):A1-A133.
215. Fraser SK, Sherriff J, Jose L, Thomson J, McClintock JM. Are glucose monitoring systems beneficial in a realworld environment? *Pediatr Diabetes.* 2019;20(S28):41-231.
216. Freckmann G, Stuhr A, Pleus S, Link M, Mende J, Haug C. "Time spent in different glucose ranges (""time in range"") varies depending on the continuous glucose monitoring system used". 2019;62.
217. Fridholm O, Hanas R. The relationship of target glucose intervals; A Swedish retrospective study. *Pediatric Diabetes.* 2021;22(S30):33-165.
218. Frontino G, Tirelli E, Di Tonno R, et al. Optical coherence tomography and C-peptide follow-up in a child with Wolfram's syndrome treated with Liraglutide for 16 Months. *Pediatric Diabetes.* 2021;22(S29):25-105.
219. Frontino G, Tirelli E, Di Tonno R, et al. Optical coherence tomography and C-peptide shortterm follow-up in a child with Wolfram's syndrome treated with Liraglutide. *Pediatr Diabetes.* 2019;20(S28):41-231.
220. Furler J, O'Neal DN, Speight J, et al. Gp-osmotic: An RCT to determine the effect of 3-monthly retrospective continuous glucose monitoring (RCGM) on 12-month HBA1C in adults with type 2 diabetes (T2D) in primary care. *Diabetes.* 2019;68(Supplement_1).
221. Gabbay MAL, Cavicchioli MGS, Pascali PM, et al. Precocious use of continuous subcutaneous insulin infusion in infants and preschool children is related to less short-term glycemic variability and HBA1c on the goals. *Diabetology & Metabolic Syndrome.* 2019;11(S1).

222. Gaggero G, Viglino F, Beccuti G, Bertaina S, Broglio F. "Improved CMG outcomes in adults with type 1 diabetes mellitus during COVID-19 lockdown in piedmont , Italy". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
223. Gal J, Li Z, Willi SM, Riddell M. Physical activity and glucose control among youth with T1D. *Diabetes.* 2021;70(Supplement_1).
224. Gal R, Cohen N, Kruger D, et al. A study to assess initiation of CGM outside of a clinic. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
225. Garcia-Tirado J, Deboer M, Myers H, et al. Fully automated closed-loop in adolescents with type 1 diabetes: A safety and feasibility study. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
226. Garg S. Managing T1D-new-onsets and DKA through telehealth. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
227. Gaur S, Phyoe A, Brown F, Elliott M, Neupane S. Greater benefits of flash glucose monitoring in patients where occupation is a barrier to self-monitored blood glucose testing. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
228. Gauthier P, Tourki Y, Desir C, et al. "Physical activity impact on a type 2 diabetes population, implications for a fully closed-loop system". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
229. Ghosh-Dastidar S, Sanchez P, Tweden K, Kaufman F. The glycemic outcomes of the eversense CGM system in an expanded cohort of 582 real-world us commercial users. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
230. Gillard P, El Malahi A, Van Elsen M, et al. Quality of life versus glycaemic variability and time in range in people with type 1 diabetes: sub study of the RESCUE-trial. 2020;63.
231. Gimenez P, Lachal S, Tourki Y, et al. Daily meal size variation does not affect glycemic control in T1D adolescent patients equipped with the closed loop DBLG1 system. *Hormone Research in Paediatrics.* 2021;94(Suppl. 1):1-445.
232. Ginsburg HL, Shelley JTR, Whalley R, Lora M, Villagra V. Automatic insulin dose monitoring: An essential technology for optimizing time in range (TiR) for multiple daily injection (MDI) patients. 2019;13.
233. Giorda S, Tinti D, Trada M, Rabbone I. Hypoglycemia reduction using high-carb diet in adolescents with type 1 diabetes wearing a continuous glucose monitoring during a sport camp. *Pediatr Diabetes.* 2019;20(S28):41-231.
234. Giraudo F, Salinas A, López P, et al. Progestin subdermal implant compared to combined oral contraceptive in young women with type 1 diabetes. *Pediatric Diabetes.* 2021;22(S30):33-165.
235. Gleich S, Gibson N, Battin M, et al. Centralized remote monitoring of CGM data at diabetes camp mitigates hypoglycemia. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
236. Gleich SE, Gibson-North ND, Puhr S, Welsh J, Walker TC, Caruso D. Remote monitoring of CGM data at diabetes camp mitigates hypoglycemia day and night. *Diabetes.* 2020;69(Supplement_1).
237. Goldenberg R, Aroda VR, Billings LK, et al. Effect of insulin degludec U100 vs insulin glargine U100 on time in range in patients with type 2 diabetes at risk of hypoglycaemia. 2020;63.
238. Goldenberg R, Aroda VR, Billings LK, et al. Association between time-in-range and a1c in basal insulintreated people with type 2 diabetes. *Diabetes.* 2021;70(Supplement_1).
239. Goldenberg R, Aroda VR, Billings LK, et al. Association between change in time-in-range and a1c in basal insulin-treated people with type 2 diabetes. *Diabetes.* 2021;70(Supplement_1).
240. Goldenberg R, Aroda VR, Billings LK, et al. Association between Time-in-Range and MC in Basal Insulin-Treated People with Type 2 Diabetes. *Diabetes.* 2021;70(Supplement_1).
241. Gomez AM, Henao Carrillo DC, Imitola Madero A, et al. Efficacy and safety of basal bolus insulin regimen in a cohort of type 2 diabetes patients hospitalized in general ward assessed by continuous glucose monitoring. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
242. Gómez Medina AM, Henao D, Muñoz O, et al. Description of the glycemic control metrics evaluated by glucose monitoring in a cohort of adult patients hospitalized with hyperglycemia and diagnosis of Covid 19. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
243. Gomez-Peralta F, Merino-Torres J. Improved glycaemic variability and hypoglycemia through flash glucose monitoring in real-world setting from Spain. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
244. Gong L, Xu W, Lin B, et al. The relationship of time-in-range (TIR) and HbA1c and the factors that contribute to a better TIR. *Diabetes.* 2021;70(Supplement_1).

245. Grace T, Salyer J. Real-time cgm coverage eligibility should include type 2 diabetes patients treated with less-intensive therapy. *Diabetes.* 2021;70(Supplement_1).
246. Grassi B, Onetto MT, Mussri D, Tapia L, Aliste M. Factors associated with lower glycemic variability in an cohort of adults with t1d on csii with predictive low glucose suspend (PLGS). *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
247. Grassi Corrales B, Revello Vega A, Mena F, Aliste M, Agüero M, Onetto Flores MT. Effects on glycemic parameters of a multidisciplinary educational program in adults with type 1 diabetes using MiniMed 640G® in Chile. Real life data. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
248. Griggs S, Strohl K, Margevicius S, Grey M, Hickman R, Jr. "Rest activity rhythms, symptom burden, and glucose variability in young adults with type 1 diabetes". *Sleep.* 2021;44(Supplement_2):A252-A252.
249. Gu A, Prahalad P, Maahs DM, Addala A, Scheinker D. "The association between time-in-range, mean glucose, and incidence of hypoglycemia in youth with newly diagnosed T1d". *Diabetes.* 2020;69(Supplement_1).
250. Guo L, Zhang M, Kuang H, et al. Improved time-in-range and glycemic variability in adults with type 1 diabetes: An analysis of 12-week flash glucose monitoring data from a multicenter prospective trial. *Diabetes.* 2020;69(Supplement_1).
251. Guzmán G, Victoria A, Marín V, Martínez V, Fériz K. Glucose control in patients treated with continuous subcutaneous insulin infusion: Hybrid closed loop system and manual standard mode. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
252. Haak T, Hanaire H, Ajjan RA, Hermanns N, Riveline JP, Rayman G. Using novel flash glucose-sensing technology for 12 months reduces hypoglycaemia in individuals with type 2 diabetes on intensive insulin therapy. *Diabetologia.* 2016;59:1-581.
253. Habif S, Constantin A, Mueller L, Singh H. Glycemic outcomes for people with type 1 and type 2 diabetes using control-iq technology: Real-world data from early adopters. *Diabetes.* 2020;69(Supplement_1).
254. Habif S, Singh H, Mueller L, et al. Glycemic outcomes by ethnicity in adults with type 1 diabetes using control-iq technology: Early results from the clio study. *Diabetes.* 2021;70(Supplement_1).
255. Hamaguchi M, Yamazaki M, Tanaka T, et al. Efficacy and safety of dapagliflozin in type 1 diabetes: The rising-star study. *Diabetes.* 2021;70(Supplement_1).
256. Hangaard S, Kronborg T, Hejlesen O, et al. The diabetes telemonitoring of patients in insulin therapy (diamont) trial: Protocol for a randomized controlled trial. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
257. Hashem R, Mulnier H, Rogers R, Halson-Brown S, Duaso M, Forbes A. Impact of lipohypertrophy on glucose variability in type 1 diabetes mellitus. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
258. Hásková A, Radovnická L, Parkin C, et al. Continuous glucose monitoring is more effective than flash glucose monitoring in preventing hypoglycemia in patients with type 1 diabetes and normal awareness of hypoglycemia. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
259. Hasnani D, Chavda V, Jaggi S, Maheriya V. Initial insights to the glycemic metrics as revealed by freestyle libre pro continuous glucose monitoring (CGM) in T2DM patients on remogliflozin. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
260. Heimbuerger SMN, Hoe B, Nielsen CN, et al. Six-day subcutaneous GIP infusion increases glycaemic time in range in patients with type 1 diabetes. 2020;63.
261. Heinemann L, Freckmann G, Faber-Heinemann G, Ehrmann D, Hermanns N. Can CGM discriminate between type 1 diabetes patients with and without severe hypoglycaemia. Results of the baseline assessment from the Hypo De study. *Diabetologia.* 2017;60(Suppl 1):1-608.
262. Heinemann L, Freckmann G, Faber-Heinemann G, Wintergerst P, Ehrmann D, Hermanns N. Can CGM discriminate between patients with type 1 diabetes with and without severe hypoglycemia? Assessment of the baseline data of the HypoDE study. *J Diabetes Sci Technol.* 2018;12(2):426-532.
263. Heinemann L, Freckmann G, Waldenmaier D, Ehrmann D, Hermanns N. rtCGM usage is associated with a significant reduction of time spent in hypoglycemia in patients with type 1 diabetes treated with multiple daily injections-results of the hypode study. 2018;67.
264. Helleputte S, De Backer T, Calders P, Shadid S, Lapauw B. The interpretative value of CGM-derived parameters in type 1 diabetes depends on glycaemic control. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.

265. Henson CJ, Barnes TL, Nickel AJ, Jennifer Abuzzahab M, Kyllo J, Gandrud LM. "Clinical experience with the minimed 670g system in children, adolescents, and young adults with type 1 diabetes". 2018;67.
266. Hermann J, Feldhahn L, Biester T, Sandig D, Schierloh U, Holl R. "Glucose variability based on 50,000 days of continuous glucose monitoring: A DPV analysis in 2,093 pediatric and adult patients with type 1 diabetes". *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
267. Hermann JM, Biester T, Meraner D, et al. "Glucose control during days at school, weekends, and school holidays in youths with type 1 diabetes: Multicentre analysis based on 62,500 days with continuous glucose monitoring". *Pediatr Diabetes.* 2017;18:47-137.
268. Hermanns N, Ehrmann D, Freckmann G, et al. Occurrence of severe hypoglycaemic events in the future: Analysis of CGM data of the HypoDE study. *Diabetologia.* 2018;61(Suppl 1):1-620.
269. Hermanns N, Ehrmann D, Kulzer B. Impact of carbohydrate counting on glycaemic control in people with type 1 and type 2 diabetes on intensified insulin therapy. *Diabetes.* 2020;69(Supplement_1).
270. Hermanns N, Heinemann L, Freckmann G, Waldenmaier D, Ehrmann D. Predictors of hypoglycemia avoidance in a randomized controlled rtCGM trial (HYPODE). 2018;67.
271. Hermanns N, Schmitt A, Ehrmann D, Haak T, Kulzer B. How frequent experience people with type 1 diabetes worries about hypoglycaemia and hyperglycaemia and how are these worries associated with the course of glucose? *Diabetologia.* 2020;63(Suppl 1):1-485.
272. Hertzberg JK, Janer C, Jhuang A-T, et al. Ischemic heart disease and type 2 diabetes complications are associated with glycemic variability measured by continuous glucose monitoring. 2021;144.
273. Hinz HA, Prado CM, Boule NG, Yardley JE. 5 - The Association of Exercise Blood Glucose on Postexercise Hypoglycemia in Type 1 Diabetes. *Canadian Journal of Diabetes.* 2020;44(7).
274. Hirsch I. Time in range(s) vs. HbA1c: Are our patients ready to change? *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
275. Hirsch I. A real-world look of time in range (TIR) and glucose management indicator (GMI). *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
276. Hu K, Jiang H, Zhang W, Peng H, Liu J. The effect of different frequency of autonomous flash glucose monitoring application on blood glucose control in patients with type 1 diabetes under 14 years old. *Diabetes.* 2021;70(Supplement_1).
277. Inverso H, Bhangui I, Moore H, et al. Demographic and glycemic factors linked with diabetes distress in teens with type 1 diabetes. *Pediatric Diabetes.* 2021;22(S30):33-165.
278. Irace C, Nuzzi A, Assaloni R, et al. Six months of long-term implantable sensor use associates with lower glycated haemoglobin and higher time in range in a real life setting. 2019;62.
279. Irwin A, Igudesman D, Crandell J, et al. "Mindfulness, disordered eating, and impulsivity in relation to glycemia among adolescents with type 1 diabetes: The flexible lifestyles empowering change (FLEX) intervention trial". *Pediatr Diabetes.* 2021;22:3-165.
280. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al. Closed-loop control (CLC) in teens and young adults improves glycemic control: Results from the international diabetes closed-loop (iDCL) trial. *Journal of Diabetes Science and Technology.* 2020;14(2):361-492.
281. Isganaitis E, Raghinaru D, Ambler-Osborn L, et al. Closed-loop control (CLC) in teens and young adults improves glycemic control: Results from a 6-month multicenter Randomized Clinical Trial (RCT). *Pediatr Diabetes.* 2019;20(S28):232-254.
282. Jain N, Lipova O. Business continuity during covid-19 pandemic for paediatric diabetes unit. *Diabetic Medicine.* 2021;38(S1).
283. Jangam S, Dunn T, Covington K, Charlesworth T, Lang J, Hayter G. Pre-prandial glycaemic level and trend associations with post-prandial hyperglycaemia: A worldwide observational analysis. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
284. Jendle JH, Hartvig NV, Kaas A, Moller J, Mårdby A-CM, Catrina S. Effect of late bolus injections on glycemic variability studied by connected pens. *Diabetes.* 2020;69(Supplement_1).
285. Jeyaventhan R, Gallen G, Choudhary P, Hussain S. A real-world evaluation of automated insulin dosing systems demonstrates superior efficacy and comparable safety with open-source systems as compared to minimed 670g. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.

286. Jia W, Zhou J, Gao F, et al. The effect of acarbose compared to metformin when combimed with premixed insulin on glycemic variability in patients with type 2 diabetes: An open-label randomized trial. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
287. Jirá?ová P, Soupal J, Plachy L, et al. An androidaps hybrid closed loop system in a home setting is safe and leads to better metabolic control. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
288. Johnson J, Malone J, Price D, et al. Study design for an objective assessment of mealtime bolus insulin behaviour and associated factors. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
289. Johnson M, Bergenstal R, Gubitosi-Klug R, et al. Continuous glucose monitoring metrics in DCCT/EDIC study participants with type 1 diabetes of over 35 years duration. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
290. Johnson ML, Dreon DM, Levy BL, Richter S, Mullen D, Bergenstal RM. Comparing patch vs pen bolus insulin delivery in type 2 diabetes using continuous glucose monitoring metrics and profiles. *Diabetologia.* 2018;61(Suppl 1):1-620.
291. Josipovic M, Davenport K, Hartnell S, Donald S, Evans ML. Successful hybrid closed-loop insulin delivery in type 1 diabetes and Addison's disease. *Diabetic Medicine.* 2020;37(S1):30-30.
292. Kaas A, Hartvig NV, Hellman J, Knudsen NN, Mardby AC, Adolfsson P. Increased time in range observed after introduction of a connected insulin pen. 2019;62.
293. Kalra S, Saboo B. The glycaemic compass: Time in range. 2021;71.
294. Kanapka L, Miller K, Laffel L. Adolescents and young adults with type 1 diabetes (T1D) experience substantial glycemic variability. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
295. Karami AJ, Pyle L, Jost E, Wadwa RP, Meltzer LJ, Cobry EC. Association of glycemic ranges and sleep measures in youth with T1D and their parents. *Diabetes.* 2021;70(Supplement_1).
296. Kariyawasam D, Morin C, Casteels K, et al. Diabeloop DBL4K hybrid closed-loop system improves time-in-range without increasing time-in-hypoglycemia in children aged 6-12 years. *Diabetes.* 2021;70(Supplement_1).
297. Kariyawasam D, Morin C, Casteels K, et al. A Randomised Controlled Cross-Over Trial of the Hybrid Closed-Loop Insulin Delivery System Diabeloop vs. Sensor-Augmented Pump Therapy in Children Aged 6-12 Years. *Hormone Research in Paediatrics.* 2021;94(Suppl. 1):1-445.
298. Karnoe A, Jakobsen MO, Nielsen SM, Ejskjaer N, Gudbergsen H. Clinically relevant improvement in glycaemic control in type 1 diabetes users of the hedia application for diabetes management: A real-world cohort study. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
299. Kesavadev J, Shankar A, Krishnan G, et al. Is time-in-range independent of A1C? A study in Asian Indian population. *Diabetes.* 2020;69(Supplement_1).
300. Kesavadev J, Shankar A, Warrier R, Krishnan G, Shamsudeen J, Jothydev S. Outlining the relationship between time in target(TIT) and HbA1c in asian Indians with diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
301. Keymeulen B, Jacobs-Tulleneers-Thevissen D, Sr., Kroon EJ, et al. Stem cell-derived islet replacement therapy (VC-02) demonstrates production of c-peptide in patients with type 1 diabetes (T1D) and hypoglycemia unawareness. *Diabetes.* 2021;70(Supplement_1).
302. Kim G, Bae J, Won J, et al. Effects of teneligliptin on continuous glucose monitoring-derived time-in range and glycaemic variability in patients aged 65 years and older with type 2 diabetes. 2020;63.
303. Kircher R, Wang Y, Dassau E, et al. Reducing postprandial hypoglycemia using fuzzy logic controller with insulin dosing governor. 2010.
304. Kohata Y, Ohara M, Fujikawa T, et al. Relationship between continuous glucose monitoring metrics and oxidative stress in patients with type 2 diabetes mellitus: A cross-sectional study. *Diabetes.* 2020;69(Supplement_1).
305. Kovatchev B. Systems-lessons learnt from clinical studies pivotal trial and real-life data of a closed-loop control (CLC) system-control IQ. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
306. Krinsley J. Time in range-the unifying metric of glycemic control in the critically ill. *Diabetes Technol Ther.* 2016;18:A1-139.
307. Kushner T, Dutta S, Sankaranarayanan S. Robust data-driven control of artificial pancreas systems using neural networks. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.

308. Kusinski LC, Brown J, Hughes D, Meek CL. Feasibility and acceptability of a novel home-based oral glucose tolerance test using continuous glucose monitoring for the diagnosis of gestational diabetes. *Diabetic Medicine.* 2021;38(S1).
309. La Banca RO, Volkening LK, Dassau E, Mehta SN, Laffel LM. Number of daily meals and snacks impacts glycemic outcomes in youth with T1D. *Diabetes.* 2020;69(Supplement_1).
310. La Banca RO, Volkening LK, Dassau E, Mehta SN, Laffel LM. Effect of macronutrient intake on glycemic outcomes over 1 year in youth with T1D. *Diabetes.* 2020;69(Supplement_1).
311. La Banca RO, Volkening LK, Milaszewski K, Dassau E, Mehta SN, Laffel LM. Inconsistent antecedent physical activity (PA) impacts nocturnal glycemia in youth with T1D. *Diabetes.* 2021;70(Supplement_1).
312. Laffel LM, Forlenza GP, Schoelwer M, et al. Omnipod® 5 automated insulin delivery system improves glycemic outcomes for people with type 1 diabetes across childhood development stages ranging from 2 to 26 years. *Pediatr Diabetes.* 2021;22:3-165.
313. Laguna Sanz AJ, Martin-San Agustín R, Ampudia-Blasco FJ, Bondia J. Impact of high-intensity interval training on nighttime glucose values by using intermittent CGM in people with type 1 diabetes: A pilot study. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
314. Lal R, Hsu L, Basina M, Buckingham B. Fiasp® (fast-acting insulin aspart) use with a medtronic™ 670G system. *Journal of Diabetes Science and Technology.* 2020;14(2):361-492.
315. Lal R, Quinlan A, Desborough L, Nykaza E. "Optimizing formulas for basal, CARB ratio and sensitivity factor for predictive controllers: lessons learned from loop". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
316. Lal R, Quinlan AE, Agris J, Desborough L, Nykaza E. Optimized carb ratio formula for pediatric type 1 diabetes. *Pediatric Diabetes.* 2021;22(S30):33-165.
317. Landau Z, Pinhas-Hamiel O, Modan-Moses D, et al. Dual diagnosis of type 1 diabetes and ADHD. *Pediatr Diabetes.* 2019;20(S28):41-231.
318. Landstra CP, Ruissen MM, Regeer H, et al. "Impact of the COVID-19 lockdown on behavior, stress, anxiety and glycemic control in patients with beta cell transplantation". *Transplantation.* 2021;105(12S1):S3-S3.
319. Lang J, Jangam S, Dunn T, Hayter G. Expanded real-world use confirms strong association between frequency of flash glucose monitoring and glucose control. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
320. Lanzinger S, Freckmann G, Grimsmann JM, et al. Temporal trends in diabetes technology use among children and adolescents with type 1 diabetes between 1995 and 2019: Results from the DPV registry. *Pediatric Diabetes.* 2021;22(S29):25-105.
321. Lathia T, Bhardwaj S, Joshi M, et al. Remote personalized continuous glucose monitoring system (CGMS) based nutritional coaching reduces glycosylated hemoglobin (HbA1c) at 90 days. *Endocr Pract.* 2020;26(2):161-166.
322. Lathia T, Joshi M, Ranadive R, et al. Personalized continuous glucose monitoring system (CGMS) based nutrition coaching has positive impact on time in range (TIR) in 14 days in patients with type 2 diabetes mellitus. 2020;26.
323. Laurenzi A, Bongiorno C, Caretto A, et al. Flash glucose monitoring improves hypoglycaemia awareness and reduces fear of hypoglycaemia in adult patients with type 1 diabetes. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
324. Laurenzi A, Pastorelli G, Caretto A, et al. Hybrid closed loop system and glucose control in patients with type 1 diabetes: Results from a single center study. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
325. Layne JE, He J, Jantz J, Zheng Y, Benjamin E, Ly TT. "Glycemic profiles and insulin use in 2,313 medicare-eligible older adults with diabetes using the omnipod insulin management system with cloud-based data management". *Diabetes.* 2019;68(Supplement_1).
326. Lecumberri E, Bengoa N, Argüeso MF, Chávez LN. Influence of glycemic control and variability on diabetic retinopathy in type 1 diabetes patients on continuous subcutaneous insulin infusion therapy. *Diabetes.* 2020;69(Supplement_1).
327. Lecumberri Pascual E, Martín Frías M, Vicente Santamaría S, et al. Effects on flash glucose monitoring parameters after 6-months use of ctfr modulators in cystic fibrosis patients with or without glucose metabolism abnormalities. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.

328. Lee M, Holmes-Walker J, Farrell K. "The impact of continuous glucose monitoring in youth with type 1 diabetes, aged 16-21". *Diabetes.* 2019;68(Supplement_1).
329. Lee MH, Vogrin S, Paldus B, et al. Postprandial glucose control using the medtronic advanced hybrid closed-loop system: faster-acting insulin Aspart vs. Insulin Aspart. *Diabetes.* 2020;69(Supplement_1).
330. Lee MY, Tanenbaum M, Maahs DM, Prahalad P. Overcoming barriers to diabetes technology in youth with type 1 diabetes and public insurance in the United States: Cases and call to action. *Pediatric Diabetes.* 2021;22(S30):33-165.
331. Leelarathna L, Thabit H, Bally L, et al. A novel composite glucose index (COGI) for evaluating closed- loop performance in type 1 diabetes. 2018;67.
332. Leiva-Gea I, Vázquez JG, Jurado FRL, Ruiz MAM, Hinojosa JJ, López-Siguero JP. Introduction of flash glucose monitoring in children with Type 1 diabetes: Experience of a single-centre in Spain. *Hormone Research in Paediatrics.* 2019;91(1):1-682.
333. Levin P, Bromberger LA, Bruce SR. Effective treatment of T2D patients uncontrolled on multiple diabetes medications by adding afrezza mealtime ultra-rapid insulin. *Diabetes.* 2019;68(Supplement_1).
334. Levin P, Snell-Bergeon J, Vigers T, Pyle L, Bromberger L. Effective treatment of patients with uncontrolled type 2 diabetes on multiple diabetes medications by adding mealtime ultra-rapid technosphere insulin. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
335. Levy CJ, O'Malley G, Brown SA, et al. Closed-loop control reduces hypoglycemia without increased hyperglycemia in subjects with increased prestudy hypoglycemia: Results from the IDCL DCLP3 randomized trial. *Diabetes.* 2020;69(Supplement_1).
336. Levy CJ, Omalley G, Brown SA, et al. Glucose variability throughout the menstrual cycle on closed-loop control in type 1 DM. *Diabetes.* 2019;68(Supplement_1).
337. Lewis DM, Swain RS, Donner TW. Improvements in A1C and Time-in-Range in DIY Closed-Loop (OpenAPS) Users. *Diabetes.* 2018;67(Supplement_1).
338. Lin YK, Hung M, Sharma A, et al. Lower Glucose Thresholds for Hyperglycemia Alarm and Narrower Threshold Range for Hyper/Hypoglycemia Alarm on Continuous Glucose Monitoring Systems Correlate with Lower Average Glucose Levels and Longer Time-in-Range. *Diabetes.* 2019;68(Supplement_1).
339. Ling J, Ozaki R, Luk A, Chan J, Chow E. Glycaemic variability and time-in-range during self-titration of once daily insulin glargine 300u/ml versus NPH (neutral protamine hagedorn) insulin in insulinnaive chinese type 2 diabetes patients. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
340. Ling P, Wang C, Yang D, et al. Relationship between time-in-range and laboratory HBA1C in pregnant women with type 1 diabetes mellitus. *Diabetes.* 2021;70(Supplement_1).
341. Ling P, Wang C, Yang D, et al. Relationship between Time-in Range and Laboratory HbAlc in Pregnant Women with Type 1 Diabetes Mellitus. *Diabetes.* 2021;70(Supplement_1).
342. Lingvay I, Koefoed M, Stachlewska K, Hansen M, Rosenstock J. Effect of three different titration algorithms of insulin icodec vs insulin glargine U100 on time in range in patients with type 2 diabetes inadequately controlled on OADs. 2020;63.
343. Liu L, Xu L, Ke W, et al. Time-in-range during short-term intensive insulin therapy is associated with clinical outcomes in patients with newly diagnosed type 2 diabetes. *Diabetes.* 2020;69(Supplement_1).
344. Liu S, Shomali M, Kumbara A, et al. A simplified approach for evaluating and visualizing cgm data in people with diabetes. *Diabetes.* 2021;70(Supplement_1).
345. Liu S, Shomali M, Kumbara A, et al. "A novel, automated ai method for detecting and classifying cgm patterns". *Diabetes.* 2021;70(Supplement_1).
346. Ljubic S, Cudina I, Jazbec A, Tomic M, Rahelic D. Increase in triglycerides seems to overwhelm glucovariability in development of diabetic retinopathy. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
347. Lu J, Ma X, Shen Y, et al. Association of time in range with carotid intima-media thickness in type 2 diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
348. Lu J, Xiaojing M, Lei Z, et al. Effects of metformin or acarbose as addon to insulin therapy on glycemic variability in type 2 diabetes. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.

349. Ludvigsson J, Nowak C, Hannelius U. Intralymphatic GAD-ALUM (Diamyd®) improves hyperglycemia and glycemic control in type 1 diabetes patients carrying HLA DR3-DQ2-exploratory analysis of continuous glucose monitoring data from the DIAGNODE-2 phase IIB clinical trial. *Pediatr Diabetes.* 2021;22:3-165.
350. Lukka M, Peet A, Tillmann V. Lowering postprandial hyperglycemia with dual-wave insulin boluses in children with type 1 diabetes mellitus. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
351. Lum J, Barnes-Lomen V, Bailey R, et al. Loop observational study: Evaluating do-it-yourself (DIY) automated insulin delivery. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
352. Lunder M, Janic M, Janez A. The addition of empagliflozin increases time in range in type 1 diabetes mellitus patients. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
353. Luo S, Ling P, Ding Y, et al. Association of continuous glucose monitoring (CGM)-derived parameters with adverse pregnancy outcomes in pregnant women with type 1 diabetes. *Diabetes.* 2020;69(Supplement_1).
354. Luxenburg J, Sayyed-Kassem L, Horowitz K. Use of a closed loop automated insulin delivery system in veterans over 65 years. *Journal of Diabetes Science and Technology.* 2020;14(2):361-492.
355. Ly T, Chernavvsky D, DeSalvo D, Shanmugham S, Breton M, Buckingham B. Day and night closed-loop control with the DIAS system in patients with type 1 diabetes at camp. *Diabetes Technology & Therapeutics.* 2015;17(S1):A-1-A-180.
356. Ly T, Roy A, Grosman B, et al. Hybrid closed-loop control using the medtronic 670G and Enlite3 system in type 1 diabetes at diabetes camp. *Diabetes Technology & Therapeutics.* 2015;17(S1):A-1-A-180.
357. Majithia AR, Kusiak C, Lee AA, et al. Improved A1c and tir in adults with T2D participating in a cgm-driven virtual diabetes clinic. *Diabetes.* 2020;69(Supplement_1).
358. Makkar BM, Soota K, Gupta V, et al. Therapeutic decisions based on interval analysis of blood glucose curves of ambulatory glucose profile help improving blood glucose and glycemic variability. *Diabetes.* 2020;69(Supplement_1).
359. Malecki M, Cao D, Liu R, Hardy TA, Bode BW, Bue-Valleskey JM. Ultra rapid lispro (URLi) improves postprandial glucose control and time in range in type 1 diabetes compared to lispro: PRONTO-T1D continuous glucose monitoring sub-study. 2019;62.
360. Maltoni G, Mozzillo E, Marigliano M, et al. The role of technology in real-life and the management of glucose variability in children and adolescents with type 1 diabetes and celiac disease. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
361. March C, Nanni M, Kavanaugh MK, et al. Time-in-Range (TIR) Is Suboptimal for Youth with Type 1 Diabetes during School. *Diabetes.* 2021;70(Supplement_1).
362. Margaritidis C, Karlafti E, Kotzakioulafi E, et al. Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring. 2021.
363. Marigliano M, Scaramuzza A, Bonfanti R, et al. Switching from basal-IQ to control-IQ technology in children and adolescents with type 1 diabetes: One week is enough to improve time in range. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
364. Marinac M, Hutton CT, Mansfield C, Sutphin J, Gallaher K, Sullivan S. How do patients and caregivers prioritize outcomes for type 1 diabetes (T1D) treatment? *Diabetes.* 2019;68(Supplement_1).
365. Marino M, Maffeis C, Chianese A, et al. Association of macronutrients intake with cgm-based time in range in children with T1D. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
366. Marlow A, King B, Johnson S, et al. "Introduction of a gluten free diet in children with type 1 diabetes and celiac disease did not impact glycemic control, nutrient intake or quality of life at 3 months". *Pediatric Diabetes.* 2021;22(S30):33-165.
367. Marlow AL, King BR, Johnson SE, et al. "Introduction of a gluten-free diet in children with type 1 diabetes and coeliac disease did not impact glycemic control, nutrient intake, or quality of life at three months". *Diabetes.* 2021;70(Supplement_1).
368. Martinez-Millana A, Årsand E, Traver V, Fernandez-Llatas C, Hartvigsen G. Discovering blood glucose regulation processes with process mining. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.

369. Martino M, Cusinato M, Gabrielli C, et al. "Anxiety, depression and glycemic control during COVID-19 pandemic: A cross sectional study in youths with type 1 diabetes". *Pediatric Diabetes.* 2021;22(S29):25-105.
370. Martyn-Nemeth P, Reutrakul S, Duffecy J, Quinn LT, Steffen AD. "A sleep intervention to improve sleep duration and variability, glucose, and distress in adults with type 1 diabetes". *Diabetes.* 2020;69(Supplement_1).
371. Masel A, Nikitina I, Todieva A, Yukhlina Y, Sorogina P. Experience of using the russified version of free style libre in children in the russian federation. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
372. Mazor-Aronovitch K, Pinhas-Hamiel O, Modan-Moses D, et al. Dual diagnosis of type 1 diabetes and ADHD. *Hormone Research in Paediatrics.* 2019;91(1):1-682.
373. Mazor-Aronovitch K, Pinhas-Hamiel O, Pivko-Levy D, et al. The effects of advanced technology in children with dual diagnosis of type 1 diabetes mellitus and attention deficit hyperactivity disorder. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
374. McAuley S, Vogrin S, Lee M, et al. Glucose time-in-range after type 1 diabetes education is not different between adults using insulin pumps and multiple daily injections. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
375. McAuley S, Vogrin S, Trawley S, et al. Older adults with type 1 diabetes: Glucose outcomes with technology and education. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
376. McAuley SA, Lee MH, Paldus B, et al. Six months at-home hybrid closed-loop vs. manual insulin delivery with finger-stick blood glucose monitoring in adults with type 1 diabetes: A randomized controlled trial. *Diabetes.* 2020;69(Supplement_1).
377. McAuley SA, Vogrin S, Trawley S, et al. Closed-loop increases time-in-range in older adults with type 1 diabetes compared with sensor-augmented pump therapy: A randomized crossover trial. *Diabetes.* 2021;70(Supplement_1).
378. McEachron KR, Yang Y, Pruett TL, Bellin M. IGLS classification for islet autotransplantation. *Diabetes.* 2020;69(Supplement_1).
379. McGill JB, Hirsch IB, Calhoun P, et al. Glycemic variability and progression of CKD: Perl substudy. *Diabetes.* 2020;69(Supplement_1).
380. McMahon C, Rodenzo W, Agrawal P, Welsh J, Vigersky R. "Glycometrics in 70,167 patients with type 2 diabetes derived from retrospective continuous glucose monitoring (CGM)". *Diabetes Technol Ther.* 2016;18:A1-139.
381. Meek C, Tundidor D, Feig D, et al. Continuous glucose monitoring metrics predict suboptimal materno-fetal outcomes in type 1 diabetes pregnancy. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
382. Meek CL, Kusinski LC, Tundidor D, et al. Optimal methods for assessment of glycaemia in type 1 diabetes pregnancy: How does HbA1c compare to continuous glucose monitoring metrics? An ancillary study of the CONCEPTT trial. *Diabetic Medicine.* 2020;37(S1):30-30.
383. Meiffren G, Andersen G, Eloy R, et al. "Ado09, a coformulation of insulin a21g and pramlintide (Pram), improves blood glucose control and reduces body weight in subjects with t1d". *Diabetes.* 2021;70(Supplement_1).
384. Meiffren G, Andersen G, Eloy R, et al. "ADO09, a coformulation of pramlintide (PRAM) and Insulin A21G, Improves Postprandial Glucose vs. Novolog in Type 1 Diabetes (T1D)". *Diabetes.* 2020;69(Supplement_1).
385. Meiffren G, Andersen G, Eloy R, et al. "ADO09, a co-formulation of pramlintide and insulin a21g improves post-prandial glucose (PPG) versus insulin aspart in type 1 diabetes (T1D)". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
386. Mena F, Revello Vega A, Grassi Corrales B, Costa Cordella S, Onetto Flores MT. Stress and metabolic goals in MiniMed640g users in a multidisciplinary educational program in Chile: Real life data. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
387. Messaaoui A, Tenoutasse S, Hajselova L, Crenier L. Flash glucose monitoring: Lower sensor usage in children with poorer diabetes control. *Pediatr Diabetes.* 2019;20(S28):41-231.
388. Messer L, Berget C, Towers L, et al. Evaluation of a Control IQ follow-up program by diabetes educators. *Pediatric Diabetes.* 2021;22(S29):25-105.

389. Messer L, Forlenza G, Wadwa RP, et al. Hybrid closed-loop (HCL) therapy in adolescents and young adults with type 1 diabetes (T1D) increases time in range. *Diabetes Technol Ther.* 2017;19(S1):A1-A133.
390. Messer LH, Hanes S, Tabatabai I, et al. Novel telehealth support intervention for young children using HCL. *Diabetes.* 2019;68(Supplement_1).
391. Michalak A, Pagacz K, Fendler W, Szadkowska A. Should we measure by the same yardstick? real-time continuous glucose monitoring and flash glucose monitoring provide different estimations of key clinical parameters. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
392. Migdal A, Zamudio KW, Perez-guzman MC, et al. Comparison of dexcom g6 continuous glucose monitoring performance between abdomen and upper arm placement in hospitalized patients with diabetes. *Diabetes.* 2021;70(Supplement_1).
393. Millar K, Cranston I, Kumar A, Nicholson E, Kar P. Assessing the implementation and impact of NHS England flash glucose monitoring reimbursement policy within Portsmouth type 1 diabetes service. *Diabet Med.* 2020;37:6-182.
394. Miller K, Kanapka L, Clements M, et al. Continuous glucose monitoring in teens and young adults (CITY) improves glycemic control: Primary results from a multi-center randomized clinical trial (RCT). *Pediatr Diabetes.* 2019;20(S28):41-231.
395. Miller K, Kanapka L, Rickels M, Pratley R. Benefit of continuous glucose monitoring (CGM) in reducing hypoglycemia is sustained through 12 months of use among older adults with type 1 diabetes (T1D). *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
396. Miyoshi A, Obara S, Wada N. Study of glycemic variability and hypoglycemia using continuous glucose monitoring in type 2 diabetes mellitus changed from basal-bolus therapy to basal-GLP-1Ra therapy. *Diabetes.* 2020;69(Supplement_1).
397. Mohebbi A, Bohm A-K, Tarp JM, Lind Jensen M, Bengtsson H, Morup M. Early Glycemic Control Assessment Based on Consensus CGM Metrics. *Annu Int Conf IEEE Eng Med Biol Soc.* 2021;2021:1269-1275.
398. Moreno CN, Ruíz DS, José E, García G, Elizagarate IM, Gila ALG. HbA1c and Glucose Management Indicator relationship: Can HbA1c determination be avoided? *Hormone Research in Paediatrics.* 2021;94(Suppl. 1):1-445.
399. Moreno-Fernandez J, Garcia-Seco JA, Seco A, Bustos R, Muñoz M, Rozas P. Real-world outcomes of two different sensor-augmented insulin pumps with suspension before low automatic function in type 1 diabetes patients. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
400. Morpurgo P, Rossi A, Lunati ME, et al. CGM-based clinical targets in adults with type1 and type2 diabetes using intermittently scanned continuous glucose monitoring (freestyle libre system): An Italian experience. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
401. Moscardó V, Gimenez M, Avari P, Reddy M, Oliver N. Influence of ambient temperature on glycaemic behaviour in type 1 diabetes patients. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
402. Moser O, Ziko H, Eckstein M, et al. Time in range (TIR) achievement in regard to clinical targets in people with type 1 diabetes (PWT1D): A real world setting. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
403. Mueller L, Constantin A, Singh H, Habif S. Control-IQ technology in the real world: The first 30 days. *Diabetes.* 2020;69(Supplement_1).
404. Mueller-Korbsch M, Frühwald L, Heer M, Fangmeyer-Binder M, Reinhart-Mikocki D. New insulin algorithm reduces carbohydrate (CHO) requirements during prolonged outdoor exercise. *Diabetes.* 2019;68(Supplement_1).
405. Mul D, Arrieta A, Dekker P, et al. Increased time in range and sustained AutoMode use in 670G hybrid closed-loop system users: real world experience in DIABETER. 2020;63.
406. Müller-Korbsch M. New insulin algorithm reduces carbohydrates (CHO) requirements during prolonged outdoor. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
407. Munch M, Smagala A, Meyer L, et al. "Randomized, multicentric, prospective study assessing the effect of adding vildagliptin to insulin in hemodialysed type 2 diabetic patients-the vilddial study". 2018;67.
408. Murphy N, Thanabalasingham G, Turner R, Hirst J, Owen KR. Pemphigoid gestation is in type 1 diabetes: Managing a rare complication of pregnancy with technology and a multidisciplinary team. *Diabetic Medicine.* 2021;38(S1).

409. Mustafa O. Glucose control during COVID-19 infection: Targets and acute derangements. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
410. Muthuvel G, Brady P, Daraiseh N, et al. Using artificial intelligence decision support to enhance care for type 1 diabetes. *Pediatric Diabetes.* 2021;22(S30):33-165.
411. Nagl K, Bozic I, Rami-Merhar B, Weimann K, Berger G, Mader J. Time-in-range without automated insulin delivery systems in children with type 1 diabetes before and during a diabetes summer camp-a glass ceiling? *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
412. Nattero-Chávez L, Silva JQ, Bengoa N, et al. The association between glycemic variability and cardiovascular autonomic neuropathy in patients with type 1 diabetes on continuous subcutaneous insulin infusion therapy. *Diabetes.* 2020;69(Supplement_1).
413. Negoita O, Cioca G, Radulian G, Elian V. Diabetes management indicator-a marker for estimating progress in management of diabetes using technology. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
414. Ng SM, Bray D, Guyers M. The Ormskirk Model: A new HbA1c-'Time in Range' solution focused model approach. *Pediatric Diabetes.* 2021;22(S29):25-105.
415. Ng SM, Katkat N, Day H, Hubbard R, Quinn M. "Improved HbA1c, time-in-range, hypoglycaemia frequency, sleep and quality of life measures with hybrid closed-loop in children and young people with type 1 diabetes and their carers". *Pediatric Diabetes.* 2021;22(S30):33-165.
416. Nimri R, Muller I, Atlas E, Phillip M. Personalized automated determination of insulin pump settings for people with type 1 diabetes switching from mdi to pump therapy and vice versa. *Diabetes.* 2020;69(Supplement_1).
417. Norlander L, Lal R, Arbiter B, Nykaza E, Buckingham B. Correlational analysis of 5AM glucose in the Tidepool Big Data Donation Project. *Pediatr Diabetes.* 2019;20(S28):41-231.
418. Norlander L, Onetto MT, Montt D, Sánchez R, Grassi B. "Self-reported physical fitness, perceived barriers, and glucose control during a 4-day trek in adults with type 1 diabetes". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
419. Norlander L, Tabatabai I, Berget C, et al. Glycemic outcomes and system adherence between age groups in pediatric subjects using a hybrid closed-loop pump. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
420. O'Malley G, Ozaslan B, Levister C, et al. Longitudinal observation of insulin use and glucose timein-range in T1D pregnancy. *Diabetes.* 2020;69(Supplement_1).
421. Ogionwo Lange E, Adolfsson P, Helm N. Glycemic control and satisfaction with analyses using an insulin pen with memory and downloading function. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
422. Onetto MT, Norlander L, Montt D, Sánchez R, Grassi B. "Time in range, insulin dose and carbohydrate loads during a 4-day trek in adults with type 1 diabetes using sensor augmented pumps: The D-experience". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
423. Ottanelli S, Clemenza S, Biagiotti C, et al. Hybrid closed-loop system used in a pregnant woman with type 1 diabetes: A case report. *The Journal of Maternal-Fetal & Neonatal Medicine.* 2021;34(sup1):1-128.
424. Ozaslan B, Levy CJ, Pinsker JE, et al. Safety and feasibility evaluation of closed-loop glycemic management in pregnant women with type 1 diabetes. *Diabetes.* 2021;70(Supplement_1).
425. Paldus B, Lee M, Morrison D, et al. A randomized trial of closed loop versus standard therapy in glycemic management during exercise. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
426. Palmer W, Greeley SAW, Letourneau LR, Naylor RN. Patients' experiences with a do-it-yourself artificial pancreas and perspectives of the endocrinologist's role in supporting their use. *Diabetes.* 2019;68(Supplement_1).
427. Paola L, Cioli P, Candeloro P, et al. Improved Glycemic Control with Insulin Glargine 300 U/ml vs. Glargine 100 U/ml in Type 1 Diabetes. *Diabetes.* 2020;69(Supplement_1).
428. Parikh S, Dyson J, Nikkel C. 24-hour wearable basal-bolus insulin delivery device improves time in range and treatment satisfaction over multiple daily injections-a pilot study. *Endocr Pract.* 2018;24(s1):1-300.
429. Parker AS, Derdzinski M, Puhr S, Welsh J, Walker T. Continuous glucose monitoring alerts for existing or impending hypoglycemia among children and adolescents. *Pediatr Diabetes.* 2019;20(S28):4-40.

430. Parker AS, Welsh J, Jimenez A, Walker T. Insights from big data (2): Benefits of self-guided retrospective review of continuous glucose monitoring reports. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
431. Parker AS, Welsh JB, Dunn LJ, Jimenez A, Balo AK. Insights from big data (1): Viewing of realtime continuous glucose monitoring data and its impact on time in range. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
432. Patel R, Crabtree TSJ, Taylor N, Langeland L, Wilmot EG, Idris I. Glycaemic outcomes of do-it-yourself artificial pancreas systems (DIYAPS) versus FreeStyle Libre (FSL) with concomitant insulin pump therapy (CSII): A cross-sectional comparison from the Royal Derby Hospital cohort. *Diabetic Medicine.* 2021;38(S1).
433. Pemberton J, Kershaw M, Dias R, et al. DYNAMIC: DYNAmic glucose Management strategies delivered through a structured education program improves time In range in a socioeconomically deprived cohort of children and young people with type 1 diabetes with a history of hypoglycemia. *Pediatr Diabetes.* 2021;22:4-105.
434. Perez-Nieves M, Hankosky ER, Fan L, et al. Continuous glucose monitoring utilization and associated metrics in people with diabetes on insulin therapy in the u.s. *Diabetes.* 2021;70(Supplement_1).
435. Peters AL, Walker MA, Ruelas VF. Improved outcomes with diabetes devices using lower-literacy teaching guides in a center for underserved individuals with type 1 diabetes. *Diabetes.* 2020;69(Supplement_1).
436. Petersson J, Åkesson K, Sundberg F, Särnblad S. Translating glycated hemoglobin A1c into time spent in glucose target range: A multicenter study. *Pediatric Diabetes.* 2018;19:14-40.
437. Petrovski G, Al Khalaf F, Campbell J, Fisher H, Umer F, Hussain K. How to successfully on-board patients with type 1 diabetes from multiple daily injection to hybrid closed loop system? *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
438. Petrovski G, Campbell J, Al Khalaf F, et al. Comparison of glycemic control between remote and in clinic initiation of advanced hybrid closed loop system MiniMed 780G in children and adolescents with type 1 diabetes. *Pediatric Diabetes.* 2021;22(S30):33-165.
439. Petrovski G, Campbell J, Alkhalaf F, Umer F, Hussain K. Six months experience on hybrid closed-loop system in children and adolescents previously treated with multiple daily injections. *Diabetes.* 2020;69(Supplement_1).
440. Petrovski G, Campbell J, Almajaly D, Al Khalaf F, Hussain K. Remote initiation of hybrid closed loop using skype in children and adolescents with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
441. Petrovski G, Campbell J, Almajy D, et al. Hybrid closed loop initiation using virtual pump training program in children and adolescents with type 1 diabetes previously treated with multiple daily injections. *Pediatric Diabetes.* 2021;22(S29):25-105.
442. Petruzelkova L, Soupal J, Plachy L, et al. An insulin pump with predictive low glucose suspend targets the time in range more effectively than MDI with CGM under repeated physical activity. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
443. Pettus J, Reeds D, Cavaiola TS, et al. "REMD-477, a human glucagon receptor (GCGR) antibody, reduces daily insulin requirements and improves glycemic control in people with type 1 diabetes (T1D)". 2017;66.
444. Pettus J, Reeds D, Santos Cavaiola T, et al. "REMD-477, a human glucagon receptor (GCGR) antibody, reduces daily insulin requirements and improves glycaemic control in people with type 1 diabetes". *Diabetologia.* 2017;60(Suppl 1):1-608.
445. Philis-Tsimikas A, Aroda VR, De Block C, et al. Higher derived time-in-range with ideglira vs. Insulin glargine u100 in patients with t2d. *Diabetes.* 2021;70(Supplement_1).
446. Phillips LS, Morehead F, Savoye LP, et al. Mealtime insulin 'rescue' with canagliflozin. *Diabetes.* 2019;68(Supplement_1).
447. Picard S. "Evolution of AGP parameters before, during and after lockdown in 80 french persons with type 1 diabetes sharing their FGM data on libreview". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
448. Piccini B, Barni F, Benucci F, et al. Lesson learnt with minimed 780g advanced hybrid closed-loop. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.

449. Piccini B, Pessina B, Barni F, et al. Metabolic control in type 1 diabetes patients switching to advanced hybrid closed loop. *Pediatric Diabetes.* 2021;22(S30):33-165.
450. Piccoli C, Puñales M, Ferreira AM, Tschiedel B. Evaluation of the metabolic control of chronically uncontrolled type 1 diabetes patients using the flash glucose monitoring followed by a quality of life and support program (PAQVIDA). *Diabetology & Metabolic Syndrome.* 2019;11(S1).
451. Pieralice S, Tuccinardi D, Kyanvash S, et al. SGLT2 inhibitors as adjuvant therapy for type 1 diabetes: An Italian center experience. *Diabetes.* 2020;69(Supplement_1).
452. Pinheiro SL, Bastos M, Barros L, Melo M, Paiva I. Flash glucose monitoring and glycemic control in type 1 diabetes with subcutaneous insulin infusion flash glucose monitoring and glycemic control. *Acta Diabetol.* 2021;59(4):509-515.
453. Pinsker JE, Deshpande S, Church MM, et al. At-home randomized crossover comparison of automated insulin delivery vs. Conventional therapy with scheduled meal challenges. *Diabetes.* 2020;69(Supplement_1).
454. Piona C, Yesxiltepe Mutlu G, Grad K, et al. Non-adjunctive flash glucose monitoring use during summer camp in children with type 1 diabetes-the free-summer study. *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
455. Plachy L, Jiranova P, Neuman V, et al. Worse glycemic control by FGM compared to CGM in children with T1D during sustained physical activity. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
456. Platonov V, Patrakeeva E, Skorodok J, Plotnikova E, Dubinina T. Influence of insulin degludec therapy on frequency of daily scanning of flash glucose monitoring system in children with type 1 diabetes with initially low glucose variability. *Pediatric Diabetes.* 2021;22(S30):33-165.
457. Platonov V, Patrakeeva E, Skorodok J, Plotnikova E, Dubinina T. "Glucose variability, glycated hemoglobin, and time in range in children with type 1 diabetes after switching from basal insulin detemir to degludec". *Pediatric Diabetes.* 2021;22(S30):33-165.
458. Polsky S, Levy CJ, Zhang X, et al. "Differences in time-in-range, glycemic variability, and the glucose management indicator in pregnant women with type 1 (T1D), type 2 (T2D), and gestational diabetes (GDM)". *Diabetes.* 2020;69(Supplement_1).
459. Polsky S, Pyle L, Garcetti R, et al. Associations between indices of glycemic variability (GV) and gestational outcomes among pregnant women with type 1 diabetes (T1D). *Diabetes.* 2019;68(Supplement_1).
460. Pozzi E, Savastio S, Ricotti R, Zanetta S, Rabbone I. Effectiveness and safety of GLARGIN 300 U/mL versus GLARGINE 100 U/mL in a cohort of patients with Type 1 diabetes. *Pediatric Diabetes.* 2021;22(S30):33-165.
461. Prahalad P, Addala A, Scheinker D, Maahs D. Publicly insured youth continue to use CGM up to 2 years following CGM initiation. *Pediatr Diabetes.* 2019;20(S28):41-231.
462. Prahalad P, Ith A, Scheinker D, et al. Successful CGM initiation early in the course of T1D results in persistence of use. *Pediatr Diabetes.* 2019;20(S28):4-40.
463. Prahalad P, Scheinker D, Hood KK, et al. Early CGM initiation in new-onset type 1 diabetes patients. *Diabetes.* 2019;68(Supplement_1).
464. Préau Y, Armand M, Galie S, Schaepelynck P, Raccah D. Potential benefit of switching from iscgm (freestyle libre) to rtcgm (DEXCOM G4) on AGP parameters in poorly controlled type 1 diabetes patients over 1-year follow-up. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
465. Préau Y, Galie S, Schaepelynck P, Armand M, Raccah D. Is estimated glucose disposal rate a pertinent score predicting the glycemic control benefit of switching from iscgm to RTCGM in type 1 diabetes patients ? *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
466. Preiser JC, Lheureux O, Thooft A, Brimioulle S, Vincent JL. Effects of near-continuous glucose monitoring as a guide for glycemic control: A cluster-randomized study. *Intensive Care Medicine Experimental.* 2016;4(S1).
467. Price DA, Riddlesworth T, Beck RW, Wolpert HA, Bergenstal RM, Ahmann AJ. Effect of continuous glucose monitoring on glycemic control in adults using multiple daily insulin injections. 2017;66.
468. Proietti A, Daghero A, Kabakian ML, et al. Short term glycemic control with a hybrid closed loop system in individuals with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
469. Proietti A, Daghero A, Kabakian ML, et al. Six month glycemic control with a hybrid closed loop system in individuals with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.

470. Proietti AE, Angós MA, Dain A, et al. Six-month glycemic control with a hybrid closed-loop system in type 1 diabetes patients during COVID-19 pandemic in Argentina. *Diabetes.* 2021;70(Supplement_1).
471. Pujante P, Ares J, Alonso C, Rodriguez-Escobedo R, Delgado E, Menendez E. Flash glucose monitoring system (FSL) improve glucose control specially in csii users. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
472. Pulkkinen MA, Tuomaala AK, Sarkola T, et al. Motivational interview to improve metabolic control in adolescents with poorly controlled type 1 diabetes: A randomized controlled trial. *Pediatr Diabetes.* 2019;20(S28):41-231.
473. Purwoto J. Hypoglycemia due to pancreatic tumor: Glycemic profile seen with continuous glucose monitoring. 2020;26.
474. Purwoto J. Comparation of continuous glucose monitoring in type 1 diabetes mellitus patient during fasting month and non-fasting times. 2020;26.
475. Quiros C, Alonso N, Valverde M, et al. Analysis of insulin pump device replacement in a group of type 1 diabetes patients in a structured program. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
476. Quirós C, Giménez M, Rossetti P, et al. Better postprandial glucose control with a new closed-loop system as compared with open-loop treatment in patients with type 1 diabetes. *Diabetologia.* 2016;59:1-581.
477. Ramkissoon CM, Bertachi A, Beneyto A, Vehi J. Insulin-only blood glucose control during unannounced aerobic exercise. 2019;13.
478. Ranjan AG, Boiroux D, Laugesen C, et al. Performance of a dual hormone closed-loop system vs. An insulin-only closed-loop system during challenging inpatient conditions: A single-blinded randomized controlled crossover trial. *Diabetes.* 2021;70(Supplement_1).
479. Rebollo Román Á, Alhambra Expósito MR, Moreno Moreno P, Palomares Ortega R, Gálvez Moreno MÁ. Flash glucose monitoring: Impact on glycemic control. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
480. Reiter M, Reiterer F, Christensen MB, Nørgaard K, Del Re L. Assessing artificial pancreas performance in T2DM. 2017;66.
481. Ren Q, Gong S, Han X, Ji L. "Hereditary renal glycosuria, diabetes, and responses to SGLT2 inhibitor". *Diabetes.* 2021;70(Supplement_1).
482. Renard E, Tubiana-Rufi N, Bonnemaison E, et al. Automated insulin delivery in free-life shows better glucose control when used 24/7 vs evening and night in pre-pubertal children with type 1 diabetes: The Free-life Kid AP Study. *Diabetologia.* 2020;63(Suppl 1):1-485.
483. Rickels MR, Bellin M, Stefanovski D, et al. A-OR ß-adrenergic blockade does not affect transplanted islet responses to hypoglycemia in type 1 diabetes (T1D). *Diabetes.* 2020;69(Supplement_1).
484. Rida R, Manzano AJ. Improving hemoglobin A1c and treatment satisfaction of elderly adults with type 2 diabetes mellitus using the omnipod system and continuous glucose monitoring. *Diabetes.* 2021;70(Supplement_1).
485. Riddell M, Li Z, Beck R, et al. More time-in-range during days with structured exercise vs. Sedentary days in adults with type 1 diabetes. *Diabetes.* 2019;68(Supplement_1).
486. Riddell M, Li Z, Gal RL, et al. Glycemic trends in a hockey camp for youth with type 1 diabetes (T1D). *Diabetes.* 2020;69(Supplement_1).
487. Rizvi AA, Eberlein C. Cgm use in ambulatory insulin-treated patients following hospital discharge. *Diabetes.* 2021;70(Supplement_1).
488. Rodbard D. Composite measures of glycemic control. *Diabetes Technol Ther.* 2016;18:A1-139.
489. Rodbard D, He X, Wang W, et al. "Use of connected insulin pen to evaluate the effects of pre-meal, delayed, missed, and correction boluses on prandial glucose control in T1D and T2D". *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
490. Rodbard D, Xue J, He X, Johnson J, Wolpert H. Missed prandial insulin boluses reduce time in range (TIR) and increase time above range (TAR): New methods of analysis. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
491. Rodrigues Ferreira F, Lyra A, Santiago Moisés RC, De Noronha RM, Calliari LE. The potential role of intermittent continuous glucose monitoring in a successful outpatient transition from insulin

to glibenclamide in a patient with transient neonatal diabetes in the context of the COVID-19 pandemic. *Pediatric Diabetes.* 2021;22(S30):33-165.
492. Romero Ugalde HM, Franc S, Charpentier G, Benhamou PY, Doron M. "Performance of the diabeloop artificial pancreas is not correlated to age, body weight, sex, or exercise". *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
493. Rossi A, Montefusco L, Pastore IF, et al. In-hospital real time continuous glucose monitoring during COVID-19 outbreak: Experience from a covid hub. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
494. Roversi C, Vettoretti M, Del Favero S, Facchinetti A, Sparacino G. Simple formulas to predict quantitative impact of meal insulin bolus timing on glycemic control indeces in type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
495. Russell S, Balliro C, Ekelund M, et al. Investigating the safety and glycaemic control of fast-acting insulin aspart with a closed-loop delivery system in adults with type 1 diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
496. Russell S, Jafri R, Sherwood J, et al. Use of the ultra-rapid insulin fiasp in the ilet bionic pancreas. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
497. Russell SJ, Balliro CA, Sherwood J, et al. Performance of the bihormonal ilet bionic pancreas with the stable glugagon analog dasiglucagon. *Journal of Diabetes Science and Technology.* 2020;14(2):361-492.
498. Sabharwal M, Palukuri S, Deka S, Chanana G, Kumar R. Using CGM as feedback tool in diabetes mellitus patients management: A retrospective real-world evidence study conducted in india. *Diabetes.* 2020;69(Supplement_1).
499. Salabelle C, Ly Sall K, Eroukhmanoff J, Franc S, Dang Duy TL, Amadou C. COVID-19 pandemic lockdown effect in adolescents and young adults with type 1 diabetes: Positive results of an unpreceded challenge for telemedicine and patient self-management. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
500. Sanchez P, Ghosh-Dastidar S, Tweden K, Kaufman F. Percent of patients with targeted time in range and time in hypoglycemia with the eversense CGM system. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
501. Sanchez P, Ghosh-Dastidar S, Tweden K, Kaufman F. Correlation between time in range and glucose management indicator with the eversense CGM system. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
502. Sandy J, Phan P, Neville K. Successful use of a hybrid closed loop system using dilute insulin in an infant with type 1 diabetes mellitus. *Pediatric Diabetes.* 2021;22(S30):33-165.
503. Scaramuzza A, Bonetti L, Cavalli C. 3-month evaluation of advanced hybrid closed-loop in children and adolescents with type 1 diabetes: A single-center experience in Italy. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
504. Scaramuzza A, Bonetti L, Soliani M, Cavalli C. Effectiveness and safety of a hybrid closed loop system in children and adolescents with type 1 diabetes: 1-year evaluation. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
505. Scaramuzza A, Hosny Awad M, Bonetti L, Soliani M, Del Miglio R, Cavalli C. 640g minimed system effectiveness in children and adolescents with type 1 diabetes: Education plus technology ensure higher %time in target range (70-160 mg/dl). *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
506. Scaramuzza A, Minuto N, Marigliano M, et al. Pros and cons of Minimed 670G hybrid closed-loop system: First 6-month experience in Italy. *Pediatr Diabetes.* 2019;20(S28):41-231.
507. Scaramuzza A, Rabbone I, Bonfanti R, et al. Predictive low-glucose suspend (Tandem t:Slim X2 basal IQ) is effective in young children with type 1 diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
508. Scaramuzza AE, Rabbone I, Bonfanti R. "Minimed 640G vs. Minimed 670G, a comparison in children and adolescents with diabetes type 1". *Diabetes.* 2019;68(Supplement_1).
509. Scawn N, Coulson N, Kemp I, et al. First clinical study data from therapeutic use of a novel continuous glucose monitoring system in the ICU. *Critical Care.* 2014;18(Suppl 1).
510. Schierloh U, Ware J, Allen JM, et al. CAMAPS FX hybrid closed-loop in very young children with T1D: A multi-national 4-month randomized trial. *Pediatr Diabetes.* 2021;22:3-165.

511. Schoelwer M, Robic J, Brown S, DeBoer M, Chernavvsky D, Breton M. Safety and efficacy of initializing a Control-IQ automated insulin delivery system with total daily insulin. *Pediatr Diabetes.* 2019;20(S28):41-231.
512. Schütz A, Schütz-Fuhrmann I, Mader J. Case series of four women with type 1 diabetes mellitus using do-it-yourself artificial pancreas systems during pregnancy. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
513. Scott R, Allen J, Jones B, et al. Neonatal outcomes are not affected by glycaemic variability in the 24h prior to delivery in women with type 1 diabetes. *Diabetic Medicine.* 2020;37(S1):30-30.
514. Scott SN, Fontana FY, Martinez-Gonzalez B, et al. Training load and time-in-range affect sleep time of professional cyclists with type 1 diabetes. *Diabetes.* 2020;69(Supplement_1).
515. Secher AL, Pedersen-Bjergaard U, Svendsen OL, et al. Intermittently scanned continuous glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: A randomized controlled trial. *Diabetes.* 2021;70(Supplement_1).
516. Shah V, Vigers T, Snell-Bergeon J. Transition from insulin pump to multiple daily injections using insulin degludec: Interim results from a randomized controlled trial. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
517. Shankar K, Hastedt P, Derdzinski M, Welsh J, Barger C, Cohen G. Automatically generated continuous glucose monitoring (CGM) notifications and their association with glycemic control. *Diabetes.* 2020;69(Supplement_1).
518. Sharifi A, Cohen N, De Livera A. The impacts of non-glycaemic variables on relationship between laboratorymeasured hba1c and glucose management indicator calculated by flash glucose monitoring system in patients with diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
519. Sherr J, Forlenza G, Buckingham B, et al. Performance of omnipod® 5 automated insulin delivery system at specific glucose targets from 110-150mg/dl over three months in children with type 1 diabetes (T1D). *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
520. Sherr JL, Bode BW, Forlenza GP, et al. Glycemic control with the Omnipod® 5 automated insulin delivery system in very young children with type 1 diabetes. *Pediatr Diabetes.* 2021;22:3-165.
521. Shin J, Bailey T, Buckingham B, et al. Study design of the MiniMed® 670G hybrid closedloop (HCL) system pivotal trial in a cohort aged 2-13 years with type 1 diabetes (T1D). *Pediatric Diabetes.* 2017;18:138-177.
522. Shin J, Cordero T, Chen X, Peng F, Cohen O, Vigersky R. The spectrum of association between HbA1c and time-in-range (TIR). *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
523. Shin J, Huang S, Troub T, Lee S, Cordero T, Kaufman F. "Study design of randomized, adaptive trial in adult and pediatric patients with type 1 diabetes using hybrid closed loop versus control (CSII, MDI or SAP)". *Diabetes Technol Ther.* 2018;20(S1):A1-A152.
524. Shlomo YB, Azulay S, Raveh-Sadka T, Cohen Y, Hanemann A. "Personalized, machine learning-based nutrition reduces diabetes markers in type 2 diabetic patients". *Diabetes.* 2019;68(Supplement_1).
525. Siegler E, Litvin M. 22 Unique challenges of treating women with cystic fibrosis-related diabetes in pregnancy. *Journal of Cystic Fibrosis.* 2021;20.
526. Singh H, Leas S, Habif S. Glycemic trends in people with type 1 diabetes based on their time of adoption of control-IQ technology. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
527. Singh H, McElwee-Malloy M, Sanchez H, Habif S. ""I feel human, i feel normal" a qualitative study of experiences with control-iq technology in early adopters". *Diabetes.* 2021;70(Supplement_1).
528. Skvarca A. The introduction of minimed 670g hybrid closed loop insulin pump auto mode system improves glycaemic control in routine clinical practice. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
529. Slover R, Brazg R, Bailey T, et al. Dynamic insulin delivery rate at nighttime. *Diabetes Technol Ther.* 2017;19(S1):A1-A133.
530. Smagala A, Munch M, Meyer L, et al. Effect of vildagliptin added to insulin on glycaemic control in haemodialysis patients with type 2 diabetes: A randomised multicentre prospective study. *Diabetologia.* 2018;61(Suppl 1):1-620.
531. Smith M, Gaetano A, Thanasekaran S, Heungyong Im G, Lewis J, MacLeod J. Smart insulin pens improve time below range in multiple daily insulin therapy. 2020;26.
532. Smith T, Venkatesh N, Roem K, et al. "Efficacy and acceptability of OptimAAPP, a novel smartphone insulin dose calculator for carbohydrate, fat and protein: A randomised cross-over

trial in children and adults with type 1 diabetes using multiple daily injection therapy". *Pediatric Diabetes.* 2021;22(S30):33-165.
533. Snell-Bergeon J, Akturk HK, Beck EA, et al. Improved time-in-range on continuous glucose monitor with Technosphere insulin compared to insulin Aspart in adults with type 1 diabetes: Stat study per protocol analysis. 2018;61.
534. Snell-Bergeon JK, Akturk HK, Rewers A, et al. Improved Time-in-Range (TIR) on Continuous Glucose Monitor (CGM) with Technosphere Inhaled Insulin (TI) Compared with Insulin Aspart in T1D Patients-STAT Study. *Diabetes.* 2018;67(Supplement_1).
535. Snowball J, Corry H, Hart A, et al. Initial impact of flash glucose monitoring for patients with Cystic Fibrosis-Related Diabetes. *Journal of Cystic Fibrosis.* 2020;19.
536. Sobel SI, Ruppert K, McCarthy PM, Siminerio LM, Rometo DA. Remission through early monitored insulin therapy: Duration month. *Diabetes.* 2020;69(Supplement_1).
537. Soriano E, Laurenceau J-P. Visible and invisible spousal support in daily diabetes self- care. *Diabetes.* 2020;69(Supplement_1).
538. Soupal J, Hásková A, Grunberger G, et al. Is real-time CGM superior to flash glucose monitoring? Results of the type 1 diabetes CORRIDA randomized control trial. *Diabetes.* 2020;69(Supplement_1).
539. Srivastava B, Deepa M, Anjana RM, Madhavi K, Mohan V. "Effect of fiasp on glycaemic targets in type 2 diabetic subjects, when used in the medtronic minimed 640g continuous subcutaneous insulin infusion (CSII) pump". 2020;26.
540. Suplotova LA, Sudnitsyna AS, Romanova NV, Shestakova MV. Time in range is a tool for assessing the quality of glycemic control in diabetes. *Diabetes mellitus.* 2021;24(3):282-290.
541. Szypowska A, Groele L, Dzyga?o K. Open hybrid closed loop insulin delivery systems in children and adults with type 1 diabetes - Polish experience. *Pediatr Diabetes.* 2019;20(S28):232-254.
542. Tait J, Velcani F, Shoger E, Wood R, Kaufman F. Time-in-range: A top metric for endocrinologists treating patients with type 1 diabetes and type 2 on intensive insulin. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
543. Takeishi S, Inoue T. Prediction of hypoglycemia in patients treated with insulin glargine 300 u/ml for basal insulin therapy. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
544. Takeishi S, Inoue T. Comparison of glycemic variability values derived from flash glucose monitor and continuous glucose monitor. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
545. Takeishi S, Inoue T. Achieving both target time-in-range and coefficient of variation. *Diabetes.* 2021;70(Supplement_1).
546. Takeishi S, Tsuboi H. Influence of glucose measurement interval on glycemic variability values. *Diabetes.* 2020;69(Supplement_1).
547. Takeishi S, Tsuboi H. Estimated HbA1c discordance: Should estimated HbA1c be derived from time-in-range or mean glucose levels? *Diabetes.* 2020;69(Supplement_1).
548. Tanenbaum M, Ngo J, Hanes S, et al. Pilot of a behavioral intervention for cgm users decreases diabetes distress and improves time in range in adults with type 1 diabetes (T1D). *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
549. Taylor GS, Stefanetti RJ, Cassidy S, et al. Moderate to vigorous physical activity is not associated with increased hypoglycaemia or glycaemic variability in individuals with type 1 diabetes. *Diabetologia.* 2018;61(Suppl 1):1-620.
550. Tejedor Hernandez M, Myhre J, Launonen I, Godtliebsen F. Evaluating reward functions for blood glucose control using reinforcement learning in the artificial pancreas. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
551. Teoh ST, Hong JYH, Hussain S. Short-term glycaemic changes from continuous glucose monitoring among children and adolescents with type 1 diabetes mellitus during fasting in Ramadan month. *Hormone Research in Paediatrics.* 2021;94(Suppl. 1):1-445.
552. Thabit H, Leelarathna L, Wilinska ME, et al. Looking beyond HBA1C-evaluating glycaemic control during closed-loop use in type 1 diabetes. 2018;67.
553. Thivolet C, Mestre B, Reffet S, Brunot S, Pollin-Javon C. Use of sensor-integrated pump therapy in people with type 1 diabetes reduces hypoglycemia unawareness and improves general health. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
554. Timmons JG, Boyle JG, Petrie JR. Time in Range as a Research Outcome Measure. *Diabetes Spectr.* 2021;34(2):133-138.

555. Tinti D, Bonfanti R, Abate Daga F, et al. Comparison of basal insulin in adolescents with type 1 diabetes during a school camp. the GLiDE Study. *Pediatr Diabetes.* 2019;20(S28):41-231.
556. Tirosh A, Shalit R, Hirsh ML, et al. Unannounced meals at home with the medtronic advanced hybrid closed-loop. *Diabetes.* 2020;69(Supplement_1).
557. Tomlinson G, Murphy HR, Feig D. Impaired awareness of hypoglycemia and maternal/neonatal outcomes in the conceptt trial jasmine bahrami. *Diabetes.* 2020;69(Supplement_1).
558. Toschi E. CGM derived data in elderly PWD treated by MDI. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
559. Toschi E, Riddlesworth T, Ruedy K, Kollman C, Price D, Beck R. A randomized trial comparing continuous subcutaenous insulin infusion versus continuing multiple daily insulin injections in patients with type 1 diabetes using continuous glucose monitoring. *Diabetes Technol Ther.* 2017;19(S1):A1-A133.
560. Toschi E, Slyne C, Atakov-Castillo A, et al. Use of real time continuous glucose monitoring (CGM) in real life clinical practice compared with finger-stick glucose monitoring. 2018;67.
561. Toschi E, Slyne C, Atakov-Castillo A, Munshi M. Use of closed-loop insulin therapy in older adults with type 1 diabetes: Real-world experience. *Diabetes.* 2021;70(Supplement_1).
562. Toschi E, Slyne C, Michals A, et al. Usefulness of cgm metrics to assess glycemic control in non-white subjects with diabetes. *Diabetes.* 2021;70(Supplement_1).
563. Tourki Y, Lachal S, Huneker E. Unannounced meal management validation. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
564. Trawley S, McAuley S, Lee M, et al. Driven to hyperglycaemia: Adults with type 1 diabetes have higher glucose levels when driving. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
565. Treiber G, Novak E, Häntschel E, Mader J. Challenges with diy loop in pregnancy with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
566. Tropeano Y, Purushothaman P, Gilbert C, Morgan K, Doodson L, Dastamani A. Efficacy of Use of Continuous Glucose Monitoring System in patients with Congenital Hyperinsulinism. *Hormone Research in Paediatrics.* 2021;94(Suppl. 1):1-445.
567. Trufanova E, Sorokin D, Rebrova O, Laptev D, Peterkova V. Clinical decision support system for personalized therapy children with type 1 diabetes mellitus. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
568. Tsoukas M, Palisaitis E, Rutkowski J, et al. Alleviating carbohydrate counting with a fiasp-and-pramlintide artificial pancreas: A randomized pilot study. *Diabetes.* 2020;69(Supplement_1).
569. Tundidor D, Meek C, Yamamoto J, Feig D, Murphy H, Corcoy R. Time in range targets in pregnant women with type 1 diabetes: Achievement and association with pregnancy outcomes. An ancillary study of the conceptt trial. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
570. Tuomaala AK, Miettinen P, Pulkkinen MA. Metabolic control of 44 type 1 diabetic toddlers followed up in helsinki university hospital is good. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
571. Tweden K, Ghosh-Dastidar S, Dehennis AD, Kaufman F. Real-world data from U.S. Patients using a long-term implantable continuous glucose monitoring (CGM) system: Age effect on glycemic control. *Diabetes.* 2020;69(Supplement_1).
572. Tweden K, Sanchez P, Ghosh-Dastidar S, Kaufman F. The effect of age on glycemic outcomes in a large cohort of eversense CGM system adult users. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
573. Tyler N, Dodier R, Mosquera-Lopez C, et al. A k-nearest-neighbors approach to the design of an mdi decision support system in type 1 diabetes. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
574. Tyler NS, Hilts W, Mosquera-Lopez CM, et al. Comparison of artificial-intelligence decision support for multiple daily injection therapy with automated insulin delivery after 3 months of use in silico. *Diabetes.* 2020;69(Supplement_1).
575. Uduku C, Jugnee N, Pendolino V, Oliver N, Fothergill R, Reddy M. The assessment of impact of real-time continuous glucose monitoring on people presenting with severe hypoglycaemia (AIR-CGM) study. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.

576. Unsworth R, Godsland I, Avari P, et al. The effect of lockdown and easing of restrictions on glycaemia in children with type 1 diabetes during the COVID-19 pandemic. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
577. Urakami T, Yoshida K, Kuwabara R, Mine Y, Aoki M, Suzuki J. Significance of CBM-derived glycemic markers in Japanese children and adolescents with type 1 diabetes. *Pediatric Diabetes.* 2021;22(S29):25-105.
578. Urakami T, Yoshida K, Kuwabara R, Mine Y, Aoki M, Suzuki J. Association between scanning frequency and CGMderived glycemic makers in children and adolescents with type 1 diabetes. *Pediatric Diabetes.* 2021;22(S29):25-105.
579. Valcarce C, Freeman J, Dunn I, et al. Future of adjunctive therapy: Simplifying the treatment of t1d through GK activation. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
580. Valcarce C, Freeman JL, Dunn I, Klein K, Buse JB. The simplici-T1 trial: Relationship between glycemic control and insulin dose. *Diabetes.* 2020;69(Supplement_1).
581. Valls A, Murillo M. Glycemic control and changes in habits in patients with type 1 diabetes during the lockdown due to the COVID-19 pandemic. *Hormone Research in Paediatrics.* 2021;94(Suppl. 1):1-445.
582. Van Der Linden JH, Puhr S, Welsh J, Walker TC. Frequent engagement with retrospective real-time cgm data is associated with improved glycemic control. *Diabetes.* 2021;70(Supplement_1).
583. Venerová J, Fialová B, Brabcová J, et al. Flash glucose monitoring in adults with T1D: Engagement needed from both patients and clinicians. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
584. Vianna AGD, De Lacerda CS, Sr., Pechmann LM, et al. "A randomized controlled trial to compare the glycemic effects of dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, and gliclazide modified release, a sulfonylurea, assessed by continuous glucose monitoring among people with type 2 diabetes". *Diabetes.* 2019;68(Supplement_1).
585. Vianna AGD, De Lacerda CS, Pechmann LM, et al. "A randomized controlled trial to compare the glycemic effects of dapagliflozin, a sodium glucose cotransporter 2 inhibitor, and gliclazide modified release, a sulphonylurea, assessed by CGMS". *Diabetology & Metabolic Syndrome.* 2019;11(S1).
586. Vieira I, Melo M, Baptista C, Barros L, Rodrigues D, Paiva I. Differential HbA1c-glucose management indicator: magnitude and relationship with continuous glicose monitoring parameters. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
587. Vigersky R, McMahon C. The relationship of hemoglobin A1c to cgm-derived time-in-range in patients with diabetes. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.
588. Vigersky RA, Thomas A, Shin J, Jiang B, McMahon C. Analysis of the minimed 670g pivotal trial data using novel composite metrics. 2017;66.
589. Vinãls C, Beneyto A, Martín-Sanjosé JF, et al. Automatic control of blood glucose under announced and unannounced exercise using a new multivariable closed loop controller with automatic carbohydrate suggestion and mitigation module. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
590. Visser M, Charleer S, Fieuws S, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: The six-month multicenter randomized controlled alertt1 trial. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
591. Von Dem Berge T, Remus K, Biester S, et al. International consensus targets are achievable for preschoolers: Hybrid closed loop use in children from 2-14 years. *Pediatr Diabetes.* 2021;22:3-165.
592. Von Dem Berge T, Remus K, Biester S, et al. Attd consensus targets are achievable for preschoolers: Hybrid closed loop use in children from 2-14 years. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
593. Vural S, Kahlert C, Gozzi T, et al. Metabolic Control and Health-Related Quality of Life in Children with Diabetes Mellitus during the COVID-19 Pandemic: Results from a Prospective Swiss Cohort Study. *Hormone Research in Paediatrics.* 2021;94(Suppl. 1):1-445.
594. Wadwa RP, Hanes S, Clay M, et al. Impact of early initiation of continuous glucose monitoring on glycemic control in pediatric patients with type 1 diabetes. *Diabetes Technology & Therapeutics.* 2019;21(S1):A-1-A-164.

595. Walker TC, Calhoun P, Johnson TK, Welsh JB, Price DA. Associations between HbA1C and continuous glucose monitoringderived glycaemic parameters. *Diabetologia.* 2018;61(Suppl 1):1-620.
596. Wang K, Florissi C, Pang C, Wood R. Examination of time in range as a correlate of subjective well-being in glucose sensor users with type 1 diabetes. 2020;63.
597. Weaver K, Minahan J, Rittereiser M, Rosenbloom S, Trence D. When translational medicine hits reality: The hybrid closed-loop insulin delivery system in real-life patient experience. *Endocr Pract.* 2018;24(s1):1-300.
598. Weiner A, Robinson E, Gandica R. Effects of the T:SLIM X2 insulin pump with basal-IQ technology on glycemic control in a pediatric urban academic diabetes practice. *Diabetes.* 2020;69(Supplement_1).
599. Weinstock R, Hirsch I, Forlenza G, et al. "Regular users of temporary basal rate or extended bolus have better glycaemic outcomes in 12,823 Omnipod® insulin management system users with type 1 diabetes". *Diabetic Medicine.* 2021;38(S1).
600. Wexler Y, Goldner D. Large-scale association of basal metabolic rate and blood glucose outcomes in people with type 2 diabetes. *Diabetes.* 2021;70(Supplement_1).
601. Wilmot E, Deshmukh H, Herring R, et al. The Association of British Clinical Diabetologists (ABCD) audit of FreeStyle Libre (FSL) in diabetes in the UK: Determinants of time in target range. *Diabetic Medicine.* 2020;37(S1):30-30.
602. Wilmot EG, Deshmukh H, Patmore J, et al. The association of british clinical diabetologists audit of freestyle libre (FSL) in diabetes in United Kingdom: Determinants of time-in-target range. *Diabetes.* 2020;69(Supplement_1).
603. Wilmot EG, Lumb A, Hammond P, et al. Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic. *Diabet Med.* 2021;38(1):e14433.
604. Wu Z, Luo S, Zheng X, Yan J, Yang D, Weng J. Use of do-it-yourself hybrid closed-loop is assosiciated with better glucose management and higher quality of life among adults with type 1 diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
605. Wyckoff JA, Brown FM. Time in Range in Pregnancy: Is There a Role? *Diabetes Spectr.* 2021;34(2):119-132.
606. Yang X, Zhu Y, Xu W, Weng J. Mean amplitude of glycaemic excursions is superior to time in range in detecting cardiovascular autonomic neuropathy in newly diagnosed and drug-naive type 2 diabetic patients. 2020;63.
607. Yeh Lee M, Leverenz J, Leverenz B, et al. Pilot study on the feasibility of weekly CGM data review in youth with new-onset type 1 diabetes. *Diabetes.* 2020;69(Supplement_1).
608. Yoo JH, Kim G, Sim KH, et al. Association between continuous glucose monitoring derived time in range and microalbuminuria in type 2 diabetes. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
609. Yorgason JB, Saylor J, Berg C, Rellaford S, Steeger DL, Davey A. Daily communal coping and blood glucose in young adult couples with type 1 diabetes. *Diabetes.* 2021;70(Supplement_1).
610. Zaharieva D, Prahalad P, Addala A, et al. Newly diagnosed pediatric patients with type 1 diabetes show steady decline in glucose time-in-range (TIR) over 1 year: Pilot study. *Diabetes.* 2020;69(Supplement_1).
611. Zaharieva DP, Addala A, Hooper J, et al. Physical activity and glucose management in newly diagnosed youth with type 1 diabetes: 4 T exercise pilot study results at 6 months. *Pediatr Diabetes.* 2021;22:3-165.
612. Zhang Y, Olawsky EA, Alvear AC, Eberly LE, Chow LS. "In patients without diabetes, glycemic variability derived from continuous glucose monitoring (CGM) data relates to hyperglycemia more than insulin resistance". *Diabetes.* 2020;69(Supplement_1).
613. Zhou Y, Deng H, Yang D, et al. Discrepancies in key metrics of glycemic control between retrospective continuous glucose monitoring system and flash glucose monitoring in adult patients with type 1 diabetes. *Diabetes.* 2020;69(Supplement_1).
614. Zhou Y, Liu H, Yang D, et al. Relationship between time-in-range and estimated hba1c derived from continuous glucose monitoring system in adults with type 1 diabetes mellitus. *Diabetes.* 2021;70(Supplement_1).

615. Ziegler R, Danne T, Axel Schweitzer M, et al. GoBolus study: Faster aspart impact on glycaemic control in a realworld population with type 1 diabetes on basal/bolus therapy as multiple daily injections using flash glucose monitoring. *Diabetologia.* 2020;63(Suppl 1):1-485.
616. Zografou I, Dimitriou P, Kefas A, Sachinidis A, Katsimadrou A, Sampanis C. Association between monitoring frequency with flash technology and glycemic measures in patients with type 1 diabetes mellitus. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
617. Zografou I, Kefas A, Dimitriou P, et al. Effect of flash glucose technology on glycemic control in patients with type 1 diabetes. *Diabetes Technol Ther.* 2021;23(S2):A1-A206.
618. Zucchini S, Di Dalmazi G, Maltoni G, et al. "Time in range and glucose variability were not similar between children, adolescents and adults with type 1 diabetes during lockdown due to CoVid-19 pandemic". *Pediatric Diabetes.* 2021;22(S29):25-105.
619. Zueger T, Lehmann V, Gloor M, et al. White coat adherence effect on glucose control in adult individuals with diabetes using continuous/flash glucose monitoring. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.
620. Zueger T, Lehmann V, Laimer M, Stettler C. Improved glycaemic control after transition to the hybrid-closed-loop (HCL) system minimed 670g-real-world experience of a tertiary referral centre. *Diabetes Technol Ther.* 2020;22(S1):A1-A250.